	Label ID	Drug Name	Gene Symbol	Gene ID	Gene Name	NCBI	Drug ID	Drug Generic Names	Label Summary
0	PA166123409	aliskiren	ABCB1	PA267	ATP-binding cassette, sub-family B (MDR/TAP), member 1	NCBI Gene:5243	PA143487910	"Rasilez,""SPP 100"",""aliskiren"""	The EMA European Public Assessment Report (EPAR) for aliskiren (Rasilez HCT) does not contain pharmacogenetic information. It contains information regarding the role of ABCB1 (P-gp, MDR1) in intestinal absorption and biliary secretion of aliskiren, and concomitant use of aliskiren with potent P-gp inhibitors is contraindicated.
1	PA166159586	aliskiren	ABCB1	PA267	ATP-binding cassette, sub-family B (MDR/TAP), member 1	NCBI Gene:5243	PA143487910	"Rasilez,""SPP 100"",""aliskiren"""	The HCSC product monograph for aliskiren (Rasilez HCT) does not contain pharmacogenetic information. It contains information regarding the role of ABCB1 (Pgp, MDR1) in intestinal absorption of aliskiren, and concomitant use of aliskiren with potent P-gp inhibitors is contraindicated.
2	PA166127660	dasatinib	ABI1	PA36144	abl-interactor 1	NCBI Gene:10006	PA162372878	"BMS-354825,""dasatinib"""	The product monograph for dasatinib (SPRYCEL) states that it is indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia. 
3	PA166127660	dasatinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA162372878	"BMS-354825,""dasatinib"""	The product monograph for dasatinib (SPRYCEL) states that it is indicated for the treatment of adults with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia. 
4	PA166104914	dasatinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA162372878	"BMS-354825,""dasatinib"""	The EMA European Public Assessment Report (EPAR) highlights information regarding the indication of Dasatinib (Sprycel) in patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia or acute lymphoblastic leukaemia.
5	PA166104781	dasatinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA162372878	"BMS-354825,""dasatinib"""	The FDA-approved drug label for dasatinib (SPRYCEL) notes that it is intended for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (Ph+ ALL) and resistance or intolerance to prior therapy. 
6	PA166123537	dasatinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA162372878	"BMS-354825,""dasatinib"""	The PMDA package insert for dasatinib states that it is indicated for individuals with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). 
7	PA166104914	dasatinib	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA162372878	"BMS-354825,""dasatinib"""	The EMA European Public Assessment Report (EPAR) highlights information regarding the indication of Dasatinib (Sprycel) in patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia or acute lymphoblastic leukaemia.
8	PA166104781	dasatinib	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA162372878	"BMS-354825,""dasatinib"""	The FDA-approved drug label for dasatinib (SPRYCEL) notes that it is intended for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (Ph+ ALL) and resistance or intolerance to prior therapy. 
9	PA166123537	dasatinib	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA162372878	"BMS-354825,""dasatinib"""	The PMDA package insert for dasatinib states that it is indicated for individuals with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). 
10	PA166127682	imatinib	ABI1	PA36144	abl-interactor 1	NCBI Gene:10006	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	The product monograph for imatinib (GLEEVEC) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including Kit (CD117), BCR-ABL1 (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements.
11	PA166127682	imatinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	The product monograph for imatinib (GLEEVEC) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including Kit (CD117), BCR-ABL1 (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements.
12	PA166104926	imatinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	The EMA European Public Assessment Report (EPAR) for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including KIT (CD117), BCR-ABL (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements. 
13	PA166104790	imatinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	The decision of whether to treat patients with imatinib is based on the presence of genetic biomarkers, including BCR-ABL (the Philadelphia chromosome), KIT, and PDGFR gene rearrangements.
14	PA166123542	imatinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	Imatinib is an inhibitor of the BCR-ABL tyrosine kinase that is created by the Philadelphia chromosome rearrangement. The PMDA package insert for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with Philadelphia chromosome positive (BCR-ABL) acute lymphoblastic leukemia.
15	PA166127682	imatinib	FIP1L1	PA134875694	factor interacting with PAPOLA and CPSF1	NCBI Gene:81608	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	The product monograph for imatinib (GLEEVEC) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including Kit (CD117), BCR-ABL1 (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements.
16	PA166104926	imatinib	FIP1L1	PA134875694	factor interacting with PAPOLA and CPSF1	NCBI Gene:81608	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	The EMA European Public Assessment Report (EPAR) for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including KIT (CD117), BCR-ABL (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements. 
17	PA166123542	imatinib	FIP1L1	PA134875694	factor interacting with PAPOLA and CPSF1	NCBI Gene:81608	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	Imatinib is an inhibitor of the BCR-ABL tyrosine kinase that is created by the Philadelphia chromosome rearrangement. The PMDA package insert for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with Philadelphia chromosome positive (BCR-ABL) acute lymphoblastic leukemia.
18	PA166127682	imatinib	KIT	PA30128	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog	NCBI Gene:3815	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	The product monograph for imatinib (GLEEVEC) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including Kit (CD117), BCR-ABL1 (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements.
19	PA166104926	imatinib	KIT	PA30128	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog	NCBI Gene:3815	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	The EMA European Public Assessment Report (EPAR) for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including KIT (CD117), BCR-ABL (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements. 
20	PA166104790	imatinib	KIT	PA30128	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog	NCBI Gene:3815	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	The decision of whether to treat patients with imatinib is based on the presence of genetic biomarkers, including BCR-ABL (the Philadelphia chromosome), KIT, and PDGFR gene rearrangements.
21	PA166123542	imatinib	KIT	PA30128	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog	NCBI Gene:3815	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	Imatinib is an inhibitor of the BCR-ABL tyrosine kinase that is created by the Philadelphia chromosome rearrangement. The PMDA package insert for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with Philadelphia chromosome positive (BCR-ABL) acute lymphoblastic leukemia.
22	PA166127682	imatinib	PDGFRA	PA33147	platelet-derived growth factor receptor, alpha polypeptide	NCBI Gene:5156	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	The product monograph for imatinib (GLEEVEC) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including Kit (CD117), BCR-ABL1 (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements.
23	PA166123542	imatinib	PDGFRA	PA33147	platelet-derived growth factor receptor, alpha polypeptide	NCBI Gene:5156	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	Imatinib is an inhibitor of the BCR-ABL tyrosine kinase that is created by the Philadelphia chromosome rearrangement. The PMDA package insert for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with Philadelphia chromosome positive (BCR-ABL) acute lymphoblastic leukemia.
24	PA166127682	imatinib	PDGFRB	PA33148	platelet-derived growth factor receptor, beta polypeptide	NCBI Gene:5159	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	The product monograph for imatinib (GLEEVEC) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including Kit (CD117), BCR-ABL1 (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements.
25	PA166104926	imatinib	PDGFRB	PA33148	platelet-derived growth factor receptor, beta polypeptide	NCBI Gene:5159	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	The EMA European Public Assessment Report (EPAR) for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including KIT (CD117), BCR-ABL (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements. 
26	PA166104926	imatinib	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	The EMA European Public Assessment Report (EPAR) for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with tumors positive for biomarkers including KIT (CD117), BCR-ABL (Philadelphia chromosome), PDGFR and FIP1L1-PDGFRalpha rearrangements. 
27	PA166104790	imatinib	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	The decision of whether to treat patients with imatinib is based on the presence of genetic biomarkers, including BCR-ABL (the Philadelphia chromosome), KIT, and PDGFR gene rearrangements.
28	PA166123542	imatinib	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA10804	"Imatinib Mesylate,""Imatinib Methansulfonate"",""sti-571"""	Imatinib is an inhibitor of the BCR-ABL tyrosine kinase that is created by the Philadelphia chromosome rearrangement. The PMDA package insert for imatinib (Glivec) contains pharmacogenetic information regarding the indication of the drug in patients with Philadelphia chromosome positive (BCR-ABL) acute lymphoblastic leukemia.
29	PA166127693	nilotinib	ABI1	PA36144	abl-interactor 1	NCBI Gene:10006	PA165958345	"amn-107,""amn107"""	The product monograph for nilotinib (TASIGNA) states that it is indicated for patients with Philadelphia chromosome positive (_BCR-ABL1_ fusion) chronic myeloid leukemia, though individuals with the BCR-ABL T315I mutation are highly resistant to the drug. The monograph also notes that patients homozygous for the UGT1A1*28 allele ([variant:rs8175347]; (TA)7) may be at risk for hyperbilirubinemia when receiving nilotinib.
30	PA166127693	nilotinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA165958345	"amn-107,""amn107"""	The product monograph for nilotinib (TASIGNA) states that it is indicated for patients with Philadelphia chromosome positive (_BCR-ABL1_ fusion) chronic myeloid leukemia, though individuals with the BCR-ABL T315I mutation are highly resistant to the drug. The monograph also notes that patients homozygous for the UGT1A1*28 allele ([variant:rs8175347]; (TA)7) may be at risk for hyperbilirubinemia when receiving nilotinib.
31	PA166105334	nilotinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA165958345	"amn-107,""amn107"""	The EMA European Public Assessment Report (EPAR) for nilotinib (Tasigna) states it is indicated for patients who have Philadelphia chromosome-positive (presence of a BCR-ABL1 gene fusion) chronic myelogenous leukemia (CML). The label differs from that of the FDA as it does not contain any information regarding UGT1A1 genotype. 
32	PA166104842	nilotinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA165958345	"amn-107,""amn107"""	Nilotinib is indicated for use in patients diagnosed with Philadelphia chromosome positive (presence of a BCR-ABL1 gene fusion) chronic myeloid leukemia, due to its mechanism of action. Individuals with the UGT1A1*28 genotype (TA)7/(TA)7 ([variant:rs8175347]) are at an increased risk of hyperbilirubinemia when taking nilotinib (testing is not required for UGT1A1). 
33	PA166105334	nilotinib	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA165958345	"amn-107,""amn107"""	The EMA European Public Assessment Report (EPAR) for nilotinib (Tasigna) states it is indicated for patients who have Philadelphia chromosome-positive (presence of a BCR-ABL1 gene fusion) chronic myelogenous leukemia (CML). The label differs from that of the FDA as it does not contain any information regarding UGT1A1 genotype. 
34	PA166104842	nilotinib	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA165958345	"amn-107,""amn107"""	Nilotinib is indicated for use in patients diagnosed with Philadelphia chromosome positive (presence of a BCR-ABL1 gene fusion) chronic myeloid leukemia, due to its mechanism of action. Individuals with the UGT1A1*28 genotype (TA)7/(TA)7 ([variant:rs8175347]) are at an increased risk of hyperbilirubinemia when taking nilotinib (testing is not required for UGT1A1). 
35	PA166151853	nilotinib	UGT1A1	PA420	UDP glucuronosyltransferase 1 family, polypeptide A1	NCBI Gene:54658	PA165958345	"amn-107,""amn107"""	Nilotinib is indicated for use in patients diagnosed with Philadelphia chromosome positive (presence of a BCR-ABL1 gene fusion) chronic myeloid leukemia, due to its mechanism of action. Individuals with the UGT1A1*28 genotype (TA)7/(TA)7 ([variant:rs8175347]) are at an increased risk of hyperbilirubinemia when taking nilotinib (testing is not required for UGT1A1). 
36	PA166151974	nilotinib	UGT1A1	PA420	UDP glucuronosyltransferase 1 family, polypeptide A1	NCBI Gene:54658	PA165958345	"amn-107,""amn107"""	The product monograph for nilotinib (TASIGNA) notes that patients homozygous for the UGT1A1*28 allele ([variant:rs8175347]; (TA)7) may be at risk for hyperbilirubinemia when receiving nilotinib.  This drug is indicated for patients with Philadelphia chromosome positive (BCR-ABL1 fusion) chronic myeloid leukemia, though individuals with the BCR-ABL T315I mutation are highly resistant to the drug. 
37	PA166129527	ponatinib	ABI1	PA36144	abl-interactor 1	NCBI Gene:10006	PA165980594	AP24534	Ponatinib (ICLUSIG) is indicated for adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), including CML or Ph+ ALL that is T315I mutation positive. The majority of patients with CML are positive for the Philadelphia chromosome (_BCR-ABL1_ gene fusion). The T315I mutation is known to cause resistance to other BCR-ABL kinase inhibitors. 
38	PA166129527	ponatinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA165980594	AP24534	Ponatinib (ICLUSIG) is indicated for adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), including CML or Ph+ ALL that is T315I mutation positive. The majority of patients with CML are positive for the Philadelphia chromosome (_BCR-ABL1_ gene fusion). The T315I mutation is known to cause resistance to other BCR-ABL kinase inhibitors. 
39	PA166122067	ponatinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA165980594	AP24534	The EMA European Public Assessment Report (EPAR) for ponatinib (Iclusig) states that indications of the drug include patients with Philadelphia chromosome positive (BCR-ABL1 gene fusion) acute lymphoblastic leukemia who are resistant or intolerant to dasatinib or patients who have the BCR-ABL T315I mutation, due to its mechanism of action as an inhibitor of BCR-ABL and inhibitor of mutant forms of the ABL kinase.
40	PA166114931	ponatinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA165980594	AP24534	The FDA-approved drug label for ponatinib (Iclusig) states that it is intended for adults with chronic, accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to prior tyrosine kinase inhibitor therapy, including those with the BCR-ABL T315I mutation. The majority of patients with CML are positive for the Philadelphia chromosome (_BCR-ABL1_ gene fusion).
41	PA166122067	ponatinib	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA165980594	AP24534	The EMA European Public Assessment Report (EPAR) for ponatinib (Iclusig) states that indications of the drug include patients with Philadelphia chromosome positive (BCR-ABL1 gene fusion) acute lymphoblastic leukemia who are resistant or intolerant to dasatinib or patients who have the BCR-ABL T315I mutation, due to its mechanism of action as an inhibitor of BCR-ABL and inhibitor of mutant forms of the ABL kinase.
42	PA166114931	ponatinib	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA165980594	AP24534	The FDA-approved drug label for ponatinib (Iclusig) states that it is intended for adults with chronic, accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to prior tyrosine kinase inhibitor therapy, including those with the BCR-ABL T315I mutation. The majority of patients with CML are positive for the Philadelphia chromosome (_BCR-ABL1_ gene fusion).
43	PA166117941	bosutinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA166114906	bosutinib monohydrate	The EMA EPAR for bosutinib (Bosulif) contains information regarding the indication of the drug in adult patients with Philadelphia chromosome positive chronic myelogenous leukaemia. This is due to its mechanism of action - the drug inhibits the abnormal BCR-ABL kinase that promotes chronic myelogenous leukaemia.
44	PA166114907	bosutinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA166114906	bosutinib monohydrate	The FDA-approved drug label for bosutinib (BOSULIF) notes that it is intended for adults with chronic, accelerated or blast phase Philadelphia chromosome-positive chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy.
45	PA166127641	bosutinib	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA166114906	bosutinib monohydrate	The product monograph for bosutinib (BOSULIF) states that it is indicated for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
46	PA166117941	bosutinib	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA166114906	bosutinib monohydrate	The EMA EPAR for bosutinib (Bosulif) contains information regarding the indication of the drug in adult patients with Philadelphia chromosome positive chronic myelogenous leukaemia. This is due to its mechanism of action - the drug inhibits the abnormal BCR-ABL kinase that promotes chronic myelogenous leukaemia.
47	PA166114907	bosutinib	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA166114906	bosutinib monohydrate	The FDA-approved drug label for bosutinib (BOSULIF) notes that it is intended for adults with chronic, accelerated or blast phase Philadelphia chromosome-positive chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy.
48	PA166127641	bosutinib	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA166114906	bosutinib monohydrate	The product monograph for bosutinib (BOSULIF) states that it is indicated for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
49	PA166159963	blinatumomab	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA166129524		The FDA-approved drug label for blinatumomab (BLINCYTO) states that it is indicated for treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Genetic testing is not discussed within the label.
50	PA166159963	blinatumomab	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA166129524		The FDA-approved drug label for blinatumomab (BLINCYTO) states that it is indicated for treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Genetic testing is not discussed within the label.
51	PA166104795	busulfan	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA448691	"Busulphan,""Busulphane"",""Butanedioldimethanesulfonate"",""Buzulfan"",""Sulfabutin"",""Sulphabutin"",""Tetramethylene Dimethane Sulfonate"",""Tetramethylenester Kyseliny Methansulfonove"",""busulfan"""	The busulfan FDA-approved drug label states it is less effective in patients with chronic myelogenous leukemia who lack the Philadelphia (Ph1) chromosome. Testing for the BCR-ABL1 gene fusion is not mentioned in the drug label.  
52	PA166104795	busulfan	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA448691	"Busulphan,""Busulphane"",""Butanedioldimethanesulfonate"",""Buzulfan"",""Sulfabutin"",""Sulphabutin"",""Tetramethylene Dimethane Sulfonate"",""Tetramethylenester Kyseliny Methansulfonove"",""busulfan"""	The busulfan FDA-approved drug label states it is less effective in patients with chronic myelogenous leukemia who lack the Philadelphia (Ph1) chromosome. Testing for the BCR-ABL1 gene fusion is not mentioned in the drug label.  
53	PA166114930	homoharringtonine	BCR	PA25321	breakpoint cluster region	NCBI Gene:613	PA166114929	"Omacetaxine,""Omacetaxine mepesuccinate"""	The FDA-approved drug label for omacetaxine mepesuccinate (homoharringtonine; SYNRIBO) notes that it is intended for adults with chronic or accelerated phase chronic myeloid leukemia (CML). The majority of patients with CML are positive for the Philadelphia chromosome (_BCR-ABL1_ gene fusion).
54	PA166114930	homoharringtonine	ABL1	PA24413	ABL proto-oncogene 1, non-receptor tyrosine kinase	NCBI Gene:25	PA166114929	"Omacetaxine,""Omacetaxine mepesuccinate"""	The FDA-approved drug label for omacetaxine mepesuccinate (homoharringtonine; SYNRIBO) notes that it is intended for adults with chronic or accelerated phase chronic myeloid leukemia (CML). The majority of patients with CML are positive for the Philadelphia chromosome (_BCR-ABL1_ gene fusion).
55	PA166104825	valproic acid	ABL2	PA24414	ABL proto-oncogene 2, non-receptor tyrosine kinase	NCBI Gene:27	PA451846	"2-propylvaleric acid,""DPA"",""Di-n-propylacetic acid"",""Di-n-propylessigsaure"",""Dipropylacetic acid"",""Kyselina 2-propylvalerova"",""Myproic Acid"",""Propylvaleric acid"",""Sodium hydrogen divalproate"",""VPA"",""Valproate semisodique [French]"",""Valproate semisodium"",""Valproato semisodico [Spanish]"",""Valproatum seminatricum [Latin]"",""n-DPA"",""n-Dipropylacetic acid"",""valproate"",""valproic acid"""	Valproic acid is used to treat patients with various types of seizures. The FDA-approved drug label for valproic acid notes that it is contraindicated in patients with known urea cycle disorders (UCDs), a group of uncommon genetic abnormalities, since these patients can sometimes experience fatal hyperammonemic encephalopathy following initiation of treatment. It is also contraindicated in patients with POLG mutations. However, the label does not explicitly mention testing for genetic mutations leading to UCDs or POLG mutations prior to valproic acid treatment.
56	PA166104825	valproic acid	ASL	PA25046	argininosuccinate lyase	NCBI Gene:435	PA451846	"2-propylvaleric acid,""DPA"",""Di-n-propylacetic acid"",""Di-n-propylessigsaure"",""Dipropylacetic acid"",""Kyselina 2-propylvalerova"",""Myproic Acid"",""Propylvaleric acid"",""Sodium hydrogen divalproate"",""VPA"",""Valproate semisodique [French]"",""Valproate semisodium"",""Valproato semisodico [Spanish]"",""Valproatum seminatricum [Latin]"",""n-DPA"",""n-Dipropylacetic acid"",""valproate"",""valproic acid"""	Valproic acid is used to treat patients with various types of seizures. The FDA-approved drug label for valproic acid notes that it is contraindicated in patients with known urea cycle disorders (UCDs), a group of uncommon genetic abnormalities, since these patients can sometimes experience fatal hyperammonemic encephalopathy following initiation of treatment. It is also contraindicated in patients with POLG mutations. However, the label does not explicitly mention testing for genetic mutations leading to UCDs or POLG mutations prior to valproic acid treatment.
57	PA166104825	valproic acid	ASS1	PA162376926	argininosuccinate synthase 1	NCBI Gene:445	PA451846	"2-propylvaleric acid,""DPA"",""Di-n-propylacetic acid"",""Di-n-propylessigsaure"",""Dipropylacetic acid"",""Kyselina 2-propylvalerova"",""Myproic Acid"",""Propylvaleric acid"",""Sodium hydrogen divalproate"",""VPA"",""Valproate semisodique [French]"",""Valproate semisodium"",""Valproato semisodico [Spanish]"",""Valproatum seminatricum [Latin]"",""n-DPA"",""n-Dipropylacetic acid"",""valproate"",""valproic acid"""	Valproic acid is used to treat patients with various types of seizures. The FDA-approved drug label for valproic acid notes that it is contraindicated in patients with known urea cycle disorders (UCDs), a group of uncommon genetic abnormalities, since these patients can sometimes experience fatal hyperammonemic encephalopathy following initiation of treatment. It is also contraindicated in patients with POLG mutations. However, the label does not explicitly mention testing for genetic mutations leading to UCDs or POLG mutations prior to valproic acid treatment.
58	PA166104825	valproic acid	CPS1	PA26840	carbamoyl-phosphate synthase 1, mitochondrial	NCBI Gene:1373	PA451846	"2-propylvaleric acid,""DPA"",""Di-n-propylacetic acid"",""Di-n-propylessigsaure"",""Dipropylacetic acid"",""Kyselina 2-propylvalerova"",""Myproic Acid"",""Propylvaleric acid"",""Sodium hydrogen divalproate"",""VPA"",""Valproate semisodique [French]"",""Valproate semisodium"",""Valproato semisodico [Spanish]"",""Valproatum seminatricum [Latin]"",""n-DPA"",""n-Dipropylacetic acid"",""valproate"",""valproic acid"""	Valproic acid is used to treat patients with various types of seizures. The FDA-approved drug label for valproic acid notes that it is contraindicated in patients with known urea cycle disorders (UCDs), a group of uncommon genetic abnormalities, since these patients can sometimes experience fatal hyperammonemic encephalopathy following initiation of treatment. It is also contraindicated in patients with POLG mutations. However, the label does not explicitly mention testing for genetic mutations leading to UCDs or POLG mutations prior to valproic acid treatment.
59	PA166123552	valproic acid	CPS1	PA26840	carbamoyl-phosphate synthase 1, mitochondrial	NCBI Gene:1373	PA451846	"2-propylvaleric acid,""DPA"",""Di-n-propylacetic acid"",""Di-n-propylessigsaure"",""Dipropylacetic acid"",""Kyselina 2-propylvalerova"",""Myproic Acid"",""Propylvaleric acid"",""Sodium hydrogen divalproate"",""VPA"",""Valproate semisodique [French]"",""Valproate semisodium"",""Valproato semisodico [Spanish]"",""Valproatum seminatricum [Latin]"",""n-DPA"",""n-Dipropylacetic acid"",""valproate"",""valproic acid"""	The PMDA package insert for valproic acid states that it is contraindicated in patients with known urea cycle disorders (UCDs), due to a risk for severe hyperammonemia. UCDs result from mutations in one of several genes, including ornithine transcarbamylase (OTC) deficiency and carbamoyl-phosphate synthetase 1 (CPS1) deficiency.
60	PA166104825	valproic acid	NAGS	PA134968729	N-acetylglutamate synthase	NCBI Gene:162417	PA451846	"2-propylvaleric acid,""DPA"",""Di-n-propylacetic acid"",""Di-n-propylessigsaure"",""Dipropylacetic acid"",""Kyselina 2-propylvalerova"",""Myproic Acid"",""Propylvaleric acid"",""Sodium hydrogen divalproate"",""VPA"",""Valproate semisodique [French]"",""Valproate semisodium"",""Valproato semisodico [Spanish]"",""Valproatum seminatricum [Latin]"",""n-DPA"",""n-Dipropylacetic acid"",""valproate"",""valproic acid"""	Valproic acid is used to treat patients with various types of seizures. The FDA-approved drug label for valproic acid notes that it is contraindicated in patients with known urea cycle disorders (UCDs), a group of uncommon genetic abnormalities, since these patients can sometimes experience fatal hyperammonemic encephalopathy following initiation of treatment. It is also contraindicated in patients with POLG mutations. However, the label does not explicitly mention testing for genetic mutations leading to UCDs or POLG mutations prior to valproic acid treatment.
61	PA166104825	valproic acid	OTC	PA32840	ornithine carbamoyltransferase	NCBI Gene:5009	PA451846	"2-propylvaleric acid,""DPA"",""Di-n-propylacetic acid"",""Di-n-propylessigsaure"",""Dipropylacetic acid"",""Kyselina 2-propylvalerova"",""Myproic Acid"",""Propylvaleric acid"",""Sodium hydrogen divalproate"",""VPA"",""Valproate semisodique [French]"",""Valproate semisodium"",""Valproato semisodico [Spanish]"",""Valproatum seminatricum [Latin]"",""n-DPA"",""n-Dipropylacetic acid"",""valproate"",""valproic acid"""	Valproic acid is used to treat patients with various types of seizures. The FDA-approved drug label for valproic acid notes that it is contraindicated in patients with known urea cycle disorders (UCDs), a group of uncommon genetic abnormalities, since these patients can sometimes experience fatal hyperammonemic encephalopathy following initiation of treatment. It is also contraindicated in patients with POLG mutations. However, the label does not explicitly mention testing for genetic mutations leading to UCDs or POLG mutations prior to valproic acid treatment.
62	PA166123552	valproic acid	OTC	PA32840	ornithine carbamoyltransferase	NCBI Gene:5009	PA451846	"2-propylvaleric acid,""DPA"",""Di-n-propylacetic acid"",""Di-n-propylessigsaure"",""Dipropylacetic acid"",""Kyselina 2-propylvalerova"",""Myproic Acid"",""Propylvaleric acid"",""Sodium hydrogen divalproate"",""VPA"",""Valproate semisodique [French]"",""Valproate semisodium"",""Valproato semisodico [Spanish]"",""Valproatum seminatricum [Latin]"",""n-DPA"",""n-Dipropylacetic acid"",""valproate"",""valproic acid"""	The PMDA package insert for valproic acid states that it is contraindicated in patients with known urea cycle disorders (UCDs), due to a risk for severe hyperammonemia. UCDs result from mutations in one of several genes, including ornithine transcarbamylase (OTC) deficiency and carbamoyl-phosphate synthetase 1 (CPS1) deficiency.
63	PA166127726	valproic acid	OTC	PA32840	ornithine carbamoyltransferase	NCBI Gene:5009	PA451846	"2-propylvaleric acid,""DPA"",""Di-n-propylacetic acid"",""Di-n-propylessigsaure"",""Dipropylacetic acid"",""Kyselina 2-propylvalerova"",""Myproic Acid"",""Propylvaleric acid"",""Sodium hydrogen divalproate"",""VPA"",""Valproate semisodique [French]"",""Valproate semisodium"",""Valproato semisodico [Spanish]"",""Valproatum seminatricum [Latin]"",""n-DPA"",""n-Dipropylacetic acid"",""valproate"",""valproic acid"""	The product monograph for valproic acid states that it is contraindicated in patients with mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG) or in patients with known urea cycle disorders, particularly ornithine transcarbamylase (OTC) deficiency.
64	PA166104825	valproic acid	POLG	PA33500	polymerase (DNA directed), gamma	NCBI Gene:5428	PA451846	"2-propylvaleric acid,""DPA"",""Di-n-propylacetic acid"",""Di-n-propylessigsaure"",""Dipropylacetic acid"",""Kyselina 2-propylvalerova"",""Myproic Acid"",""Propylvaleric acid"",""Sodium hydrogen divalproate"",""VPA"",""Valproate semisodique [French]"",""Valproate semisodium"",""Valproato semisodico [Spanish]"",""Valproatum seminatricum [Latin]"",""n-DPA"",""n-Dipropylacetic acid"",""valproate"",""valproic acid"""	Valproic acid is used to treat patients with various types of seizures. The FDA-approved drug label for valproic acid notes that it is contraindicated in patients with known urea cycle disorders (UCDs), a group of uncommon genetic abnormalities, since these patients can sometimes experience fatal hyperammonemic encephalopathy following initiation of treatment. It is also contraindicated in patients with POLG mutations. However, the label does not explicitly mention testing for genetic mutations leading to UCDs or POLG mutations prior to valproic acid treatment.
65	PA166127726	valproic acid	POLG	PA33500	polymerase (DNA directed), gamma	NCBI Gene:5428	PA451846	"2-propylvaleric acid,""DPA"",""Di-n-propylacetic acid"",""Di-n-propylessigsaure"",""Dipropylacetic acid"",""Kyselina 2-propylvalerova"",""Myproic Acid"",""Propylvaleric acid"",""Sodium hydrogen divalproate"",""VPA"",""Valproate semisodique [French]"",""Valproate semisodium"",""Valproato semisodico [Spanish]"",""Valproatum seminatricum [Latin]"",""n-DPA"",""n-Dipropylacetic acid"",""valproate"",""valproic acid"""	The product monograph for valproic acid states that it is contraindicated in patients with mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG) or in patients with known urea cycle disorders, particularly ornithine transcarbamylase (OTC) deficiency.
66	PA166104794	phenylacetic acid	ASL	PA25046	argininosuccinate lyase	NCBI Gene:435	PA165950342	sodium phenylacetate	Sodium phenylacetate and sodium benzoate provides an alternate vehicle to urea for waste nitrogen excretion in patients with urea cycle disorders. Urea cycle disorders may be caused by mutations in the genes NAGS, CPS1, OTC, ASS1, ASL and ARG1.
67	PA166104794	phenylacetic acid	ASS1	PA162376926	argininosuccinate synthase 1	NCBI Gene:445	PA165950342	sodium phenylacetate	Sodium phenylacetate and sodium benzoate provides an alternate vehicle to urea for waste nitrogen excretion in patients with urea cycle disorders. Urea cycle disorders may be caused by mutations in the genes NAGS, CPS1, OTC, ASS1, ASL and ARG1.
68	PA166104794	phenylacetic acid	CPS1	PA26840	carbamoyl-phosphate synthase 1, mitochondrial	NCBI Gene:1373	PA165950342	sodium phenylacetate	Sodium phenylacetate and sodium benzoate provides an alternate vehicle to urea for waste nitrogen excretion in patients with urea cycle disorders. Urea cycle disorders may be caused by mutations in the genes NAGS, CPS1, OTC, ASS1, ASL and ARG1.
69	PA166104794	phenylacetic acid	NAGS	PA134968729	N-acetylglutamate synthase	NCBI Gene:162417	PA165950342	sodium phenylacetate	Sodium phenylacetate and sodium benzoate provides an alternate vehicle to urea for waste nitrogen excretion in patients with urea cycle disorders. Urea cycle disorders may be caused by mutations in the genes NAGS, CPS1, OTC, ASS1, ASL and ARG1.
70	PA166104794	phenylacetic acid	OTC	PA32840	ornithine carbamoyltransferase	NCBI Gene:5009	PA165950342	sodium phenylacetate	Sodium phenylacetate and sodium benzoate provides an alternate vehicle to urea for waste nitrogen excretion in patients with urea cycle disorders. Urea cycle disorders may be caused by mutations in the genes NAGS, CPS1, OTC, ASS1, ASL and ARG1.
71	PA166104794	phenylacetic acid	ARG1	PA24947	arginase 1	NCBI Gene:383	PA165950342	sodium phenylacetate	Sodium phenylacetate and sodium benzoate provides an alternate vehicle to urea for waste nitrogen excretion in patients with urea cycle disorders. Urea cycle disorders may be caused by mutations in the genes NAGS, CPS1, OTC, ASS1, ASL and ARG1.
72	PA166104794	sodium benzoate	ASL	PA25046	argininosuccinate lyase	NCBI Gene:435	PA451374		Sodium phenylacetate and sodium benzoate provides an alternate vehicle to urea for waste nitrogen excretion in patients with urea cycle disorders. Urea cycle disorders may be caused by mutations in the genes NAGS, CPS1, OTC, ASS1, ASL and ARG1.
73	PA166104794	sodium benzoate	ASS1	PA162376926	argininosuccinate synthase 1	NCBI Gene:445	PA451374		Sodium phenylacetate and sodium benzoate provides an alternate vehicle to urea for waste nitrogen excretion in patients with urea cycle disorders. Urea cycle disorders may be caused by mutations in the genes NAGS, CPS1, OTC, ASS1, ASL and ARG1.
74	PA166104794	sodium benzoate	CPS1	PA26840	carbamoyl-phosphate synthase 1, mitochondrial	NCBI Gene:1373	PA451374		Sodium phenylacetate and sodium benzoate provides an alternate vehicle to urea for waste nitrogen excretion in patients with urea cycle disorders. Urea cycle disorders may be caused by mutations in the genes NAGS, CPS1, OTC, ASS1, ASL and ARG1.
75	PA166104794	sodium benzoate	NAGS	PA134968729	N-acetylglutamate synthase	NCBI Gene:162417	PA451374		Sodium phenylacetate and sodium benzoate provides an alternate vehicle to urea for waste nitrogen excretion in patients with urea cycle disorders. Urea cycle disorders may be caused by mutations in the genes NAGS, CPS1, OTC, ASS1, ASL and ARG1.
76	PA166104794	sodium benzoate	OTC	PA32840	ornithine carbamoyltransferase	NCBI Gene:5009	PA451374		Sodium phenylacetate and sodium benzoate provides an alternate vehicle to urea for waste nitrogen excretion in patients with urea cycle disorders. Urea cycle disorders may be caused by mutations in the genes NAGS, CPS1, OTC, ASS1, ASL and ARG1.
77	PA166104794	sodium benzoate	ARG1	PA24947	arginase 1	NCBI Gene:383	PA451374		Sodium phenylacetate and sodium benzoate provides an alternate vehicle to urea for waste nitrogen excretion in patients with urea cycle disorders. Urea cycle disorders may be caused by mutations in the genes NAGS, CPS1, OTC, ASS1, ASL and ARG1.
78	PA166114381	sodium phenylbutyrate	ASS1	PA162376926	argininosuccinate synthase 1	NCBI Gene:445	PA166114316		The EMA European Public Assessment Report (EPAR) for Sodium phenylbutyrate (Ammonaps) contains information regarding the indication of the drug in patients with urea acid disorders. It states that early diagnosis of such disorders and immediate treatment with Sodium phenylbutyrate is important to improve clinical outcome.
79	PA166114317	sodium phenylbutyrate	ASS1	PA162376926	argininosuccinate synthase 1	NCBI Gene:445	PA166114316		BUPHENYL(sodium phenylbutyrate) is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).
80	PA166127712	sodium phenylbutyrate	ASS1	PA162376926	argininosuccinate synthase 1	NCBI Gene:445	PA166114316		The product monograph for sodium phenylbutyrate (Pheburane) states that it is indicated for treatment of urea cycle disorders due to deficiencies of carbamylphosphate synthetase (_CPS1_), ornithine transcarbamylase (_OTC_) or argininosuccinate synthetase (_ASS1_). 
81	PA166114381	sodium phenylbutyrate	CPS1	PA26840	carbamoyl-phosphate synthase 1, mitochondrial	NCBI Gene:1373	PA166114316		The EMA European Public Assessment Report (EPAR) for Sodium phenylbutyrate (Ammonaps) contains information regarding the indication of the drug in patients with urea acid disorders. It states that early diagnosis of such disorders and immediate treatment with Sodium phenylbutyrate is important to improve clinical outcome.
82	PA166114317	sodium phenylbutyrate	CPS1	PA26840	carbamoyl-phosphate synthase 1, mitochondrial	NCBI Gene:1373	PA166114316		BUPHENYL(sodium phenylbutyrate) is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).
83	PA166127712	sodium phenylbutyrate	CPS1	PA26840	carbamoyl-phosphate synthase 1, mitochondrial	NCBI Gene:1373	PA166114316		The product monograph for sodium phenylbutyrate (Pheburane) states that it is indicated for treatment of urea cycle disorders due to deficiencies of carbamylphosphate synthetase (_CPS1_), ornithine transcarbamylase (_OTC_) or argininosuccinate synthetase (_ASS1_). 
84	PA166114381	sodium phenylbutyrate	OTC	PA32840	ornithine carbamoyltransferase	NCBI Gene:5009	PA166114316		The EMA European Public Assessment Report (EPAR) for Sodium phenylbutyrate (Ammonaps) contains information regarding the indication of the drug in patients with urea acid disorders. It states that early diagnosis of such disorders and immediate treatment with Sodium phenylbutyrate is important to improve clinical outcome.
85	PA166114317	sodium phenylbutyrate	OTC	PA32840	ornithine carbamoyltransferase	NCBI Gene:5009	PA166114316		BUPHENYL(sodium phenylbutyrate) is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).
86	PA166127712	sodium phenylbutyrate	OTC	PA32840	ornithine carbamoyltransferase	NCBI Gene:5009	PA166114316		The product monograph for sodium phenylbutyrate (Pheburane) states that it is indicated for treatment of urea cycle disorders due to deficiencies of carbamylphosphate synthetase (_CPS1_), ornithine transcarbamylase (_OTC_) or argininosuccinate synthetase (_ASS1_). 
87	PA166119825	carglumic acid	NAGS	PA134968729	N-acetylglutamate synthase	NCBI Gene:162417	PA165958402	"(s)-2-ureidopentanedioic acid,""n-carbamyl-l-glutamate"""	The EMA European Public Assessment Report (EPAR) for carglumic acid (Carbaglu) contains information regarding its mechanism of action as an activator of carbamoyl phosphate synthetase and one of the therapeutic indications is hyperammonaemia due to N-acetylglutamate synthase (NAGS) primary deficiency.
88	PA166114908	carglumic acid	NAGS	PA134968729	N-acetylglutamate synthase	NCBI Gene:162417	PA165958402	"(s)-2-ureidopentanedioic acid,""n-carbamyl-l-glutamate"""	Carglumic acid (Carbaglu) is a synthetic structural analogue of N-acetylglutamate (NAG), and is indicated as adjunctive therapy for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency or maintenance therapy for treatment of chronic hyperammonemia due to NAGS deficiency. 
89	PA166129525	carglumic acid	NAGS	PA134968729	N-acetylglutamate synthase	NCBI Gene:162417	PA165958402	"(s)-2-ureidopentanedioic acid,""n-carbamyl-l-glutamate"""	Carglumic acid (Carbaglu) indicated for patients for the treatment of acute or chronic hyperammonemia due to deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). 
90	PA166127663	divalproex sodium	POLG	PA33500	polymerase (DNA directed), gamma	NCBI Gene:5428	PA164783479	"Divalproex sodium,""Valproate semisodium"""	The FDA-approved drug label for divalproex states that it is contraindicated in individuals with known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), and suspected POLG-related disorders in children under 2 years old.
91	PA166127665	divalproex sodium	POLG	PA33500	polymerase (DNA directed), gamma	NCBI Gene:5428	PA164783479	"Divalproex sodium,""Valproate semisodium"""	The product monograph for divalproex states that it is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), and in children under two years of age who are suspected of having a POLG-related disorder.
92	PA166104779	indacaterol	ADRB2	PA39	adrenoceptor beta 2, surface	NCBI Gene:154	PA165958348	5-(2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1h-quinolin-2-one	The EMA European Public Assessment Report (EPAR) for indacaterol (Hirobriz Breezhaler) does not contain pharmacogenetic information, but does contain information regarding the pharmacodynamics of the drug as a beta2-adrenoceptor (ADRB2) agonist and also contains information regarding the pharmackinetics of indacaterol involving UGT1A1, CYP3A4 and ABCB1.
93	PA166104800	indacaterol	UGT1A1	PA420	UDP glucuronosyltransferase 1 family, polypeptide A1	NCBI Gene:54658	PA165958348	5-(2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1h-quinolin-2-one	Steady-state AUC and Cmax of indacaterol were 1.2-fold higher in patients with the (TA)7, (TA)7 (*28) genotype than in patients with the (TA)6, (TA)6 genotype, suggesting no relevant effect of UGT1A1 genotype of indacaterol exposure
94	PA166123543	indacaterol	UGT1A1	PA420	UDP glucuronosyltransferase 1 family, polypeptide A1	NCBI Gene:54658	PA165958348	5-(2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1h-quinolin-2-one	The PMDA package insert for indacaterol (Onbrez) states that individuals who have low UGT1A1 expression have increased steady-state area under the concentration-time curve (AUC) and maximum plasma concentration (Cmax) as compared to UGT1A1 wild-type individuals.
95	PA166160056	cholic acid	AKR1D1	PA24681	aldo-keto reductase family 1, member D1	NCBI Gene:6718	PA166160055		The FDA-approved drug label for cholic acid (CHOLBAM) states that one of the indications of the drug is for bile acid synthesis disorders due to single enzyme defects. This includes deficiencies in the 3&beta;-HSD (_HSD3B7_), AKR1D1 (_AKR1D1_), CYP27A1 (_CYP27A1_), AMACR (_AMACR_), and CYP7A1 (_CYP7A1_) enzymes.
96	PA166160056	cholic acid	AMACR	PA24757	alpha-methylacyl-CoA racemase	NCBI Gene:23600	PA166160055		The FDA-approved drug label for cholic acid (CHOLBAM) states that one of the indications of the drug is for bile acid synthesis disorders due to single enzyme defects. This includes deficiencies in the 3&beta;-HSD (_HSD3B7_), AKR1D1 (_AKR1D1_), CYP27A1 (_CYP27A1_), AMACR (_AMACR_), and CYP7A1 (_CYP7A1_) enzymes.
97	PA166160056	cholic acid	CYP27A1	PA135	cytochrome P450, family 27, subfamily A, polypeptide 1	NCBI Gene:1593	PA166160055		The FDA-approved drug label for cholic acid (CHOLBAM) states that one of the indications of the drug is for bile acid synthesis disorders due to single enzyme defects. This includes deficiencies in the 3&beta;-HSD (_HSD3B7_), AKR1D1 (_AKR1D1_), CYP27A1 (_CYP27A1_), AMACR (_AMACR_), and CYP7A1 (_CYP7A1_) enzymes.
98	PA166160056	cholic acid	CYP7A1	PA132	cytochrome P450, family 7, subfamily A, polypeptide 1	NCBI Gene:1581	PA166160055		The FDA-approved drug label for cholic acid (CHOLBAM) states that one of the indications of the drug is for bile acid synthesis disorders due to single enzyme defects. This includes deficiencies in the 3&beta;-HSD (_HSD3B7_), AKR1D1 (_AKR1D1_), CYP27A1 (_CYP27A1_), AMACR (_AMACR_), and CYP7A1 (_CYP7A1_) enzymes.
99	PA166160056	cholic acid	DHCR7	PA27321	7-dehydrocholesterol reductase	NCBI Gene:1717	PA166160055		The FDA-approved drug label for cholic acid (CHOLBAM) states that one of the indications of the drug is for bile acid synthesis disorders due to single enzyme defects. This includes deficiencies in the 3&beta;-HSD (_HSD3B7_), AKR1D1 (_AKR1D1_), CYP27A1 (_CYP27A1_), AMACR (_AMACR_), and CYP7A1 (_CYP7A1_) enzymes.
100	PA166160056	cholic acid	HSD3B7	PA134940289	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7	NCBI Gene:80270	PA166160055		The FDA-approved drug label for cholic acid (CHOLBAM) states that one of the indications of the drug is for bile acid synthesis disorders due to single enzyme defects. This includes deficiencies in the 3&beta;-HSD (_HSD3B7_), AKR1D1 (_AKR1D1_), CYP27A1 (_CYP27A1_), AMACR (_AMACR_), and CYP7A1 (_CYP7A1_) enzymes.
101	PA166129449	ceritinib	ALK	PA24719	anaplastic lymphoma receptor tyrosine kinase	NCBI Gene:238	PA166124616	2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine	The EMA European Public Assessment Report (EPAR) for ceritinib (Zykadia) states that it is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
102	PA166124617	ceritinib	ALK	PA24719	anaplastic lymphoma receptor tyrosine kinase	NCBI Gene:238	PA166124616	2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine	The FDA-approved drug label for ceritinib (ZYKADIA) states that it is indicated for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.
103	PA166129526	ceritinib	ALK	PA24719	anaplastic lymphoma receptor tyrosine kinase	NCBI Gene:238	PA166124616	2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine	Ceritinib (ZYKADIA) is indicated as a monotherapy for patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer who have progressed on or were intolerant to crizotinib.
104	PA166104909	crizotinib	ALK	PA24719	anaplastic lymphoma receptor tyrosine kinase	NCBI Gene:238	PA165946122	crizotinib	The EMA European Public Assessment Report (EPAR) requires testing of ALK prior to treatment with crizotinib, indicated for patients with ALK-positive advanced non-small cell lung cancer.
105	PA166104859	crizotinib	ALK	PA24719	anaplastic lymphoma receptor tyrosine kinase	NCBI Gene:238	PA165946122	crizotinib	The drug label for crizotinib (XALKORI) states that detection of ALK-positive non-small cell lung cancer (NSCLC) using an FDA-approved test is necessary for selection of patients for treatment with the drug, as it is only indicated for use in these patients. 
106	PA166127655	crizotinib	ALK	PA24719	anaplastic lymphoma receptor tyrosine kinase	NCBI Gene:238	PA165946122	crizotinib	The product monograph for crizotinib (XALKORI) states that it is indicated for patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer. 
107	PA166123536	crizotinib	ALK	PA24719	anaplastic lymphoma receptor tyrosine kinase	NCBI Gene:238	PA165946122	crizotinib	Crizotinib is indicated for the treatment of patients with non-small cell lung cancer. The PMDA package insert for crizotinib states positive confirmation of the ALK fusion gene is necessary prior to treatment.
108	PA166160051	alectinib	ALK	PA24719	anaplastic lymphoma receptor tyrosine kinase	NCBI Gene:238	PA166160050		The FDA-approved drug label for alectinib (ALECENSA) states that it is indicated for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.
109	PA166121250	lomitapide	APOB	PA50	apolipoprotein B	NCBI Gene:338	PA166114922		"The EMA European Public Assessment Report (EPAR) for lomitapide (Lojuxta) states it is indicated only for use in adult patients with homozygous familial hypercholesterolaemia and that genetic conformation should be obtained when possible. Genetic tests include screening for variants in the LDLR, APOB and PCSK9 genes (see the [Genetic Test Registry](http://www.ncbi.nlm.nih.gov/gtr/) for more information).

"
110	PA166121250	lomitapide	LDLR	PA227	low density lipoprotein receptor	NCBI Gene:3949	PA166114922		"The EMA European Public Assessment Report (EPAR) for lomitapide (Lojuxta) states it is indicated only for use in adult patients with homozygous familial hypercholesterolaemia and that genetic conformation should be obtained when possible. Genetic tests include screening for variants in the LDLR, APOB and PCSK9 genes (see the [Genetic Test Registry](http://www.ncbi.nlm.nih.gov/gtr/) for more information).

"
111	PA166114923	lomitapide	LDLR	PA227	low density lipoprotein receptor	NCBI Gene:3949	PA166114922		Lomitapide (JUXTAPID) is indicated as an adjunct to a low-fat diet and other lipid lowering treatments in patients with homozygous familial hypercholesterolemia (HoFH). Mutations in the LDL receptor gene (_LDLR_) are the most common cause of HoFH, however, mutations in other genes (such as _APOB_) can also lead to HoFH.
112	PA166127688	lomitapide	LDLR	PA227	low density lipoprotein receptor	NCBI Gene:3949	PA166114922		Lomitapide (JUXTAPID) is indicated as an adjunct to a low-fat diet and other lipid lowering treatments in patients with homozygous familial hypercholesterolemia (HoFH). Mutations in the LDL receptor gene (_LDLR_) are the most common cause of HoFH, however, mutations in other genes (such as _APOB_) can also lead to HoFH.
113	PA166121250	lomitapide	PCSK9	PA38617	proprotein convertase subtilisin/kexin type 9	NCBI Gene:255738	PA166114922		"The EMA European Public Assessment Report (EPAR) for lomitapide (Lojuxta) states it is indicated only for use in adult patients with homozygous familial hypercholesterolaemia and that genetic conformation should be obtained when possible. Genetic tests include screening for variants in the LDLR, APOB and PCSK9 genes (see the [Genetic Test Registry](http://www.ncbi.nlm.nih.gov/gtr/) for more information).

"
114	PA166159962	alirocumab	LDLR	PA227	low density lipoprotein receptor	NCBI Gene:3949	PA166159961		Although the alirocumab (PRALUENT) drug label does not specifically mention genetic testing, one of the indications listed is for the treatment of adults with heterozygous familial hypercholesterolemia. Familial hypercholesterolemia is commonly caused by mutations in the _LDLR_ gene.
115	PA166104775	atorvastatin	LDLR	PA227	low density lipoprotein receptor	NCBI Gene:3949	PA448500	Atorvastatin calcium	Although the atorvastatin drug label does not specifically mention genetic testing, one of the indications listed is for the treatment of familial hypercholesterolemia, a genetically determined condition caused by mutations in the low density lipoprotein receptor (LDLR); one of the drug's mechanisms of action is increasing LDLR cell surface expression. 
116	PA166127634	atorvastatin	LDLR	PA227	low density lipoprotein receptor	NCBI Gene:3949	PA448500	Atorvastatin calcium	The product monograph for atorvastatin states that it is indicated for hyperlipidemic and dyslipidemic conditions, including homozygous and heterozygous familial hypercholesterolemia, genetically determined conditions caused by mutations in the low density lipoprotein receptor (_LDLR_)
117	PA166123529	atorvastatin	LDLR	PA227	low density lipoprotein receptor	NCBI Gene:3949	PA448500	Atorvastatin calcium	The PMDA package insert for atorvastatin states that an indication for the drug is familial hypercholesterolemia, a genetically determined condition caused by mutations in the low density lipoprotein receptor gene (_LDLR_).
118	PA166160039	evolocumab	LDLR	PA227	low density lipoprotein receptor	NCBI Gene:3949	PA166160027		The FDA-approved drug label for REPATHA (evolocumab) states that it is indicated for the treatment of heterozygous familial hypercholesterolemia (HeFH) or homozygous familial hypercholesterolemia (HoFH). Familial hypercholesterolemia is commonly caused by mutations in the _LDLR_ gene.
119	PA166114928	mipomersen	LDLR	PA227	low density lipoprotein receptor	NCBI Gene:3949	PA166114927		Mipomersen (KYNAMRO) is indicated as an adjunct to diet and lipid lowering treatments in patients with homozygous familial hypercholesterolemia (HoFH). Mutations in the LDL receptor gene (_LDLR_) are the most common cause of HoFH, however, mutations in other genes (such as _APOB_) can also lead to HoFH.
120	PA166114941	pravastatin	LDLR	PA227	low density lipoprotein receptor	NCBI Gene:3949	PA451089	"Pravastatin Sodium,""Pravastatina [Spanish]"",""Pravastatine [French]"",""Pravastatinum [Latin]"""	The FDA-approved drug label for pravastatin (PRAVACHOL) states that the drug is intended for patients with familial hypercholesterolemia (_Fredrickson_ Type IIa), among other indications. Familial hypercholesterolemia is commonly caused by mutations in the _LDLR_ (low density lipoprotein receptor) gene; pravastatin has only been evaluated in patients with heterozygous familial hypercholesterolemia (i.e. patients with only one abnormal copy of the _LDLR_ gene).
121	PA166104866	pravastatin	APOE	PA55	apolipoprotein E	NCBI Gene:348	PA451089	"Pravastatin Sodium,""Pravastatina [Spanish]"",""Pravastatine [French]"",""Pravastatinum [Latin]"""	"The FDA drug label contains pharmacogenetic information regarding response results in patients with APOE genotype E2/E2 and Fredrickson Type III dysbetalipoproteinemia. __This drug-biomarkers pair was previously in the FDA's ""Table of Pharmacogenomic Biomarkers in Drug Labels"" but has subsequently been removed, and replaced by pravastatin and _LDLR_.__"
122	PA166105023	rosuvastatin	LDLR	PA227	low density lipoprotein receptor	NCBI Gene:3949	PA134308647	"ZD-4522,""rosuvastatin calcium"""	The FDA-approved drug label for rosuvastatin (CRESTOR) states that it is indicated for treatment of homozygous or heterozygous familial hypercholesterolemia, a genetically determined condition often caused by mutations in the low density lipoprotein receptor gene (_LDLR_). It is also indicated for other conditions. The label also states that higher plasma concentrations of the drug have been seen in small groups of patients homozygous for the _SLCO1B1_ rs4149056 variant.
123	PA166127709	rosuvastatin	LDLR	PA227	low density lipoprotein receptor	NCBI Gene:3949	PA134308647	"ZD-4522,""rosuvastatin calcium"""	The product monograph for rosuvastatin states that it is indicated for hyperlipidemic and dyslipidemic conditions, including homozygous familial hypercholesterolemia, a genetically determined condition caused by mutations in the low density lipoprotein receptor (_LDLR_)
124	PA166105023	rosuvastatin	SLCO1B1	PA134865839	solute carrier organic anion transporter family, member 1B1	NCBI Gene:10599	PA134308647	"ZD-4522,""rosuvastatin calcium"""	The FDA-approved drug label for rosuvastatin (CRESTOR) states that it is indicated for treatment of homozygous or heterozygous familial hypercholesterolemia, a genetically determined condition often caused by mutations in the low density lipoprotein receptor gene (_LDLR_). It is also indicated for other conditions. The label also states that higher plasma concentrations of the drug have been seen in small groups of patients homozygous for the _SLCO1B1_ rs4149056 variant.
125	PA166122970	succinylcholine	BCHE	PA25294	butyrylcholinesterase	NCBI Gene:590	PA451522	"Scoline,""Succinylcholine Chloride"",""Suxamethonium chloride"",""succinyldicholine"""	Succinylcholine is rapid acting, depolarizing skeletal muscle relaxant indicated as an adjunct to general anesthesia, to facilitate tracheal intubation and mechanical ventilation. 
126	PA166127713	succinylcholine	BCHE	PA25294	butyrylcholinesterase	NCBI Gene:590	PA451522	"Scoline,""Succinylcholine Chloride"",""Suxamethonium chloride"",""succinyldicholine"""	The product monograph for succinylcholine notes that it should be used with caution, if at all, in patients know or suspected of being homozygous for the atypical plasma cholinesterase gene (_BCHE_), due to the risk for prolonged muscle paralysis.
127	PA166122970	succinylcholine	CACNA1S	PA85	calcium channel, voltage-dependent, L type, alpha 1S subunit	NCBI Gene:779	PA451522	"Scoline,""Succinylcholine Chloride"",""Suxamethonium chloride"",""succinyldicholine"""	Succinylcholine is rapid acting, depolarizing skeletal muscle relaxant indicated as an adjunct to general anesthesia, to facilitate tracheal intubation and mechanical ventilation. 
128	PA166122970	succinylcholine	RYR1	PA34896	ryanodine receptor 1 (skeletal)	NCBI Gene:6261	PA451522	"Scoline,""Succinylcholine Chloride"",""Suxamethonium chloride"",""succinyldicholine"""	Succinylcholine is rapid acting, depolarizing skeletal muscle relaxant indicated as an adjunct to general anesthesia, to facilitate tracheal intubation and mechanical ventilation. 
129	PA166129515	desflurane	CACNA1S	PA85	calcium channel, voltage-dependent, L type, alpha 1S subunit	NCBI Gene:779	PA164749136	"Desflurano [INN-Spanish],""Desfluranum [INN-Latin]"""	Desflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia. 
130	PA166129516	desflurane	CACNA1S	PA85	calcium channel, voltage-dependent, L type, alpha 1S subunit	NCBI Gene:779	PA164749136	"Desflurano [INN-Spanish],""Desfluranum [INN-Latin]"""	"Desflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia.

"
131	PA166129515	desflurane	RYR1	PA34896	ryanodine receptor 1 (skeletal)	NCBI Gene:6261	PA164749136	"Desflurano [INN-Spanish],""Desfluranum [INN-Latin]"""	Desflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia. 
132	PA166129516	desflurane	RYR1	PA34896	ryanodine receptor 1 (skeletal)	NCBI Gene:6261	PA164749136	"Desflurano [INN-Spanish],""Desfluranum [INN-Latin]"""	"Desflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia.

"
133	PA166129517	isoflurane	CACNA1S	PA85	calcium channel, voltage-dependent, L type, alpha 1S subunit	NCBI Gene:779	PA450106		"Isoflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia.

"
134	PA166129518	isoflurane	CACNA1S	PA85	calcium channel, voltage-dependent, L type, alpha 1S subunit	NCBI Gene:779	PA450106		"Isoflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia.

"
135	PA166129517	isoflurane	RYR1	PA34896	ryanodine receptor 1 (skeletal)	NCBI Gene:6261	PA450106		"Isoflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia.

"
136	PA166129518	isoflurane	RYR1	PA34896	ryanodine receptor 1 (skeletal)	NCBI Gene:6261	PA450106		"Isoflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia.

"
137	PA166129519	sevoflurane	CACNA1S	PA85	calcium channel, voltage-dependent, L type, alpha 1S subunit	NCBI Gene:779	PA451341	"Sevofluran,""Sevoflurano [INN-Spanish]"",""Sevofluranum [INN-Latin]"""	The FDA-approved drug label for sevoflurane (ULTANE) states that it should not be used in patients with known or suspected susceptibility to malignant hyperthermia. Specific variants in the _RYR1_ and _CACNA1S_ genes are associated with risk of malignant hyperthermia in individuals administered potent inhalational anesthetics, including sevoflurane. The label does not mention genetic testing.
138	PA166129520	sevoflurane	CACNA1S	PA85	calcium channel, voltage-dependent, L type, alpha 1S subunit	NCBI Gene:779	PA451341	"Sevofluran,""Sevoflurano [INN-Spanish]"",""Sevofluranum [INN-Latin]"""	"Sevoflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia.

"
139	PA166129519	sevoflurane	RYR1	PA34896	ryanodine receptor 1 (skeletal)	NCBI Gene:6261	PA451341	"Sevofluran,""Sevoflurano [INN-Spanish]"",""Sevofluranum [INN-Latin]"""	The FDA-approved drug label for sevoflurane (ULTANE) states that it should not be used in patients with known or suspected susceptibility to malignant hyperthermia. Specific variants in the _RYR1_ and _CACNA1S_ genes are associated with risk of malignant hyperthermia in individuals administered potent inhalational anesthetics, including sevoflurane. The label does not mention genetic testing.
140	PA166129520	sevoflurane	RYR1	PA34896	ryanodine receptor 1 (skeletal)	NCBI Gene:6261	PA451341	"Sevofluran,""Sevoflurano [INN-Spanish]"",""Sevofluranum [INN-Latin]"""	"Sevoflurane is a potent (volatile) inhalational anesthetic used to induce or maintain general anesthesia.

"
141	PA166104823	methylene blue	BLVRB	PA25374	biliverdin reductase B	NCBI Gene:645	PA450457	"aniline violet,""methylthionine chloride"",""methylthioninium chloride"",""tetrametylthionine chloride"""	The EMA European Public Assessment Report (EPAR) for methylthioninium chloride Proveblue (also known as methylene blue) contains information regarding contraindication of the drug in patients with G6PD deficiency due to risk of hemolytic anemia, and in patients with a deficiency in NADPH reductase (encoded by the BLVRB gene). The label also states that failure to respond to the drug may indicate a deficiency in cytochrome b5 reductase (CYB5R3) or G6PD.
142	PA166104823	methylene blue	CYB5R3	PA27331	cytochrome b5 reductase 3	NCBI Gene:1727	PA450457	"aniline violet,""methylthionine chloride"",""methylthioninium chloride"",""tetrametylthionine chloride"""	The EMA European Public Assessment Report (EPAR) for methylthioninium chloride Proveblue (also known as methylene blue) contains information regarding contraindication of the drug in patients with G6PD deficiency due to risk of hemolytic anemia, and in patients with a deficiency in NADPH reductase (encoded by the BLVRB gene). The label also states that failure to respond to the drug may indicate a deficiency in cytochrome b5 reductase (CYB5R3) or G6PD.
143	PA166104823	methylene blue	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA450457	"aniline violet,""methylthionine chloride"",""methylthioninium chloride"",""tetrametylthionine chloride"""	The EMA European Public Assessment Report (EPAR) for methylthioninium chloride Proveblue (also known as methylene blue) contains information regarding contraindication of the drug in patients with G6PD deficiency due to risk of hemolytic anemia, and in patients with a deficiency in NADPH reductase (encoded by the BLVRB gene). The label also states that failure to respond to the drug may indicate a deficiency in cytochrome b5 reductase (CYB5R3) or G6PD.
144	PA166104878	methylene blue	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA450457	"aniline violet,""methylthionine chloride"",""methylthioninium chloride"",""tetrametylthionine chloride"""	Although the methylene blue drug label does not specifically mention genetic testing, precaution prior to initiating treatment with methylene blue is highlighted for G6PD deficient individuals, a condition caused by variants in the _G6PD_ gene which can be determined by enzymatic or genetic tests.
145	PA166105178	lidocaine	CYB5R3	PA27331	cytochrome b5 reductase 3	NCBI Gene:1727	PA450226	"Dilocaine,""L-Caine"""	The FDA-approved drug label for ORAQIX (lidocaine and prilocaine) states that patients with G6PD deficiency are more susceptible to drug-induced methemoglobinemia, and that it should not be used in patients with congenital methemoglobinemia (cytochrome b5 reductase deficiency).
146	PA166105178	lidocaine	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA450226	"Dilocaine,""L-Caine"""	The FDA-approved drug label for ORAQIX (lidocaine and prilocaine) states that patients with G6PD deficiency are more susceptible to drug-induced methemoglobinemia, and that it should not be used in patients with congenital methemoglobinemia (cytochrome b5 reductase deficiency).
147	PA166105178	lidocaine	CYB5R1	PA134979668	cytochrome b5 reductase 1	NCBI Gene:51706	PA450226	"Dilocaine,""L-Caine"""	The FDA-approved drug label for ORAQIX (lidocaine and prilocaine) states that patients with G6PD deficiency are more susceptible to drug-induced methemoglobinemia, and that it should not be used in patients with congenital methemoglobinemia (cytochrome b5 reductase deficiency).
148	PA166105178	lidocaine	CYB5R2	PA142672060	cytochrome b5 reductase 2	NCBI Gene:51700	PA450226	"Dilocaine,""L-Caine"""	The FDA-approved drug label for ORAQIX (lidocaine and prilocaine) states that patients with G6PD deficiency are more susceptible to drug-induced methemoglobinemia, and that it should not be used in patients with congenital methemoglobinemia (cytochrome b5 reductase deficiency).
149	PA166105178	lidocaine	CYB5R4	PA134904907	cytochrome b5 reductase 4	NCBI Gene:51167	PA450226	"Dilocaine,""L-Caine"""	The FDA-approved drug label for ORAQIX (lidocaine and prilocaine) states that patients with G6PD deficiency are more susceptible to drug-induced methemoglobinemia, and that it should not be used in patients with congenital methemoglobinemia (cytochrome b5 reductase deficiency).
150	PA166105178	prilocaine	CYB5R3	PA27331	cytochrome b5 reductase 3	NCBI Gene:1727	PA451101		The FDA-approved drug label for ORAQIX (lidocaine and prilocaine) states that patients with G6PD deficiency are more susceptible to drug-induced methemoglobinemia, and that it should not be used in patients with congenital methemoglobinemia (cytochrome b5 reductase deficiency).
151	PA166105178	prilocaine	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451101		The FDA-approved drug label for ORAQIX (lidocaine and prilocaine) states that patients with G6PD deficiency are more susceptible to drug-induced methemoglobinemia, and that it should not be used in patients with congenital methemoglobinemia (cytochrome b5 reductase deficiency).
152	PA166105178	prilocaine	CYB5R1	PA134979668	cytochrome b5 reductase 1	NCBI Gene:51706	PA451101		The FDA-approved drug label for ORAQIX (lidocaine and prilocaine) states that patients with G6PD deficiency are more susceptible to drug-induced methemoglobinemia, and that it should not be used in patients with congenital methemoglobinemia (cytochrome b5 reductase deficiency).
153	PA166105178	prilocaine	CYB5R2	PA142672060	cytochrome b5 reductase 2	NCBI Gene:51700	PA451101		The FDA-approved drug label for ORAQIX (lidocaine and prilocaine) states that patients with G6PD deficiency are more susceptible to drug-induced methemoglobinemia, and that it should not be used in patients with congenital methemoglobinemia (cytochrome b5 reductase deficiency).
154	PA166105178	prilocaine	CYB5R4	PA134904907	cytochrome b5 reductase 4	NCBI Gene:51167	PA451101		The FDA-approved drug label for ORAQIX (lidocaine and prilocaine) states that patients with G6PD deficiency are more susceptible to drug-induced methemoglobinemia, and that it should not be used in patients with congenital methemoglobinemia (cytochrome b5 reductase deficiency).
155	PA166105195	metoclopramide	CYB5R3	PA27331	cytochrome b5 reductase 3	NCBI Gene:1727	PA450475	"Metaclopramide,""Metaclopromide"",""Methochlopramide"",""Methoclopramide"",""Metochlopramide"",""Metoclopramida [INN-Spanish]"",""Metoclopramide Hcl"",""Metoclopramide Hydrochloride"",""Metoclopramidum [INN-Latin]"",""metoclopramide"""	Metoclopramide (reglan) is indicated as a short-term treatment for adults with gastroesophageal reflux who fail to respond to conventional therapy. The FDA-approved drug label for metoclopramide notes that patients with NADH-cytochrome b5 reductase deficiency have an increased risk of developing methemglobinemia and/or sulfhemoglobinemia when treated with metoclopramide.
156	PA166105195	metoclopramide	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA450475	"Metaclopramide,""Metaclopromide"",""Methochlopramide"",""Methoclopramide"",""Metochlopramide"",""Metoclopramida [INN-Spanish]"",""Metoclopramide Hcl"",""Metoclopramide Hydrochloride"",""Metoclopramidum [INN-Latin]"",""metoclopramide"""	Metoclopramide (reglan) is indicated as a short-term treatment for adults with gastroesophageal reflux who fail to respond to conventional therapy. The FDA-approved drug label for metoclopramide notes that patients with NADH-cytochrome b5 reductase deficiency have an increased risk of developing methemglobinemia and/or sulfhemoglobinemia when treated with metoclopramide.
157	PA166105195	metoclopramide	CYB5R1	PA134979668	cytochrome b5 reductase 1	NCBI Gene:51706	PA450475	"Metaclopramide,""Metaclopromide"",""Methochlopramide"",""Methoclopramide"",""Metochlopramide"",""Metoclopramida [INN-Spanish]"",""Metoclopramide Hcl"",""Metoclopramide Hydrochloride"",""Metoclopramidum [INN-Latin]"",""metoclopramide"""	Metoclopramide (reglan) is indicated as a short-term treatment for adults with gastroesophageal reflux who fail to respond to conventional therapy. The FDA-approved drug label for metoclopramide notes that patients with NADH-cytochrome b5 reductase deficiency have an increased risk of developing methemglobinemia and/or sulfhemoglobinemia when treated with metoclopramide.
158	PA166105195	metoclopramide	CYB5R2	PA142672060	cytochrome b5 reductase 2	NCBI Gene:51700	PA450475	"Metaclopramide,""Metaclopromide"",""Methochlopramide"",""Methoclopramide"",""Metochlopramide"",""Metoclopramida [INN-Spanish]"",""Metoclopramide Hcl"",""Metoclopramide Hydrochloride"",""Metoclopramidum [INN-Latin]"",""metoclopramide"""	Metoclopramide (reglan) is indicated as a short-term treatment for adults with gastroesophageal reflux who fail to respond to conventional therapy. The FDA-approved drug label for metoclopramide notes that patients with NADH-cytochrome b5 reductase deficiency have an increased risk of developing methemglobinemia and/or sulfhemoglobinemia when treated with metoclopramide.
159	PA166105195	metoclopramide	CYB5R4	PA134904907	cytochrome b5 reductase 4	NCBI Gene:51167	PA450475	"Metaclopramide,""Metaclopromide"",""Methochlopramide"",""Methoclopramide"",""Metochlopramide"",""Metoclopramida [INN-Spanish]"",""Metoclopramide Hcl"",""Metoclopramide Hydrochloride"",""Metoclopramidum [INN-Latin]"",""metoclopramide"""	Metoclopramide (reglan) is indicated as a short-term treatment for adults with gastroesophageal reflux who fail to respond to conventional therapy. The FDA-approved drug label for metoclopramide notes that patients with NADH-cytochrome b5 reductase deficiency have an increased risk of developing methemglobinemia and/or sulfhemoglobinemia when treated with metoclopramide.
160	PA166104783	rasburicase	CYB5R3	PA27331	cytochrome b5 reductase 3	NCBI Gene:1727	PA10176	"Urate oxidase,""Uricase"",""rasburicase"""	The FDA-approved drug label for rasburicase (Elitek) states that is unclear whether patients with NADH cytochrome b5 reductase (_CYB5R1, 2, 3, 4_) deficiency are at risk for methemoglobinemia or hemolytic anemia. It also states that patients at higher risk for G6PD deficiency, such as those of African or Mediterranean ancestry, should be screened prior to starting treatment, as rasburicase is contraindicated in patients with G6PD deficiency. 
161	PA166104894	rasburicase	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA10176	"Urate oxidase,""Uricase"",""rasburicase"""	The EMA European Public Assessment Report (EPAR) contraindicates the use of rasburicase (Fasturtec) in patients with G6PD deficiency due to a risk of hemolytic anemia or methemoglobinemia. Testing or screening for G6PD deficiency is not mentioned. 
162	PA166151881	rasburicase	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA10176	"Urate oxidase,""Uricase"",""rasburicase"""	The FDA-approved drug label for rasburicase (Elitek) states that patients at higher risk for G6PD deficiency, such as those of African or Mediterranean ancestry, should be screened prior to starting treatment, as rasburicase is contraindicated in patients with G6PD deficiency. The label also states that It is unclear whether patients with NADH cytochrome b5 reductase (_CYB5R1, 2, 3, 4_) deficiency are at risk for methemoglobinemia or hemolytic anemia. 
163	PA166127707	rasburicase	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA10176	"Urate oxidase,""Uricase"",""rasburicase"""	The product monograph for rasburicase (FASTURTEC) states that patients at higher risk for G6PD deficiency (e.g. those of African or Mediterranean ancestry) be screened prior to starting treatment, due to the risk of severe hemolytic anemia.
164	PA166123548	rasburicase	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA10176	"Urate oxidase,""Uricase"",""rasburicase"""	The PMDA package insert for rasburicase notes that foreign clinical studies have shown that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency can have severe hemolytic reactions when administered rasburicase, and patients should be carefully screened for a family history of G6PD deficiency or other red blood cell enzyme defects.
165	PA166104783	rasburicase	CYB5R1	PA134979668	cytochrome b5 reductase 1	NCBI Gene:51706	PA10176	"Urate oxidase,""Uricase"",""rasburicase"""	The FDA-approved drug label for rasburicase (Elitek) states that is unclear whether patients with NADH cytochrome b5 reductase (_CYB5R1, 2, 3, 4_) deficiency are at risk for methemoglobinemia or hemolytic anemia. It also states that patients at higher risk for G6PD deficiency, such as those of African or Mediterranean ancestry, should be screened prior to starting treatment, as rasburicase is contraindicated in patients with G6PD deficiency. 
166	PA166104783	rasburicase	CYB5R2	PA142672060	cytochrome b5 reductase 2	NCBI Gene:51700	PA10176	"Urate oxidase,""Uricase"",""rasburicase"""	The FDA-approved drug label for rasburicase (Elitek) states that is unclear whether patients with NADH cytochrome b5 reductase (_CYB5R1, 2, 3, 4_) deficiency are at risk for methemoglobinemia or hemolytic anemia. It also states that patients at higher risk for G6PD deficiency, such as those of African or Mediterranean ancestry, should be screened prior to starting treatment, as rasburicase is contraindicated in patients with G6PD deficiency. 
167	PA166104783	rasburicase	CYB5R4	PA134904907	cytochrome b5 reductase 4	NCBI Gene:51167	PA10176	"Urate oxidase,""Uricase"",""rasburicase"""	The FDA-approved drug label for rasburicase (Elitek) states that is unclear whether patients with NADH cytochrome b5 reductase (_CYB5R1, 2, 3, 4_) deficiency are at risk for methemoglobinemia or hemolytic anemia. It also states that patients at higher risk for G6PD deficiency, such as those of African or Mediterranean ancestry, should be screened prior to starting treatment, as rasburicase is contraindicated in patients with G6PD deficiency. 
168	PA166127702	primaquine	CYB5R3	PA27331	cytochrome b5 reductase 3	NCBI Gene:1727	PA451103		The product monograph for primaquine states that caution should be used in individuals with glucose-6-phosphate dehydrogenase (_G6PD_) deficiency or NADH methemoglobin reductase (_CYB5R1-4_) deficiency due to the risk of hemolytic anemia and methemoglobinemia, respectively.
169	PA166127702	primaquine	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451103		The product monograph for primaquine states that caution should be used in individuals with glucose-6-phosphate dehydrogenase (_G6PD_) deficiency or NADH methemoglobin reductase (_CYB5R1-4_) deficiency due to the risk of hemolytic anemia and methemoglobinemia, respectively.
170	PA166104876	primaquine	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451103		Primaquine is used to prevent vivax malaria relapse.  Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency who are treated with primaquine are at risk of moderate to severe hemolytic reactions. Patients with cytochrome b5 reductase deficiency (CYB5R3, also known as NADH methemoglobin reductase) who are treated with primaquine are at risk of methemoglobinemia. 
171	PA166127702	primaquine	CYB5R1	PA134979668	cytochrome b5 reductase 1	NCBI Gene:51706	PA451103		The product monograph for primaquine states that caution should be used in individuals with glucose-6-phosphate dehydrogenase (_G6PD_) deficiency or NADH methemoglobin reductase (_CYB5R1-4_) deficiency due to the risk of hemolytic anemia and methemoglobinemia, respectively.
172	PA166127702	primaquine	CYB5R2	PA142672060	cytochrome b5 reductase 2	NCBI Gene:51700	PA451103		The product monograph for primaquine states that caution should be used in individuals with glucose-6-phosphate dehydrogenase (_G6PD_) deficiency or NADH methemoglobin reductase (_CYB5R1-4_) deficiency due to the risk of hemolytic anemia and methemoglobinemia, respectively.
173	PA166127702	primaquine	CYB5R4	PA134904907	cytochrome b5 reductase 4	NCBI Gene:51167	PA451103		The product monograph for primaquine states that caution should be used in individuals with glucose-6-phosphate dehydrogenase (_G6PD_) deficiency or NADH methemoglobin reductase (_CYB5R1-4_) deficiency due to the risk of hemolytic anemia and methemoglobinemia, respectively.
174	PA166105232	quinine	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451213	"6'-Methoxycinchonidine,""6'-Methoxycinchonine"",""Quinine sulfate"",""Quinine, Anhydrous"",""Quinineanhydrous"",""Quinoline Alkaloid"""	The FDA-approved drug label for quinine (QUALAQUIN) states that it is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolysis. G6PD deficiency is a condition caused by variants in the _G6PD_ gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.
175	PA166127705	quinine	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451213	"6'-Methoxycinchonidine,""6'-Methoxycinchonine"",""Quinine sulfate"",""Quinine, Anhydrous"",""Quinineanhydrous"",""Quinoline Alkaloid"""	The product monograph for quinine states that it is contraindicated in patients with G6PD deficiency. However, it makes no statements regarding testing for G6PD deficiency prior to treatment.
176	PA166105232	quinine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451213	"6'-Methoxycinchonidine,""6'-Methoxycinchonine"",""Quinine sulfate"",""Quinine, Anhydrous"",""Quinineanhydrous"",""Quinoline Alkaloid"""	The FDA-approved drug label for quinine (QUALAQUIN) states that it is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolysis. G6PD deficiency is a condition caused by variants in the _G6PD_ gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.
177	PA166120370	glimepiride	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA449761	"Glimepirid,""Glimepirida"",""Glimepiridum"",""Glimepride"""	The EMA European Public Assessment Report (EPAR) for pioglitazone and glimepiride (Tandemact) states that caution should be taken in patients with G6PD deficiency as glimepiride is a sulfonylurea agent and a non-sulfonylurea alternative should be considered. 
178	PA166105147	glimepiride	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA449761	"Glimepirid,""Glimepirida"",""Glimepiridum"",""Glimepride"""	The FDA-approved drug label for glimepiride (AMARYL) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients. G6PD deficiency is a condition caused by variants in the _G6PD_ gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.
179	PA166127678	glimepiride	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA449761	"Glimepirid,""Glimepirida"",""Glimepiridum"",""Glimepride"""	Glimepiride (AMARYL) belongs to a class of drugs known as sulfonylurea agents. The product monograph for glimepiride states that caution should be used when administering this drug to patients with G6PD deficiency due to the risk for hemolytic anemia, and that a nonsulfonylurea agent should be considered in these individuals.
180	PA166121327	pegloticase	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA165963961	"885051-90-1,""D09316"""	The EMA European Public Assessment Report (EPAR) for pegloticase (Krystexxa) states that screening in patients at higher risk for G6PD deficiency should be carried out prior to pegloticase treatment. It is contraindicated in these patients due to a higher risk of hemolysis and methemoglobinemia.
181	PA166104900	pegloticase	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA165963961	"885051-90-1,""D09316"""	Pegloticase is used to treat chronic gout.  Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency who are treated with pegloticase are at risk of hemolysis and methemoglobinemia. Pegloticase is contraindicated for such patients. 
182	PA166104786	chloroquine	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA448948	"Chloraquine,""Chlorochine"",""Chloroquina"",""Chloroquine Phosphate"",""Chloroquinium"",""Chlorquin"",""Clorochina"",""Hydroxychloroquine Sulfate"""	The FDA-approved drug label for chloroquine (Aralan) states caution should be taken when administering treatment to G6PD deficient individuals due to the possibility of hematological effects. G6PD deficiency is a condition caused by variants in the _G6PD_ gene which can be determined by enzymatic or genetic tests, however  the drug label does not specifically mention testing.
183	PA166114910	chlorpropamide	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA448966	chlorporpamide	The FDA-approved drug label for chlorpropamide (DIABINESE) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients. G6PD deficiency is a condition caused by variants in the _G6PD_ gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.
184	PA166127649	chlorpropamide	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA448966	chlorporpamide	The product monograph for chlorpropamide notes that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients. G6PD deficiency is a condition caused by variants in the G6PD gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.
185	PA166114913	dabrafenib	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA166114911		The drug label for dabrafenib (TAFINLAR) states that it is indicated for use in patients with unresectable or metastatic melanoma with a BRAF V600E mutation, as detected by an FDA-approved test. The label also notes that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency have a risk for developing hemolytic anemia, and that these patients should be closely observed when taking dabrafenib. 
186	PA166119826	dabrafenib	BRAF	PA25408	B-Raf proto-oncogene, serine/threonine kinase	NCBI Gene:673	PA166114911		Dabrafenib (Tafinlar) is indicated in adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation due to its mechanism of action as an inhibitor of RAF kinases. The EMA European Public Assessment Report (EPAR) states that testing for tumor BRAF V600 mutations is required as efficacy and safety of dabrafenib has not been established in patients with wildtype BRAF.
187	PA166114912	dabrafenib	BRAF	PA25408	B-Raf proto-oncogene, serine/threonine kinase	NCBI Gene:673	PA166114911		The drug label for dabrafenib (TAFINLAR) states that it is indicated for use in patients with unresectable or metastatic melanoma with a BRAF V600E mutation, or in combination with trametinib for patients with the V600K mutation, as detected by an FDA-approved test; the drug is not indicated for treatment of patients with wild-type BRAF melanoma.
188	PA166127656	dabrafenib	BRAF	PA25408	B-Raf proto-oncogene, serine/threonine kinase	NCBI Gene:673	PA166114911		The product monograph for dabrafenib (TAFINLAR) states that it is indicated for treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. 
189	PA166104845	dapsone	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA449211	"Acedapsone,""DADPS"",""DDS"",""DSS"",""Dapson"",""Dapsonum"",""Dds, Diaphenylsulfone"",""Dds, Pharmaceutical"",""Diamino-diphenyl sulphone"",""Diaminodifenilsulfona"",""Diaminodiphenyl Sulfone"",""Diaphenylsulfon"",""Diaphenylsulfone"",""Diaphenylsulphon"",""Diaphenylsulphone"",""Diphenasone"",""Metabolite C"",""N, N'-Diphenyl Sulfondiamide"",""P, P'-Sulfonyldianiline"",""P,P'-Diaminodiphenyl Sulfone"",""P,P-Diaminodiphenyl Sulphone"",""P,P-Sulfonylbisbenzamine"",""P,P-Sulfonylbisbenzenamine"",""P,P-Sulphonylbisbenzamine"",""P,P-Sulphonylbisbenzenamine"",""P,P-Sulphonyldianiline"",""P-Aminophenyl Sulfone"",""Sulfonyldianiline"",""Sulphadione"",""Sulphonyldianiline"",""dapsone"""	The FDA-approved label for dapsone gel provides a precautionary warning that G6PD deficient individuals may be at an increased risk of hemolytic adverse reactions, as oral dapsone treatment is associated with dose-related hemolysis and hemolytic anemia in these individuals. This enzyme deficiency is due to underlying genetic variants in the G6PD gene and can be tested for by enzyme activity or genetic tests.
190	PA166127657	dapsone	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA449211	"Acedapsone,""DADPS"",""DDS"",""DSS"",""Dapson"",""Dapsonum"",""Dds, Diaphenylsulfone"",""Dds, Pharmaceutical"",""Diamino-diphenyl sulphone"",""Diaminodifenilsulfona"",""Diaminodiphenyl Sulfone"",""Diaphenylsulfon"",""Diaphenylsulfone"",""Diaphenylsulphon"",""Diaphenylsulphone"",""Diphenasone"",""Metabolite C"",""N, N'-Diphenyl Sulfondiamide"",""P, P'-Sulfonyldianiline"",""P,P'-Diaminodiphenyl Sulfone"",""P,P-Diaminodiphenyl Sulphone"",""P,P-Sulfonylbisbenzamine"",""P,P-Sulfonylbisbenzenamine"",""P,P-Sulphonylbisbenzamine"",""P,P-Sulphonylbisbenzenamine"",""P,P-Sulphonyldianiline"",""P-Aminophenyl Sulfone"",""Sulfonyldianiline"",""Sulphadione"",""Sulphonyldianiline"",""dapsone"""	The product monograph for dapsone (ACZONE) notes that oral dapsone treatment can result in hemolysis and hemolytic anemia, particularly in patients who are glucose-6-phosphate dehydrogenase (G6PD)-deficient. However, for this topical formulation of the drug, a study showed no clinically relevant cases of hemolysis or anemia in G6PD-deficient individuals. 
191	PA166104895	erythromycin	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA449493	"EM,""Erythrocin"",""Erythrocin Stearate"",""Erythromycin Stearate"",""Erythromycin estolate"",""Erythromycin ethylsuccinate"",""Erythromycin glucoheptonate"",""Erythromycin lactobionate"",""Erythromycin oxime"""	Erythromycin ethylsuccinate and sulfisoxazole acetyl is used to treat acute otitis media in children caused by certain strains of _Haemophilus influenzae_.  The label warns that hemolysis may occur in G6PD deficient patients on this drug.
192	PA166127717	erythromycin	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA449493	"EM,""Erythrocin"",""Erythrocin Stearate"",""Erythromycin Stearate"",""Erythromycin estolate"",""Erythromycin ethylsuccinate"",""Erythromycin glucoheptonate"",""Erythromycin lactobionate"",""Erythromycin oxime"""	The product monograph for erythromycin and sulfisoxazole states that it is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, due to the risk for hemolysis. However, the monograph does not discuss testing for G6PD deficiency prior to treatment.
193	PA166104895	sulfisoxazole	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA164748964	"Sulfadimethylisoxazole,""Sulfafurazol"",""Sulfafurazole"",""Sulfaisoxazole"",""Sulfasoxazole"",""Sulfisonazole"",""Sulfisoxasole"",""Sulfisoxazol"",""Sulfisoxazole Dialamine"",""Sulfisoxazole Diolamine"",""Sulfofurazole"",""Sulphafurazol"",""Sulphafurazole"",""Sulphafurazolum"",""Sulphaisoxazole"",""Sulphisoxazol"",""Sulphofurazole"""	Erythromycin ethylsuccinate and sulfisoxazole acetyl is used to treat acute otitis media in children caused by certain strains of _Haemophilus influenzae_.  The label warns that hemolysis may occur in G6PD deficient patients on this drug.
194	PA166127717	sulfisoxazole	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA164748964	"Sulfadimethylisoxazole,""Sulfafurazol"",""Sulfafurazole"",""Sulfaisoxazole"",""Sulfasoxazole"",""Sulfisonazole"",""Sulfisoxasole"",""Sulfisoxazol"",""Sulfisoxazole Dialamine"",""Sulfisoxazole Diolamine"",""Sulfofurazole"",""Sulphafurazol"",""Sulphafurazole"",""Sulphafurazolum"",""Sulphaisoxazole"",""Sulphisoxazol"",""Sulphofurazole"""	The product monograph for erythromycin and sulfisoxazole states that it is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, due to the risk for hemolysis. However, the monograph does not discuss testing for G6PD deficiency prior to treatment.
195	PA166104881	glibenclamide	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA449782	"Apo-Glibenclamide,""Glibenclamida [INN-Spanish]"",""Glibenclamidum [INN-Latin]"",""Glyburide"",""glibenclamide"""	Although the glibenclamide (glyburide; GLYNASE PresTab) drug label does not specifically mention genetic testing, the FDA highlight precaution labeling prior to initiating treatment with glibenclamide for G6PD deficient individuals due to risk of hemolytic anemia. Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia; caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered.
196	PA166127677	glibenclamide	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA449782	"Apo-Glibenclamide,""Glibenclamida [INN-Spanish]"",""Glibenclamidum [INN-Latin]"",""Glyburide"",""glibenclamide"""	"Glibenclamide (glyburide; GLYBE) belongs to a class of drugs known as sulfonylurea agents. The product monograph for glibenclamide states that caution should be used when administering this drug to patients with G6PD deficiency due to the risk for hemolytic anemia, and that a nonsulfonylurea agent should be considered in these individuals.

"
197	PA166105148	glipizide	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA449762	"Glipizida [INN-Spanish],""Glipizidum [INN-Latin]"",""Glydiazinamide"""	The FDA-approved drug label for glipizide (GLUCOTROL) states that caution should be used in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency due to the risk for hemolytic anemia, and that a non-sulfonylurea alternative should be considered in this subset of patients. G6PD deficiency is a condition caused by variants in the _G6PD_ gene which can be determined by enzymatic or genetic tests, however the drug label does not specifically mention testing.
198	PA166114926	mafenide	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA166114925		"The FDA-approved drug label for mafenide (SULFAMYLON) mentions that fatal hemolytic anemia with disseminated intravascular coagulation has been reported following treatment with SULFAMYLON cream, possibly due to a glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD deficiency is a condition caused by variants in the _G6PD_ gene which can be determined by enzymatic or genetic tests. However, the drug label does not specifically mention testing.

"
199	PA166104891	nalidixic acid	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA164746384		Nalidixic acid is used to treat urinary tract infections due to gram-negative bacteria.  Although the nalidixic acid (NegGram) drug label does not specifically mention genetic testing, the FDA highlight precaution labeling prior to initiating treatment with nalidixic acid for G6PD deficient individuals due to an association with hemolytic anemia.
200	PA166104903	nitrofurantoin	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA450640		Nitrofurantion is used to treat urinary tract infections caused by certain strains of bacteria.  A link between nitrofurantoin-induced hemolytic anemia and G6PD deficiency is highlighted in the Warnings section. Hemolysis appears to be linked to a glucose-6-phosphate dehydrogenase deficiency in the red blood cells of the affected patients.
201	PA166127694	nitrofurantoin	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA450640		The product monograph for nitrofurantoin states that individuals with a glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at risk for hemolytic anemia when receiving the drug, and that it should be discontinued if the patient exhibits signs of hemolysis.
202	PA166104885	norfloxacin	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA450654		Norfloxacin is used to treat urinary tract infections, sexually transmitted diseases and prostatitis caused by certain microorganisms.  The label reports hemolytic reactions have been seen in G6PD deficient individuals in association with this drug.
203	PA166127696	norfloxacin	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA450654		The product monograph for norfloxacin states that hemolytic reactions have occurred in patients with glucose-6-phosphate dehydrogenase deficiency.
204	PA166104906	probenecid	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451106	probenicid	Probenecid is used to treat chronic gouty arthritis.  An association between probenecid-induced hemolytic anemia and G6PD deficiency is highlighted in the Adverse Reactions section of the probenecid label.
205	PA166115362	sodium nitrite	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA166115361		Sodium nitrite is intended for sequential use with sodium thiosulfate, in order to treat acute and life-threatening cyanide poisoning. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency who are treated with sodium nitrite are at risk for a hemolytic crisis. Alternative treatments should be considered in these individuals, or they should be monitored for an acute drop in hematocrit. G6PD deficiency is a condition caused by variants in the _G6PD_ gene which can be determined by enzymatic or genetic tests. However, the drug label does not specifically mention testing
206	PA166129528	sodium nitrite	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA166115361		Sodium nitrite is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning judged to be life-threatening. Patients with G6PD deficiency are at increased risk for hemolytic crisis when administered sodium nitrite; the product monograph notes that alternative therapeutic approaches should be considered in these patients. G6PD deficiency is a condition caused by variants in the _G6PD_ gene which can be determined by enzymatic or genetic tests. However, the drug label does not specifically mention testing
207	PA166115363	succimer	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451521	"DMSA,""Dimercaptosuccinic acid"""	Succimer (CHEMET) is used for treating lead poisoning in pediatric patients with blood lead levels greater than 45 mcg/dL. The drug label notes that succimer has been used to treat five patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency without any adverse reactions.
208	PA166104902	sulfadiazine	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451539	"SDA,""Sulfadiazene"",""Sulfadiazin"",""Sulfanilamidopyrimidine"",""Sulfapirimidin"",""Sulfapyrimidin"",""Sulfapyrimidine"",""Sulphadiazine"""	Sulfadiazine is an antimicrobial topical drug used to prevent and treat wound sepsis in second and third degree burns.  A link between sulfadiazine-induced hemolytic anemia and G6PD deficiency is highlighted in the Warnings section of the label.
209	PA166127714	sulfadiazine	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451539	"SDA,""Sulfadiazene"",""Sulfadiazin"",""Sulfanilamidopyrimidine"",""Sulfapirimidin"",""Sulfapyrimidin"",""Sulfapyrimidine"",""Sulphadiazine"""	The product monograph for sulfadiazine states that it should be used in caution in patients who are deficient for glucose-6-phosphate dehydrogenase (G6PD) due to the risk for hemolysis. However, the monograph makes no mention of testing for G6PD deficiency prior to treatment.
210	PA166104874	sulfamethoxazole	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451544		Sulfamethoxazole and trimethoprim is used to prevent and treat infections caused by certain bacteria. The label warns that hemolysis may occur in G6PD deficient individuals.
211	PA166127715	sulfamethoxazole	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451544		The product monograph for sulfamethoxazole and trimethoprim (SULFATRIM) states that hemolysis may occur in individuals taking the drug who are deficient in glucose-6-phosphate dehydrogenase (G6PD). However, it does not make any statements regarding testing for G6PD deficiency prior to treatment.
212	PA166104874	trimethoprim	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451788		Sulfamethoxazole and trimethoprim is used to prevent and treat infections caused by certain bacteria. The label warns that hemolysis may occur in G6PD deficient individuals.
213	PA166127715	trimethoprim	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451788		The product monograph for sulfamethoxazole and trimethoprim (SULFATRIM) states that hemolysis may occur in individuals taking the drug who are deficient in glucose-6-phosphate dehydrogenase (G6PD). However, it does not make any statements regarding testing for G6PD deficiency prior to treatment.
214	PA166104892	sulfasalazine	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451547	"Sulfasalazin,""Sulphasalazine"""	Sulfasalazine is used to treat and prolong remission for ulcerative colitis.  The label warns that people with G6PD are susceptible to hemolytic anemia on this drug.
215	PA166127716	sulfasalazine	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451547	"Sulfasalazin,""Sulphasalazine"""	The product monograph for sulfasalazine (SALAZOPYRIN) notes that patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency should be closely monitored for signs of hemolytic anemia when receiving the drug. However, no statement is made regarding testing for G6PD deficiency prior to treatment.
216	PA166104897	vitamin c	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451898	"AA,""Ascorbate"",""Ascorbic Acid"",""L-Ascorbate"",""L-Ascorbic Acid"",""L-Lyxoascorbic Acid"",""L-Xyloascorbic Acid"""	MoviPrep, a solution containing Vitamin C, is a laxative used for colon cleansing in preparation for a colonoscopy.  Because it contains Vitamin C (ascorbic acid), the label warns that hemolytic reactions are possible in those with G6PD deficiency.
217	PA166127729	vitamin c	G6PD	PA28469	glucose-6-phosphate dehydrogenase	NCBI Gene:2539	PA451898	"AA,""Ascorbate"",""Ascorbic Acid"",""L-Ascorbate"",""L-Ascorbic Acid"",""L-Lyxoascorbic Acid"",""L-Xyloascorbic Acid"""	MoviPrep, a solution containing Vitamin C, is a laxative used for colon cleansing in preparation for a colonoscopy. Because it contains Vitamin C (ascorbic acid), the label warns that hemolytic reactions are possible in those with G6PD deficiency.
218	PA166129450	trametinib	BRAF	PA25408	B-Raf proto-oncogene, serine/threonine kinase	NCBI Gene:673	PA166115364		The EMA European Public Assessment Report (EPAR) for trametinib (Mekinist) states that it is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected using a validated test.
219	PA166115365	trametinib	BRAF	PA25408	B-Raf proto-oncogene, serine/threonine kinase	NCBI Gene:673	PA166115364		The drug label for trametinib (MEKINIST) states that it is indicated for use in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test. 
220	PA166127722	trametinib	BRAF	PA25408	B-Raf proto-oncogene, serine/threonine kinase	NCBI Gene:673	PA166115364		The product monograph for trametinib (MEKINIST) states that it is indicated for patients with unresectable or metastatic melanoma with a BRAF V600 mutation. 
221	PA166114482	vemurafenib	BRAF	PA25408	B-Raf proto-oncogene, serine/threonine kinase	NCBI Gene:673	PA165946873	PLX4032	The EMA European Public Assessment Report (EPAR) for vemurafenib (Zelboraf) requires testing of tumours for the BRAF V600 mutation prior to initiating treatment.
222	PA166104858	vemurafenib	BRAF	PA25408	B-Raf proto-oncogene, serine/threonine kinase	NCBI Gene:673	PA165946873	PLX4032	Vemurafenib is a kinase inhibitor used to treat patients with unresectable or metastatic melanoma ONLY in cases where the BRAF V600E mutation is found by an FDA-approved test.  _In vitro_ evidence points to BRAF wild-type cells proliferation with exposure to BRAF inhibitors.  Therefore, testing is required.
223	PA166127728	vemurafenib	BRAF	PA25408	B-Raf proto-oncogene, serine/threonine kinase	NCBI Gene:673	PA165946873	PLX4032	The product monograph for vemurafenib (ZELBORAF) states that it is indicated for the treatment of patients with BRAF V600 mutation-positive melanoma, and that it should not be used in patients with BRAF wild-type melanoma.
224	PA166160045	cobimetinib	BRAF	PA25408	B-Raf proto-oncogene, serine/threonine kinase	NCBI Gene:673	PA166160044		The FDA-approved drug label for cobimetinib (COTELLIC) states that it is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.
225	PA166160046	cobimetinib	BRAF	PA25408	B-Raf proto-oncogene, serine/threonine kinase	NCBI Gene:673	PA166160044		The FDA-approved drug label for cobimetinib (COTELLIC) states that it is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.
226	PA166160121	nivolumab	BRAF	PA25408	B-Raf proto-oncogene, serine/threonine kinase	NCBI Gene:673	PA166129522		The FDA-approved drug label for nivolumab (OPDIVO) states that it is indicated for the treatment of patients with BRAF V600 wild-type or BRAF V600 mutation-positive unresectable or metastatic melanoma as a single agent, among other indications. Nivolumab works by blocking the interaction between PD-L1 (_CD274_) and PD-L2.
227	PA166160121	nivolumab	CD274	PA134915280	CD274 molecule	NCBI Gene:29126	PA166129522		The FDA-approved drug label for nivolumab (OPDIVO) states that it is indicated for the treatment of patients with BRAF V600 wild-type or BRAF V600 mutation-positive unresectable or metastatic melanoma as a single agent, among other indications. Nivolumab works by blocking the interaction between PD-L1 (_CD274_) and PD-L2.
228	PA166160009	pembrolizumab	BRAF	PA25408	B-Raf proto-oncogene, serine/threonine kinase	NCBI Gene:673	PA166124615		The FDA-approved drug label for KEYTRUDA (pembrolizumab) states that it is indicated for the treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (_CD274_) as detected by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy. The label also mentions BRAF V600 mutations.
229	PA166160009	pembrolizumab	CD274	PA134915280	CD274 molecule	NCBI Gene:29126	PA166124615		The FDA-approved drug label for KEYTRUDA (pembrolizumab) states that it is indicated for the treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (_CD274_) as detected by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy. The label also mentions BRAF V600 mutations.
230	PA166159964	olaparib	BRCA1	PA25411	breast cancer 1, early onset	NCBI Gene:672	PA164920420		The FDA-approved drug label for olaparib (Lynparza) states that it is indicated for treatment of patients with advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy, and have deleterious or suspected deleterious germline _BRCA_ mutatations as detected by an FDA-approved test.
231	PA166159964	olaparib	BRCA2	PA25412	breast cancer 2, early onset	NCBI Gene:675	PA164920420		The FDA-approved drug label for olaparib (Lynparza) states that it is indicated for treatment of patients with advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy, and have deleterious or suspected deleterious germline _BRCA_ mutatations as detected by an FDA-approved test.
232	PA166160040	Parathyroid Hormones And Analogues	CASR	PA26097	calcium-sensing receptor	NCBI Gene:846	PA164713150	Parathyroid hormones and analogues	The FDA-approved drug label for NATPARA (parathyroid hormone) states that it was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor (_CASR_) mutations.
233	PA166104924	maraviroc	CCR5	PA26170	chemokine (C-C motif) receptor 5 (gene/pseudogene)	NCBI Gene:1234	PA164768835	maraviroc	The drug labeling for maraviroc is not related to genetic testing of the patient, rather testing of the HIV-1 strain that has infected the patient. The EMA European Public Assessment Report (EPAR) for Maraviroc (CELSENTRI) contains information regarding its indication only in patients with CCR5-tropic HIV-1 and not CXCR4- or dual/mixed tropic virus, due to its mechanism of action as a CCR5 antagonist.
234	PA166104803	maraviroc	CCR5	PA26170	chemokine (C-C motif) receptor 5 (gene/pseudogene)	NCBI Gene:1234	PA164768835	maraviroc	The drug labeling for maraviroc is not related to genetic testing of the patient, rather testing of the HIV-1 strain that has infected the patient. The FDA-approved label states that HIV tropism testing be carried out before treatment with Maraviroc. This drug is indicated only for CCR5-tropic HIV-1 infection, and due to its mechanism of action, is not effective against CXCR4-tropic and dual-tropic HIV-1.
235	PA166127689	maraviroc	CCR5	PA26170	chemokine (C-C motif) receptor 5 (gene/pseudogene)	NCBI Gene:1234	PA164768835	maraviroc	The product monograph for maraviroc contains information related to testing of the HIV-1 strain that has infected the patient. The product monograph states maraviroc is indicated for CCR5-tropic HIV-1 infection, and is not recommended in CXCR4-tropic or dual/mixed-tropic HIV-1 infection due to lack of efficacy.
236	PA166104928	ivacaftor	CFTR	PA109	cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)	NCBI Gene:1080	PA165950341	"ivacaftor,""vx-770"""	The EMA European Public Assessment Report (EPAR) contains pharmacogenetic information regarding the indication of ivacaftor (Kalydeco) in cystic fibrosis patients who have one of the following variants in the _CFTR_ gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R. Treatment in patients who do not have one of these variants is not recommended, and if a patient's genotype is not known, testing should be carried out before treatment. 
237	PA166104890	ivacaftor	CFTR	PA109	cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)	NCBI Gene:1080	PA165950341	"ivacaftor,""vx-770"""	"Ivacaftor is indicated in patients with cystic fibrosis (CF) who have one of the following variants in the CFTR gene: G551D ([variant:rs75527207]), G1244E ([variant:rs267606723]), G1349D ([variant:rs193922525]), G178R ([variant:rs80282562]), G551S ([variant:rs121909013]), S1251N ([variant:rs74503330]), S1255P ([variant:rs121909041]), S549N ([variant:rs121908755]), S549R ([variant:rs121908757] and [variant:rs121909005]) or R117H ([variant:rs78655421]). Genetic testing is required prior to initiating treatment with Ivacaftor if a patient's CFTR genotype is not known. The label also states that ivacaftor is not effective in patients homozygous for the F508del variant ([variant:rs113993960] and [variant:rs199826652]). 

"
238	PA166127684	ivacaftor	CFTR	PA109	cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)	NCBI Gene:1080	PA165950341	"ivacaftor,""vx-770"""	Ivacaftor (KALYDECO) is indicated in cystic fibrosis patients 6 years and older who have one of the following variants in CFTR: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R or G970R, or in patients 18 years and older with the R117H variant. The product monograph also states that ivacaftor is not effective in patients homozygous for the F508del variant.
239	PA166152939	ivacaftor / lumacaftor	CFTR	PA109	cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)	NCBI Gene:1080	PA166152935		The FDA-approved drug label for ivacaftor and lumacaftor combination (ORKAMBI) states that it is indicated for treatment of cystic fibrosis in patients age 12 years and older who are homozygous for the _F508del_ mutation (rs113993960) in the _CFTR_ gene.
240	PA166124618	abiraterone	CYP17A1	PA27090	cytochrome P450, family 17, subfamily A, polypeptide 1	NCBI Gene:1586	PA166123407		The FDA-approved drug label for abiraterone (ZYTIGA) states that it is indicated for use in patients with metastatic castration-resistant prostate cancer, and is a CYP17 inhibitor. 
241	PA166104915	olanzapine	CYP1A2	PA27093	cytochrome P450, family 1, subfamily A, polypeptide 2	NCBI Gene:1544	PA450688	olanzapine	The EMA European Public Assessment Report (EPAR) for olanzapine (Zalasta) contains information regarding the metabolism of the drug by the enzymes CYP1A2 and CYP2D6: factors that induce or inhibit CYP1A2 may alter the concentration of olanzapine and thus may require dosage monitoring. The EPAR does not mention pharmacogenetics or testing of genetic variants in these genes.
242	PA166104915	olanzapine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA450688	olanzapine	The EMA European Public Assessment Report (EPAR) for olanzapine (Zalasta) contains information regarding the metabolism of the drug by the enzymes CYP1A2 and CYP2D6: factors that induce or inhibit CYP1A2 may alter the concentration of olanzapine and thus may require dosage monitoring. The EPAR does not mention pharmacogenetics or testing of genetic variants in these genes.
243	PA166104788	olanzapine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA450688	olanzapine	Symbyax, a drug mixture of fluoxetine and olanzapine, is used for the treatment of bipolar disorder and treatment resistant depression and, due to its potent CYP2D6 inhibition as a result of fluoxetine, exhibits drug interactions with other medications also metabolized by CYP2D6. Coadministration with other drugs that are metabolized by CYP2D6 should be approached with caution.
244	PA166104852	citalopram	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA449015	"Citalopram Hydrobromide,""Citalopramum [INN-Latin]"""	The FDA-approved drug label recommends a maximum dose of 20 mg/day of citalopram (Celexa) in patients who are CYP2C19 poor metabolizers, due to an increase in citalopram exposure. This increased exposure leads to a greater risk for QT prolongation, a potentially fatal abnormality in the heart's electrical activity.
245	PA166104852	citalopram	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA449015	"Citalopram Hydrobromide,""Citalopramum [INN-Latin]"""	The FDA-approved drug label recommends a maximum dose of 20 mg/day of citalopram (Celexa) in patients who are CYP2C19 poor metabolizers, due to an increase in citalopram exposure. This increased exposure leads to a greater risk for QT prolongation, a potentially fatal abnormality in the heart's electrical activity.
246	PA166127650	citalopram	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA449015	"Citalopram Hydrobromide,""Citalopramum [INN-Latin]"""	The product monograph for citalopram recommends that patients who are CYP2C19 poor metabolizers receive an initial dose of 10 mg daily during the first two weeks of treatment, and should not receive a dose of greater than 20 mg/day. However, it makes no statements regarding genetic testing of CYP2C19 prior to treatment.
247	PA166104820	doxepin	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA449409	"Doxepin Hcl,""Doxepin, Hydrochloride"",""Doxepina [INN-Spanish]"",""Doxepine"",""Doxepinum [INN-Latin]"""	Doxepin is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6. The drug label notes that CYP2D6 and CYP2C19 poor metabolizers have higher than expected plasma concentrations of doxepin when given typical doses. Additionally, inhibitors of these CYP isozymes may increase the exposure of doxepin. 
248	PA166104820	doxepin	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA449409	"Doxepin Hcl,""Doxepin, Hydrochloride"",""Doxepina [INN-Spanish]"",""Doxepine"",""Doxepinum [INN-Latin]"""	Doxepin is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6. The drug label notes that CYP2D6 and CYP2C19 poor metabolizers have higher than expected plasma concentrations of doxepin when given typical doses. Additionally, inhibitors of these CYP isozymes may increase the exposure of doxepin. 
249	PA166105012	escitalopram	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA10074	"Cipralex,""Escitalopram Oxalate"",""escitalopram"""	The FDA-approved drug label for escitalopram (Lexapro) notes that escitalopram exposure under a supratherapeutic 30 mg dose is similar to the steady state concentrations expected in CYP2C19 poor metabolizers following a therapeutic dose of 20 mg. The label also comments on the relationship between CYP2D6 and escitalopram.
250	PA166105012	escitalopram	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA10074	"Cipralex,""Escitalopram Oxalate"",""escitalopram"""	The FDA-approved drug label for escitalopram (Lexapro) notes that escitalopram exposure under a supratherapeutic 30 mg dose is similar to the steady state concentrations expected in CYP2C19 poor metabolizers following a therapeutic dose of 20 mg. The label also comments on the relationship between CYP2D6 and escitalopram.
251	PA166153432	flibanserin	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA166153431		The FDA-approved drug label for flibanserin (ADDYI) states that poor metabolizers of CYP2C19 had increased exposure to the drug as compared to extensive metabolizers. One subject who was a poor metabolizer experienced syncope. The label also notes the influence of CYP2D6 and CYP2C9 on flibanserin exposure.
252	PA166153432	flibanserin	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA166153431		The FDA-approved drug label for flibanserin (ADDYI) states that poor metabolizers of CYP2C19 had increased exposure to the drug as compared to extensive metabolizers. One subject who was a poor metabolizer experienced syncope. The label also notes the influence of CYP2D6 and CYP2C9 on flibanserin exposure.
253	PA166153432	flibanserin	CYP2C9	PA126	cytochrome P450, family 2, subfamily C, polypeptide 9	NCBI Gene:1559	PA166153431		The FDA-approved drug label for flibanserin (ADDYI) states that poor metabolizers of CYP2C19 had increased exposure to the drug as compared to extensive metabolizers. One subject who was a poor metabolizer experienced syncope. The label also notes the influence of CYP2D6 and CYP2C9 on flibanserin exposure.
254	PA166104899	aripiprazole	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA10026	"OPC 31,""OPC-14597"",""aripiprazole"""	The EMA European Public Assessment Report (EPAR) recommends dose adjustments when aripiprazole is taken with CYP3A4 inhibitors in CYP2D6 poor metabolizers, or concomitant use of CYP3A4 or CYP2D6 inhibitors, or CYP3A4 inducers. 
255	PA166104839	aripiprazole	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA10026	"OPC 31,""OPC-14597"",""aripiprazole"""	The FDA-approved drug label for aripiprazole states that in CYP2D6 poor metabolizers, the dose should be reduced to 50% of the usual dose then adjusted to receive a favorable clinical response. Poor metabolizers who are given a strong CYP3A4 inhibitor should have their dose reduced by 25% of the usual dose. It also states that laboratory tests are available to identify CYP2D6 poor metabolizers.
256	PA166127631	aripiprazole	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA10026	"OPC 31,""OPC-14597"",""aripiprazole"""	The product monograph for aripiprazole (ABILIFY) notes that CYP2D6 poor metabolizers have approximately an 80% increase in aripiprazole exposure and approximately a 30% decrease in exposure to the active metabolite compared to CYP2D6 extensive metabolizers. 
257	PA166104899	aripiprazole	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA10026	"OPC 31,""OPC-14597"",""aripiprazole"""	The EMA European Public Assessment Report (EPAR) recommends dose adjustments when aripiprazole is taken with CYP3A4 inhibitors in CYP2D6 poor metabolizers, or concomitant use of CYP3A4 or CYP2D6 inhibitors, or CYP3A4 inducers. 
258	PA166122966	darifenacin	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA164774901	darifenacin	The EMA European Public Assessment Report (EPAR) for darifenacin (Emselex) contains information regarding differences in exposure to drug in patients who are CYP2D6 poor metabolizers compared to extensive metabolizers. Darifenacin is primarily metabolized by CYP3A4 in CYP2D6 poor metabolizers, therefore exposure to darifenacin may be greater in CYP2D6 poor metabolizers when CYP3A4 inhibitors are taken concomitantly. 
259	PA166122971	darifenacin	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA164774901	darifenacin	The FDA-approved drug label for darifenacin (Enablex) notes that CYP2D6 poor metabolizers may have increased maximum plasma concentrations of darifenacin, as compared to CYP2D6 extensive metabolizers. However, the label does not comment on the clinical significance of these increased concentrations.
260	PA166127659	darifenacin	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA164774901	darifenacin	The product monograph for darifenacin notes that CYP2D6 poor metabolizers may have higher levels of the drug as compared to extensive metabolizers. However, it also notes that there are no special dosing requirements for poor metabolizers. 
261	PA166119827	dextromethorphan	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA449273	"D-Methorphan,""D-Methorphan Hydrobromide"",""Delta-Methorphan"",""Demorphan"",""Demorphan Hydrobromide"",""Demorphine"",""Destrometerfano [Dcit]"",""Dextromethorfan [Czech]"",""Dextromethorphan Bromhydrate"",""Dextromethorphan Bromide"",""Dextrometorfano [INN-Spanish]"",""Dextrometorphan"",""Dextromorphan"",""Dexyromethorphan"",""L-Methorphan"",""Levomethorphan"",""Levomethorphan [Ban:Dcf:Inn]"",""Levomethorphane [INN-French]"",""Levomethorphanum [INN-Latin]"",""Levometorfano [INN-Spanish]"""	The EMA European Public Assessment Report (EPAR) for dextromethorphan and quinidine (Nuedexta) does not require dose adjustment based on CYP2D6 genotype. Efficacy is not expected to be affected in CYP2D6 poor metabolizers, however adverse reactions to quinidine are possible. Dextromethorphan is rapidly metabolized in CYP2D6 ultrametabolizers, and may result in subtherapeutic concentrations.
262	PA166104886	dextromethorphan	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA449273	"D-Methorphan,""D-Methorphan Hydrobromide"",""Delta-Methorphan"",""Demorphan"",""Demorphan Hydrobromide"",""Demorphine"",""Destrometerfano [Dcit]"",""Dextromethorfan [Czech]"",""Dextromethorphan Bromhydrate"",""Dextromethorphan Bromide"",""Dextrometorfano [INN-Spanish]"",""Dextrometorphan"",""Dextromorphan"",""Dexyromethorphan"",""L-Methorphan"",""Levomethorphan"",""Levomethorphan [Ban:Dcf:Inn]"",""Levomethorphane [INN-French]"",""Levomethorphanum [INN-Latin]"",""Levometorfano [INN-Spanish]"""	"The quinidine component of NUEDEXTA is a CYP2D6 inhibitor used to increase the plasma availability of dextromethorphan, which is metabolized by CYP2D6. Therefore, CYP2D6 poor metabolizers may be at risk of experiencing toxicity.

The label states, ""The quinidine component of NUEDEXTRA is not expected to contribute to the effectiveness of NUEDEXTA in PMs \[CYP2D6 poor metabolizers], but adverse events of the quinidine are still possible. In those patients who may be at risk of significant toxicity due to quinidine, genotyping to determine if they are PMs should be considered prior to making the decision to treat with NUEDEXTA."""
263	PA166119827	quinidine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451209	"Quinidine Gluconate,""Quinidine Sulfate"""	The EMA European Public Assessment Report (EPAR) for dextromethorphan and quinidine (Nuedexta) does not require dose adjustment based on CYP2D6 genotype. Efficacy is not expected to be affected in CYP2D6 poor metabolizers, however adverse reactions to quinidine are possible. Dextromethorphan is rapidly metabolized in CYP2D6 ultrametabolizers, and may result in subtherapeutic concentrations.
264	PA166104886	quinidine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451209	"Quinidine Gluconate,""Quinidine Sulfate"""	"The quinidine component of NUEDEXTA is a CYP2D6 inhibitor used to increase the plasma availability of dextromethorphan, which is metabolized by CYP2D6. Therefore, CYP2D6 poor metabolizers may be at risk of experiencing toxicity.

The label states, ""The quinidine component of NUEDEXTRA is not expected to contribute to the effectiveness of NUEDEXTA in PMs \[CYP2D6 poor metabolizers], but adverse events of the quinidine are still possible. In those patients who may be at risk of significant toxicity due to quinidine, genotyping to determine if they are PMs should be considered prior to making the decision to treat with NUEDEXTA."""
265	PA166104811	quinidine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451209	"Quinidine Gluconate,""Quinidine Sulfate"""	Quinidine inhibits the action of cytochrome P450IID6, effectively converting CYP2D extensive metabolizers into poor metabolizers. The drug label advises caution whenever quinidine is prescribed together with drugs metabolized by CYP2D6.
266	PA166123414	dronedarone	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA153619853		The EMA European Public Assessment Report (EPAR) for dronedarone (MULTAQ) states that it is a mild inhibitor of CYP2D6, and that the effect on metoprolol and propranol exposure is much below the difference seen between poor and extensive CYP2D6 metabolisers. It also contains information regarding metabolism of by dronedarone CYP3A4, and that concomitant drugs that are potent CYP3A4 inhibitors are contraindicated and potent CYP3A4 inducers are not recommended.
267	PA166123414	dronedarone	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA153619853		The EMA European Public Assessment Report (EPAR) for dronedarone (MULTAQ) states that it is a mild inhibitor of CYP2D6, and that the effect on metoprolol and propranol exposure is much below the difference seen between poor and extensive CYP2D6 metabolisers. It also contains information regarding metabolism of by dronedarone CYP3A4, and that concomitant drugs that are potent CYP3A4 inhibitors are contraindicated and potent CYP3A4 inducers are not recommended.
268	PA166129447	eliglustat	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA166123486		The EMA European Public Assessment Report (EPAR) for eliglustat (Cerdelga) states that it is indicated for adults with Gaucher disease type 1. CYP2D6 intermediate and extensive metabolizers have a recommended dose of 84 mg twice daily, while poor metabolizers have a recommended dose of 84 mg once daily. The label notes that eliglustat should not be used in patients who are CYP2D6 ultra-rapid metabolizers or indeterminate metabolizers. 
269	PA166123487	eliglustat	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA166123486		The FDA-approved drug label for eliglustat (CERDELGA) states that it is indicated for patients with Gaucher disease type 1. CYP2D6 intermediate and extensive metabolizers have a recommended dose of 84 mg twice daily, while poor metabolizers have a recommended dose of 84 mg once daily. The label notes that CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations of eliglustat to achieve a therapeutic effect.
270	PA166122967	fesoterodine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA165958376		The EMA European Public Assessment Report (EPAR) for fesoterodine (Toviaz) contains information regarding differences in exposure to drug in patients who are CYP2D6 poor metabolizers compared to extensive metabolizers. Exposure to fesoterodine may be greater in CYP2D6 poor metabolizers, particularly when CYP3A4 inhibitors are taken concomitantly.
271	PA166122972	fesoterodine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA165958376		The FDA-approved drug label for fesoterodine (Toviaz) notes that CYP2D6 poor metabolizers may have increased maximum plasma concentrations of the active metabolite of fesoterodine, as compared to CYP2D6 extensive metabolizers. However, the label does not comment on the clinical significance of these increased concentrations.
272	PA166127673	fesoterodine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA165958376		The product monograph for fesoterodine (TOVIAZ) states that CYP2D6 poor metabolizers have increased levels of the active metabolite of the drug as compared to extensive metabolizers. However, it makes no statements regarding genetic testing of CYP2D6.
273	PA166104930	gefitinib	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA131301952	"ZD-1839,""ZD1839"""	The EMA European Public Assessment Report (EPAR) contains biomarker information regarding the indication of gefitinib (Iressa) in patients with tumors that have activating EGFR mutations, due to its mechanism of action.
274	PA166104930	gefitinib	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA131301952	"ZD-1839,""ZD1839"""	The EMA European Public Assessment Report (EPAR) contains biomarker information regarding the indication of gefitinib (Iressa) in patients with tumors that have activating EGFR mutations, due to its mechanism of action.
275	PA166104930	gefitinib	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA131301952	"ZD-1839,""ZD1839"""	The EMA European Public Assessment Report (EPAR) contains biomarker information regarding the indication of gefitinib (Iressa) in patients with tumors that have activating EGFR mutations, due to its mechanism of action.
276	PA166104789	gefitinib	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA131301952	"ZD-1839,""ZD1839"""	The FDA-approved drug label for gefinitib states that it is indicated for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. The label also notes the potential clinical importance of considering CYP2D6 phenotype, though CYP2D6 testing is not mentioned.
277	PA166127676	gefitinib	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA131301952	"ZD-1839,""ZD1839"""	The product monograph for gefitinib (IRESSA) states that it is indicated for patients with activating EGFR mutations, and should not be used in those with EGFR mutation negative tumors.
278	PA166123541	gefitinib	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA131301952	"ZD-1839,""ZD1839"""	The PMDA package insert for gefitinib (Iressa) states that patients should be tested for EGFR gene mutations prior to administration. It also discusses the role of CYP2D6 is the metabolism of gefitinib.
279	PA166122487	propranolol	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451145	"Dl-Propranolol Hydrochloride,""Propanalol"",""Propanolol"",""Propranalol"",""Propranolol Hcl"",""Propranolol Hydrochloride"",""R,S-Propranolol Hydrochloride"",""propranolol"""	The EMA European Public Assessment Report (EPAR) for propranolol hydrochloride (Hemangiol) gives information regarding the metabolism of the drug by three different routes which varies between individuals, but that no difference in oral clearance or elimination is observed between CYP2D6 extensive and poor metabolizers. 
280	PA166104798	propranolol	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451145	"Dl-Propranolol Hydrochloride,""Propanalol"",""Propanolol"",""Propranalol"",""Propranolol Hcl"",""Propranolol Hydrochloride"",""R,S-Propranolol Hydrochloride"",""propranolol"""	Propranolol is metabolized primarily by CYP2D6. CYP1A2 and CYP2C19 may also play a role in propranolol metabolism. The drug label states that proranolol should be used with caution when co-administered with drugs that have an affect on CYP2D6, 1A2, or 2C19 metabolic pathways. Co-administration of such drugs with propranolol may lead to clinically relevant drug interactions and changes on its efficacy and/or toxicity. 
281	PA166122947	ranolazine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA164746007	"(-)-Ranolazine,""Ranolazine 2HCl"",""Ranolazine Dihydrochloride"",""ranolazine"""	The EMA European Public Assessment Report (EPAR) for ranolazine (Ranexa) lists subgroups of patients in which caution should be taken when prescribing or uptitrating the drug. These precuations are based on the risk in CYP2D6 poor metabolizer patients (who are at risk of increased exposure to the drug leading to  adverse events), and the EPAR states that there is a lower need for precautions in patients who are CYP2D6 extensive metabolizers. 
282	PA166123410	ritonavir	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451260	"Abbott 84538,""ritonavir"""	The EMA European Public Assessment Report (EPAR) for ritonavir (Norvir) does not contain pharmacogenetic information. It contains information regarding use of ritonavir as a pharmacokinetic enhancer for certain drugs to prolong their therapeutic effects. It is a potent inhibitor of CYP3A and CYP2D6-mediated biotransformation, and the EPAR provides a list of drugs contraindicated for concomitant use with ritonavir.
283	PA166123410	ritonavir	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA451260	"Abbott 84538,""ritonavir"""	The EMA European Public Assessment Report (EPAR) for ritonavir (Norvir) does not contain pharmacogenetic information. It contains information regarding use of ritonavir as a pharmacokinetic enhancer for certain drugs to prolong their therapeutic effects. It is a potent inhibitor of CYP3A and CYP2D6-mediated biotransformation, and the EPAR provides a list of drugs contraindicated for concomitant use with ritonavir.
284	PA166115435	timolol	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451690	"Timolol maleate,""Timololum [INN-Latin]"""	The EMA EPAR for timolol contains information regarding potentiated beta-blockade when treatment is combined with CYP2D6 inhibitors. No pharmacogenetic information was found in the label. 
285	PA166104925	timolol	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451690	"Timolol maleate,""Timololum [INN-Latin]"""	"Timolol is a non-selective beta adrenergic agonist applied to the eye to reduce intraocular pressure.  __This drug-biomarker pair was previously in the FDA's ""Table of Pharmacogenomic Biomarkers in Drug Labels"" but has subsequently been removed.__ "
286	PA166123408	vortioxetine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA166122595		The EMA European Public Assessment Report (EPAR) for vortioxetine (Brintellix) contains information regarding CYP2D6 poor metabolizers, who may have higher exposure to vortioxetine when coadministered a CYP3A4 or CYP2C9 inhibitor. The EPAR recommends considering dose adjustments depending on individual patient response. 
287	PA166122607	vortioxetine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA166122595		Vortioxetine (BRINTELLIX) is indicated as a treatment for major depressive disorder. The FDA-approved drug label for vortioxetine notes that the maximum recommended dose in patients who are known CYP2D6 poor metabolizers is 10 mg/day.
288	PA166127731	vortioxetine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA166122595		The product monograph for vortioxetine (TRINTELLIX) states that the concentration of the drug is approximately 2 times higher in CYP2D6 poor metabolizers as compared to extensive metabolizers.
289	PA166104856	amitriptyline	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA448385	"Amitriprolidine,""Amitriptylin"",""Amitriptyline HCL"",""Amitriptyline Hydrochloride"",""Amitryptiline"",""Amitryptyline"",""Amytriptiline"""	The FDA-approved drug label for amitriptyline contains information regarding the metabolism of tricyclic antidepressants by CYP2D6: CYP2D6 poor metabolizers may have higher plasma concentrations of tricyclic antidepressants, and the label suggests monitoring of plasma levels if this drug is co-administrered with a CYP2D6 inhibitor. 
290	PA166127662	arformoterol	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA164743977	"(R,R)-formoterol,""arformoterol"""	The FDA-approved label for arformoterol (BROVANA) states those with reduced CYP2D6 and/or UGT1A1 activity do not show changes in their systemic exposure to the drug compared to those with normal CYP2D6 and/or UGT1A1 enzymatic activities.
291	PA166127662	arformoterol	UGT1A1	PA420	UDP glucuronosyltransferase 1 family, polypeptide A1	NCBI Gene:54658	PA164743977	"(R,R)-formoterol,""arformoterol"""	The FDA-approved label for arformoterol (BROVANA) states those with reduced CYP2D6 and/or UGT1A1 activity do not show changes in their systemic exposure to the drug compared to those with normal CYP2D6 and/or UGT1A1 enzymatic activities.
292	PA166161219	aripiprazole lauroxil	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565			The FDA-approved drug label for aripiprazole lauroxil (ARISTADA) states that CYP2D6 poor metabolizers who are taking a concomitant medicine that is a strong CYP3A4 inhibitor should have their dose reduced to 441 mg from 662 mg or 882 mg. No adjustment is necessary in patients taking the 441 mg dose, if it is tolerated.
293	PA166104827	atomoxetine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA134688071	"Tomoxetina [Spanish],""Tomoxetine"",""Tomoxetine [INN]"",""Tomoxetinum [Latin]"""	The FDA-approved drug label for atomoxetine (Strattera) recommends a dose adjustment in children or adolescents who are CYP2D6 poor metabolizers, or who are administered strong CYP2D6 inhibitors. Additionally, the label notes a number of adverse events that occurred more frequently in CYP2D6 poor metabolizers than extensive metabolizers in clinical trials. Laboratory tests are available to identify CYP2D6 poor metabolizers.
294	PA166127633	atomoxetine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA134688071	"Tomoxetina [Spanish],""Tomoxetine"",""Tomoxetine [INN]"",""Tomoxetinum [Latin]"""	The product monograph for atomoxetine notes that CYP2D6 poor metabolizers (PMs) have a 10-fold higher area under the curve (AUC) and a 5-fold higher peak concentration of the drug as compared to extensive metabolizers (EM); this leads to a higher rate of some adverse events for PMs compared to EMs.  
295	PA166123528	atomoxetine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA134688071	"Tomoxetina [Spanish],""Tomoxetine"",""Tomoxetine [INN]"",""Tomoxetinum [Latin]"""	The PMDA package insert for atomoxetine (Strattera) states that individuals who are CYP2D6 poor metabolizers (PMs) and administered atomoxetine may have higher exposure to the drug and be at a greater risk of experiencing adverse events. The insert recommends dosing these patients with discretion.
296	PA166160054	brexpiprazole	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA166160053		The FDA-approved drug label for brexpiprazole (REXULTI) states that known CYP2D6 poor metabolizers should have their usual dosage reduced by half, and that known CYP2D6 poor metabolizers who are also taking strong/moderate CYP3A4 inhibitors should be administered a quarter of the usual dose. However, the label does not mention genetic testing.
297	PA166104813	carvedilol	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA448817	"Carvedilolum [Latin],""carvedilol"""	Carvedilol is metabolized by CYP2D6 and CYP2C9. The drug label states that carvedilol is affected by the poor metabolizers of debrisoquin (a marker for cytochrome P450 2D6) resulting in higher plasma concentrations of R( + )-carvedilol. Additionally, retrospective analysis of side effects in clinical trials showed that poor CYP2D6 metabolizers had a higher rate of dizziness during up-titration, presumably resulting from vasodilating effects of the higher concentrations of the a-blocking R(+) enantiomer.
298	PA166127646	carvedilol	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA448817	"Carvedilolum [Latin],""carvedilol"""	The product monograph for carvedilol notes that CYP2D6 poor metabolizers exhibit 2- to 3-fold higher plasma concentrations of R( + )-carvedilol compared to extensive metabolizers. Plasma levels of S( - )-carvedilol are increased only about 20 - 25% in poor metabolizers. 
299	PA166104787	cevimeline	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA164754754	"Cevimeline hydrochloride,""Cevimeline hydrochloride hemihydrate"",""Cevimeline hydrochloride hydrate"""	CYP2D6 and CYP3A3/4 are responsible for the metabolism of cevimeline, therefore the drug label states that drugs which inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline. Additionally, cevimeline should be used with caution in individuals known or suspected to be CYP2D6 poor metabolizers, based on previous experience, as they may be at a higher risk of adverse events.
300	PA166104875	clomipramine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA449048	"3-Chloroimipramine,""Chlorimipramine"",""Clomipramina [INN-Spanish]"",""Clomipramine HCL"",""Clomipraminum [INN-Latin]"",""Monochlorimipramine"""	The drug label for clomipramine (Anafranil) notes that CYP2D6 poor metabolizers have higher than expected plasma concentrations of tricyclic  antidepressants (TCAs), such as clomipramine, when given typical doses. Additionally, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. It is therefore desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be a CYP2D6 inhibitor.
301	PA166104815	clozapine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA449061	Clozapin	Clozapine is a substrate of CYP1A2, CYP3A4, and CYP2D6. The drug label notes to use caution when administering it concomitantly with drugs that are inducers or inhibitors of these enzymes. Additionally, it may be necessary to reduce the clozapine dose in patients with significant renal or hepatic impairment, or in CYP2D6 poor metabolizers.
302	PA166104916	codeine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA449088	"Codeine anhydrous,""L-Codeine"",""Methylmorphine"",""Morphine monomethyl ether"",""Norcodeine, N-Methyl"",""Norcodine, N-Methyl"""	"CYP2D6 ultra-rapid metabolizers may experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing at normal dosing regimens.  Mothers who are ultra-rapid metabolizers and breast-feeding have higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants, potentially leading to serious adverse reactions, including death, in nursing infants.  A black box warning on the label states ""Respiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism.""  However, no recommendations for testing for CYP2D6 metabolizer status are provided on the label."
303	PA166127654	codeine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA449088	"Codeine anhydrous,""L-Codeine"",""Methylmorphine"",""Morphine monomethyl ether"",""Norcodeine, N-Methyl"",""Norcodine, N-Methyl"""	CYP2D6 ultra-rapid metabolizers may experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing at normal dosing regimens of codeine. Mothers who are ultra-rapid metabolizers and breast-feeding have higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. 
304	PA166104862	desipramine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA449233	"DMI,""Demethylimipramine"",""Desimipramine"",""Desimpramine"",""Desipramin"",""Desipramine Hcl"",""Desmethylimipramine"",""Dezipramine"",""Dimethylimipramine"",""Methylaminopropyliminodibenzyl"",""Monodemethylimipramine"",""Norimipramine"",""Norpramine"""	The FDA-approved drug label for desipramine (NORPRAMIN) notes that CYP2D6 poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs), such as desipramine, when given typical doses. Additionally, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. It is therefore desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be a CYP2D6 inhibitor.
305	PA166104835	fluoxetine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA449673	"Fluoxetina [INN-Spanish],""Fluoxetina [Spanish]"",""Fluoxetine Hcl"",""Fluoxetine Hydrochloride"",""Fluoxetinum [INN-Latin]"""	Fluoxetine is a selective serotonin reuptake inhibitor (SSRI). Fluoxetine is indicated for the treatment of major depressive disorder, obsessive compulsive disorder, bulimia nervosa, and panic disorder. Fluoxetine is metabolized by several cytochrome P450 enzymes with CYP2D6 being a major contributor. At the same time, fluoxetine is an inhibitor of CYP2D6 mediated reactions.
306	PA166104788	fluoxetine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA449673	"Fluoxetina [INN-Spanish],""Fluoxetina [Spanish]"",""Fluoxetine Hcl"",""Fluoxetine Hydrochloride"",""Fluoxetinum [INN-Latin]"""	Symbyax, a drug mixture of fluoxetine and olanzapine, is used for the treatment of bipolar disorder and treatment resistant depression and, due to its potent CYP2D6 inhibition as a result of fluoxetine, exhibits drug interactions with other medications also metabolized by CYP2D6. Coadministration with other drugs that are metabolized by CYP2D6 should be approached with caution.
307	PA166104854	fluvoxamine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA449690	"Fluvoxamina [INN-Spanish],""Fluvoxamine maleate"",""Fluvoxaminum [INN-Latin]"",""fluvoxamine"",""fluvoxamine-CR"""	The FDA-approved drug label for fluvoxamine states that it appears to be metabolized, at least in part, by CYP2D6, and that caution should be used in treating patients with low CYP2D6 activity and those receiving other medication known to inhibit CYP2D6.
308	PA166104869	galantamine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA449726	"(-)-Galanthamine,""Galanthamine"",""Galanthamine hydrobromide"""	Dosage adjustment of galantamine is not necessary in patients identified as CYP2D6 poor metabolizers as the dose is individually titrated to tolerability.
309	PA166127675	galantamine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA449726	"(-)-Galanthamine,""Galanthamine"",""Galanthamine hydrobromide"""	The product monograph for galantamine notes that CYP2D6 poor metabolizers have decreased clearance and increased AUC of galantamine as compared to extensive metabolizers. However, it also states that dosage adjustment based on CYP2D6 genotype is not necessary since the drug is individually titrated to tolerability.
310	PA166104887	iloperidone	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA161199368		Co-administration of FANAPT with known strong inhibitors of CYP2D6 like fluoxetine results in a 2.3 fold increase in iloperidone plasma exposure, and therefore one-half of the FANAPT dose should be administered. Similarly, PMs of CYP2D6 have higher exposure to iloperidone compared with EMs and PMs should have their dose reduced by one half.
311	PA166104879	imipramine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA449969		Poor metabolizers have higher than expected plasma concentrations of TCAs when given usual doses. Concomitant use of TCAs with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug; monitor TCA plasma levels.
312	PA166104836	metoprolol	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA450480	"Metoprolol Tartrate,""Metoprolol succinate"""	Metoprolol is metabolized by the cytochrome P450 enzymes in the liver with a major contribution of CYP2D6. Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity.
313	PA166127691	metoprolol	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA450480	"Metoprolol Tartrate,""Metoprolol succinate"""	The product monograph for metoprolol notes that CYP2D6 poor metabolizers exhibit higher plasma concentrations of the drug as compared to extensive metabolizers, however these differences in plasma concentrations seem to have little to no effect on safety or tolerability.
314	PA166104868	modafinil	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA450530	modafinil	Modafinil, used to improve wakefulness, is metabolized by many cytochrome P450s. Patients that are poor metabolizers for CYP2D6 may need dose modifications for medications that have ancillary metabolism via CYP2C19, such as tricyclic antidepressants (TCAs).
315	PA166104880	nefazodone	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA450603	"Nefazodona [Spanish],""Nefazodone Hcl"",""Nefazodone Hydrochloride"",""Nefazodonum [Latin]"""	Nefazodone treatment adjustment is not required based on CYP2D6 metabolizer status. Caution should be used when co-prescribing nefazodone with other drugs metabolized by CYP3A4.
316	PA166104888	nortriptyline	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA450657		"Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers; co-administration with these inhibitors' can make the patient abruptly toxic.

It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor."
317	PA166127697	nortriptyline	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA450657		The product monograph for nortriptyline notes that individuals who are CYP2D6 poor metabolizers may have higher than expected levels of tricyclic antidepressants (of which nortriptyline is a member) when given usual doses. 
318	PA166160052	palonosetron	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA10352	palonosetron	The FDA-approved drug label for palonosetron (ALOXI) states that there is no significant difference in clinical pharmacokinetic parameters between CYP2D6 poor and extensive metabolizers.
319	PA166104864	paroxetine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA450801	"Paroxetina [INN-Spanish],""Paroxetine Hcl"",""Paroxetinum [INN-Latin]"",""paroxetine"""	The metabolism of paroxetine is accomplished in part by cytochrome CYP2D6. Coadministration of paroxetine with other drugs that are metabolized by this isozyme should be approached with caution. Due to the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, paroxetine and thioridazine should not be coadministered.
320	PA166104893	perphenazine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA450882	"Chlorperphenazine,""Etaperazin"",""Etaperazine"",""Ethaperazine"",""PZC"",""Perfenazina"",""Perfenazine"",""Perphenazin"""	CYP2D6 is involved in the pharmacokinetics of perphenazine. Poor metabolizers demonstrate higher plasma concentrations of antipsychotic drugs at usual doses, which may correlate with emergence of side effects. Prospective phenotyping of elderly patients prior to antipsychotic treatment may identify those at risk for adverse events.
321	PA166104870	pimozide	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA450965	"Pimozida [INN-Spanish],""Pimozidum [INN-Latin]"""	CYP2D6 genotyping should be performed at doses above 0.05mg/kg/day in children or above 4 mg/day in adults. In poor CYP2D6 metabolizers, pimozide doses should not exceed 0.05mg/kg/day in children or 4 mg/day in adults and doses should not be increased earlier than 14 days.
322	PA166104837	propafenone	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451131	"Propafenona [INN-Spanish],""Propafenone HCl"",""Propafenone hydrochloride"",""Propafenone-HCl"",""Propafenonum [INN-Latin]"""	Propafenone is metabolized by CYP2D6,CYP3A4,and CYP1A2 isoenzymes. Inhibitors of CYP2D6, 1A2, and 3A4 may increase propafenone levels which may lead to cardiac arrhythmias. Simultaneous use with both a CYP3A4 and CYP2D6 inhibitor (or in a patient with CYP2D6 deficiency) should be avoided.
323	PA166127704	propafenone	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451131	"Propafenona [INN-Spanish],""Propafenone HCl"",""Propafenone hydrochloride"",""Propafenone-HCl"",""Propafenonum [INN-Latin]"""	The product monograph for propafenone notes that individuals with reduced CYP2D6 activity may have higher plasma concentrations of the drug as compared to those who do not have reduced CYP2D6 activity.
324	PA166104812	protriptyline	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451168	Protryptyline	Protriptyline hydrochloride is an antidepressant agent and belongs to the class of tricyclic antidepressants. CYP2D6 poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
325	PA166104793	risperidone	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451257	"Risperidona [Spanish],""Risperidonum [Latin]"",""risperdone"",""risperidone"""	Risperidone is metabolized to 9-hydroxyrisperidone by CYP2D6. Co-administration of drugs that are inhibitors or inducers of CYP2D6 along with risperidone may alter the plasma concentration of risperidone.
326	PA166127708	risperidone	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451257	"Risperidona [Spanish],""Risperidonum [Latin]"",""risperdone"",""risperidone"""	The product monograph for risperidone notes that since CYP2D6 is responsible for the metabolism of risperidone to 9-hydroxyrisperidone, the levels of each differ between CYP2D6 poor and extensive metabolizers. However, the concentration of risperidone and 9-hydroxyrisperidone combined does not differ substantially between poor and extensive metabolizers.
327	PA166104822	terbinafine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451614	"Terbinafine HCl,""Terbinafine hydrochloride"",""Ternbinafine HCl"",""terbinafine"""	Terbinafine is an antifungal drug.  It is an inhibitor of CYP450 2D6  and has an effect on metabolism of desipramine, cimetidine, fluconazole, cyclosporine, rifampin, and caffeine. Coadministration of terbinafine with drugs dependent on CYP2D6 for metabolism should be done with careful monitoring and may require a reduction in dose of the 2D6-metabolized drug.
328	PA166104829	tetrabenazine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA140222719	"Tetra benazin,""Tetrabenazina [inn-spanish]"",""Tetrabenazinum [inn-latin]"",""Tetrabenzaine"",""Tetrabenzine"""	Tetrabenazine is used to treat Huntington's Disease chorea. Its primary metabolites are metabolized mainly by CYP2D6. Patients requiring doses above 50 mg per day should be genotyped for the drug metabolizing enzyme CYP2D6 to determine if the patient is a poor metabolizer (PM) or an extensive metabolizer (EM). People with CYP2D6 poor metabolizer genotypes should be treated with lower doses.
329	PA166127719	tetrabenazine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA140222719	"Tetra benazin,""Tetrabenazina [inn-spanish]"",""Tetrabenazinum [inn-latin]"",""Tetrabenzaine"",""Tetrabenzine"""	The product monograph for tetrabenazine notes that the tetrabenazine active metabolite HTBZ is likely increased in CYP2D6 poor metabolizers as compared to extensive metabolizers, and that caution in dosing should be exercised. 
330	PA166104805	thioridazine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451666	"Thioridazin,""Thioridazine Chloride"",""Thioridazine Hcl"",""Thioridazine Hydrochloride"",""Thoridazine Hydrochloride"""	Thioridazine is used to treat schizophrenia, but has been associated with Torsades de pointes and sudden death.  Due to the potentially fatal side effects, it is typically reserved for patients who do not respond well to other anti-psychotics.  This drug is contraindicated in patients with reduced CYP2D6 activity.
331	PA166104830	tiotropium	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA164769056	Tiotropium bromide	"Tiotropium is an inhalation powder used daily for the treatment of bronchospasms associated with chronic obstructive pulmonary disease (COPD), and believed to be in small part metabolized by CYP2D6 and CYP3A4.  __This drug-biomarker pair was previously in the FDA's ""Table of Pharmacogenomic Biomarkers in Drug Labels"" but has subsequently been removed.__ "
332	PA166104806	tolterodine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA164746757	"Tolterodina [INN-Spanish],""Tolterodine L-Tartrate"",""Tolterodine Tartrate"",""Tolterodine [INN]"",""Tolterodinum [INN-Latin]"",""Tolterondine Tartrate"",""tolterodine extended release capsules"""	Tolterodine is used for the treatment of overactive bladder and is primarily metabolized by CYP2D6.  Poor metabolizers may have greater plasma concentrations of the drug which could possibly have an effect QT interval.  However, no recommendations for testing for CYP2D6 metabolizer status are provided on the label.
333	PA166127721	tolterodine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA164746757	"Tolterodina [INN-Spanish],""Tolterodine L-Tartrate"",""Tolterodine Tartrate"",""Tolterodine [INN]"",""Tolterodinum [INN-Latin]"",""Tolterondine Tartrate"",""tolterodine extended release capsules"""	The product monograph for tolterodine notes that CYP2D6 is responsible for the metabolism of tolterodine to its active metabolite DD 01. However, since tolterodine and DD 01 have similar pharmacological effects, the net activity of tolterodine is expected to be similar regardless of CYP2D6 metabolizer status. 
334	PA166123549	tolterodine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA164746757	"Tolterodina [INN-Spanish],""Tolterodine L-Tartrate"",""Tolterodine Tartrate"",""Tolterodine [INN]"",""Tolterodinum [INN-Latin]"",""Tolterondine Tartrate"",""tolterodine extended release capsules"""	Tolterodine is metabolized by CYP2D6 into the pharmacologically active and equipotent 5-hydroxymethyl metabolite (DD01). The PMDA package insert for tolterodine (Detrusitol) notes that CYP2D6 poor metabolizers have negligible concentrations of the 5-hydroxymethyl metabolite and significantly increased concentrations of tolterodine, as compared to extensive metabolizers.
335	PA166104799	tramadol	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451735	"Tramadol HCl,""Tramadol hydrochloride"",""Tramadolum [INN-Latin]"",""Tramodol Hcl"",""tramadol"""	The FDA-approved label contains information regarding metabolism of Tramadol by CYP2D6: CYP2D6 poor metabolizers may have higher tramadol concentrations, and  concomitant use of CYP2D6 or CYP3A4 inhibitors may reduce clearance of tramadol and increase a patient's risk for adverse events.
336	PA166127628	tramadol	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451735	"Tramadol HCl,""Tramadol hydrochloride"",""Tramadolum [INN-Latin]"",""Tramodol Hcl"",""tramadol"""	The product monographs for tramadol and acetaminophen (APO-TRAMADOL/ACET) and tramadol (APO-TRAMADOL) note that patients who are CYP2D6 poor metabolizers may have increased tramadol concentrations as compared to those who are CYP2D6 extensive metabolizers.
337	PA166104857	trimipramine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451791	"Trimeprimina [Italian],""Trimeprimine"",""Trimipramina [INN-Spanish]"",""Trimipraminum [INN-Latin]"",""beta-Methylimipramine"""	Trimipramine _(Surmontil)_ is a tricyclic antidepressant used to treat depression.  Like many antidepressants, it has a black box warning for increased risk of suicidal thoughts and behavior.  Trimipramine is metabolized by CYP2D6 and poor metabolizers my experience higher plasma concentrations of the drug at typical doses.
338	PA166104847	venlafaxine	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451866	"Venlafaxina [INN-Spanish],""Venlafaxine [INN:Ban]"",""Venlafaxinum [INN-Latin]"""	Venlafaxine _(Effexor)_ is an inhibitor of neuronal serotonin and norepinephrine reuptake and weak inhibitor of dopamine reuptake used in the treatment of depression.  It is metabolized by CYP2D6, and to a lesser extent, CYP3A4 (shown _in vitro)_.
339	PA166127628	acetaminophen	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA448015	"APAP,""Acetaminofen"",""Paracetamol"",""Paracetamolo"",""Paracetanol"""	The product monographs for tramadol and acetaminophen (APO-TRAMADOL/ACET) and tramadol (APO-TRAMADOL) note that patients who are CYP2D6 poor metabolizers may have increased tramadol concentrations as compared to those who are CYP2D6 extensive metabolizers.
340	PA166127718	tamoxifen	CYP2D6	PA128	cytochrome P450, family 2, subfamily D, polypeptide 6	NCBI Gene:1565	PA451581	"Tamoxifen Citrate,""Tamoxifene [INN-French]"",""Tamoxifeno [INN-Spanish]"",""Tamoxifenum [INN-Latin]"",""Trans-Tamoxifen"""	The product monograph for tamoxifen states that it is indicated for treatment of early breast cancer in women with estrogen receptor positive tumors. It also notes that individuals with low CYP2D6 activity (or using CYP2D6 inhibitors) may have reductions in plasma concentrations of the active metabolite of tamoxifen. 
341	PA166127718	tamoxifen	ESR1	PA156	estrogen receptor 1	NCBI Gene:2099	PA451581	"Tamoxifen Citrate,""Tamoxifene [INN-French]"",""Tamoxifeno [INN-Spanish]"",""Tamoxifenum [INN-Latin]"",""Trans-Tamoxifen"""	The product monograph for tamoxifen states that it is indicated for treatment of early breast cancer in women with estrogen receptor positive tumors. It also notes that individuals with low CYP2D6 activity (or using CYP2D6 inhibitors) may have reductions in plasma concentrations of the active metabolite of tamoxifen. 
342	PA166104819	tamoxifen	ESR1	PA156	estrogen receptor 1	NCBI Gene:2099	PA451581	"Tamoxifen Citrate,""Tamoxifene [INN-French]"",""Tamoxifeno [INN-Spanish]"",""Tamoxifenum [INN-Latin]"",""Trans-Tamoxifen"""	Tamoxifen is an anti-estrogen used in the treatment and prevention of breast neoplasms particularly those with estrogen receptor positive breast cancer. 
343	PA166127718	tamoxifen	ESR2	PA27886	estrogen receptor 2 (ER beta)	NCBI Gene:2100	PA451581	"Tamoxifen Citrate,""Tamoxifene [INN-French]"",""Tamoxifeno [INN-Spanish]"",""Tamoxifenum [INN-Latin]"",""Trans-Tamoxifen"""	The product monograph for tamoxifen states that it is indicated for treatment of early breast cancer in women with estrogen receptor positive tumors. It also notes that individuals with low CYP2D6 activity (or using CYP2D6 inhibitors) may have reductions in plasma concentrations of the active metabolite of tamoxifen. 
344	PA166104819	tamoxifen	ESR2	PA27886	estrogen receptor 2 (ER beta)	NCBI Gene:2100	PA451581	"Tamoxifen Citrate,""Tamoxifene [INN-French]"",""Tamoxifeno [INN-Spanish]"",""Tamoxifenum [INN-Latin]"",""Trans-Tamoxifen"""	Tamoxifen is an anti-estrogen used in the treatment and prevention of breast neoplasms particularly those with estrogen receptor positive breast cancer. 
345	PA166104819	tamoxifen	F2	PA157	coagulation factor II (thrombin)	NCBI Gene:2147	PA451581	"Tamoxifen Citrate,""Tamoxifene [INN-French]"",""Tamoxifeno [INN-Spanish]"",""Tamoxifenum [INN-Latin]"",""Trans-Tamoxifen"""	Tamoxifen is an anti-estrogen used in the treatment and prevention of breast neoplasms particularly those with estrogen receptor positive breast cancer. 
346	PA166104819	tamoxifen	F5	PA159	coagulation factor V (proaccelerin, labile factor)	NCBI Gene:2153	PA451581	"Tamoxifen Citrate,""Tamoxifene [INN-French]"",""Tamoxifeno [INN-Spanish]"",""Tamoxifenum [INN-Latin]"",""Trans-Tamoxifen"""	Tamoxifen is an anti-estrogen used in the treatment and prevention of breast neoplasms particularly those with estrogen receptor positive breast cancer. 
347	PA166123422	efavirenz	CYP2B6	PA123	cytochrome P450, family 2, subfamily B, polypeptide 6	NCBI Gene:1555	PA449441	"EFV,""efavirenz"""	The EMA European Public Assessment Report (EPAR) for efavirenz, emtricitabine and tenofovir disoproxil (Atripla) contains pharmacogenetic information related to possible increased exposure to efavirenz in patients homozygous for the CYP2B6 G516T variant ([variant:rs3745274] genotype TT), and though the clinical implications of this are unknown, the potential for an increased frequency and severity of adverse events cannot be excluded.
348	PA166127667	efavirenz	CYP2B6	PA123	cytochrome P450, family 2, subfamily B, polypeptide 6	NCBI Gene:1555	PA449441	"EFV,""efavirenz"""	The product monograph for efavirenz, emtricitabine and tenofovir (ATRIPLA) states that patients homozygous for the G516T genetic variant in CYP2B6 may have increased plasma exposure of the drug. However, the effect of this increase on the occurrence of adverse events is unclear. 
349	PA166123422	emtricitabine	CYP2B6	PA123	cytochrome P450, family 2, subfamily B, polypeptide 6	NCBI Gene:1555	PA10069	emtricitabine	The EMA European Public Assessment Report (EPAR) for efavirenz, emtricitabine and tenofovir disoproxil (Atripla) contains pharmacogenetic information related to possible increased exposure to efavirenz in patients homozygous for the CYP2B6 G516T variant ([variant:rs3745274] genotype TT), and though the clinical implications of this are unknown, the potential for an increased frequency and severity of adverse events cannot be excluded.
350	PA166127667	emtricitabine	CYP2B6	PA123	cytochrome P450, family 2, subfamily B, polypeptide 6	NCBI Gene:1555	PA10069	emtricitabine	The product monograph for efavirenz, emtricitabine and tenofovir (ATRIPLA) states that patients homozygous for the G516T genetic variant in CYP2B6 may have increased plasma exposure of the drug. However, the effect of this increase on the occurrence of adverse events is unclear. 
351	PA166123422	tenofovir	CYP2B6	PA123	cytochrome P450, family 2, subfamily B, polypeptide 6	NCBI Gene:1555	PA10204	"D,L-Tenofovir,""PMPA"",""TDF"",""Tenofovir disoproxil"",""Tenofovir disoproxil fumarate"""	The EMA European Public Assessment Report (EPAR) for efavirenz, emtricitabine and tenofovir disoproxil (Atripla) contains pharmacogenetic information related to possible increased exposure to efavirenz in patients homozygous for the CYP2B6 G516T variant ([variant:rs3745274] genotype TT), and though the clinical implications of this are unknown, the potential for an increased frequency and severity of adverse events cannot be excluded.
352	PA166127667	tenofovir	CYP2B6	PA123	cytochrome P450, family 2, subfamily B, polypeptide 6	NCBI Gene:1555	PA10204	"D,L-Tenofovir,""PMPA"",""TDF"",""Tenofovir disoproxil"",""Tenofovir disoproxil fumarate"""	The product monograph for efavirenz, emtricitabine and tenofovir (ATRIPLA) states that patients homozygous for the G516T genetic variant in CYP2B6 may have increased plasma exposure of the drug. However, the effect of this increase on the occurrence of adverse events is unclear. 
353	PA166104917	prasugrel	CYP2B6	PA123	cytochrome P450, family 2, subfamily B, polypeptide 6	NCBI Gene:1555	PA154410481	cs-747	The FDA drug label for prasugrel contains information regarding a lack of effect of genetic variants on prasugrel pharmacokinetics.
354	PA166104917	prasugrel	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA154410481	cs-747	The FDA drug label for prasugrel contains information regarding a lack of effect of genetic variants on prasugrel pharmacokinetics.
355	PA166105321	prasugrel	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA154410481	cs-747	The EMA European Public Assessment Report (EPAR) for prasugrel (Efient) contains information regarding the lack of effect of genetic variants in the CYP3A5, CYP2B6, CYP2C9 and CYP2C19 genes on the pharmacokinetics of prasugrel or response. 
356	PA166104917	prasugrel	CYP2C9	PA126	cytochrome P450, family 2, subfamily C, polypeptide 9	NCBI Gene:1559	PA154410481	cs-747	The FDA drug label for prasugrel contains information regarding a lack of effect of genetic variants on prasugrel pharmacokinetics.
357	PA166104917	prasugrel	CYP3A5	PA131	cytochrome P450, family 3, subfamily A, polypeptide 5	NCBI Gene:1577	PA154410481	cs-747	The FDA drug label for prasugrel contains information regarding a lack of effect of genetic variants on prasugrel pharmacokinetics.
358	PA166123421	atazanavir	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA10251	"ATV,""ATZ"",""Atazanavir sulfate"",""BMS-232632"",""atazanavir"""	The EMA European Public Assessment Report (EPAR) for atazanavir (Reyataz) contains pharmacogenetic information related to co-treatment with voriconazole and ritonavir: atazanavir exposure is expected to be decreased and voriconazole exposure is expected to be increased in patients who do not have a functional CYP2C19 allele. The EPAR states that at the time of voriconazole treatment, a test for CYP2C19 genotype should be performed if feasible, and provides therapeutic recommendations based on CYP2C19 genotype.
359	PA166159707	atazanavir	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA10251	"ATV,""ATZ"",""Atazanavir sulfate"",""BMS-232632"",""atazanavir"""	The HCSC for atazanavir (Reyataz) contains pharmacogenetic information related to co-treatment with voriconazole and ritonavir: atazanavir exposure is expected to be decreased and voriconazole exposure is expected to be increased in patients who do not have a functional CYP2C19 allele.
360	PA166123387	axitinib	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA164924493		The EMA European Public Assessment Report (EPAR) for axitinib contains pharmacogenetic information related to there being no clinically relevant effects of UGT1A1 genotype or CYP2C19 genotype on axitinib pharmacokinetics.
361	PA166123387	axitinib	UGT1A1	PA420	UDP glucuronosyltransferase 1 family, polypeptide A1	NCBI Gene:54658	PA164924493		The EMA European Public Assessment Report (EPAR) for axitinib contains pharmacogenetic information related to there being no clinically relevant effects of UGT1A1 genotype or CYP2C19 genotype on axitinib pharmacokinetics.
362	PA166104841	clopidogrel	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA449053		The EMA European Public Assessment Report (EPAR) contains information regarding a diminished response to clopidogrel in CYP2C19 poor metabolizers. It also precautions the use of concomitant drugs that are CYP2C19 inhibitors.
363	PA166104777	clopidogrel	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA449053		The FDA-approved drug label for clopidogrel (Plavix) warns that patients who are CYP2C19 poor metabolizers may have diminished effectiveness of the drug as compared to patients with normal CYP2C19 function. The drug label suggests that a different platelet P2Y12 inhibitor be used in patients identified as CYP2C19 poor metabolizers.
364	PA166127653	clopidogrel	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA449053		The product monograph for clopidogrel (PLAVIX) states that CYP2C19 poor metabolizers may be at increased risk for experiencing cardiovascular events when taking the drug at recommended doses as compared to normal CYP2C19 metabolizers, and that an alternative treatment or treatment strategies should be considered in these patients.
365	PA166123535	clopidogrel	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA449053		The PMDA package insert for clopidogrel states that in clinical pharmacological studies, CYP2C19 poor metabolizers had diminished inhibition of platelet aggregation.
366	PA166120286	esomeprazole	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA10075	"(-)-omeprazole,""(s)-omeprazole"",""Esomeprazole Sodium"",""Esomperazole"",""esomeprazole"""	The EMA European Public Assessment Report (EPAR) for esomeprazole (Nexium Control) notes that CYP2C19 poor metabolizers have higher plasma concentrations of the drug compared to extensive metabolizers, but there are no implications for dosing.
367	PA166104816	esomeprazole	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA10075	"(-)-omeprazole,""(s)-omeprazole"",""Esomeprazole Sodium"",""Esomperazole"",""esomeprazole"""	The FDA-approved drug label for esomeprazole (NEXIUM) notes that individuals who are CYP2C19 poor metabolizers may have double the steady state area under the plasma concentration-time curve (AUC) of esomeprazole compared to extensive metabolizers. 
368	PA166127670	esomeprazole	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA10075	"(-)-omeprazole,""(s)-omeprazole"",""Esomeprazole Sodium"",""Esomperazole"",""esomeprazole"""	The product monograph for esomeprazole states that CYP2C19 poor metabolizers have increased concentrations of the drug as compared to the rest of the population, but that dosage adjustment based on CYP2C19 genotype is not necessary.
369	PA166114382	ticagrelor	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA165374673		The EMA European Public Assessment Report (EPAR) for ticagrelor (Brilique) contains information regarding a study in which CYP2C19 and ABCB1 genotyping was carried out (PLATO - platelet inhibition and patient outcomes). In patients with one or more CYP2C19 loss of function allele, non-coronary artery by-pass grafting (non-CABG) PLATO major bleeding was increased when treated with ticagrelor compared to clopidogrel, but was similar in patients with no loss of function alleles.
370	PA166104851	ticagrelor	CYP3A5	PA131	cytochrome P450, family 3, subfamily A, polypeptide 5	NCBI Gene:1577	PA165374673		Ticagrelor is a platelet inhibitor used to reduce the risk of thrombotic cardiovascular events for patients with acute coronary syndrome.  It is metabolized by CYP3A4/5; the label advises against using the drug in conjunction with CYP3A inhibitors and inducers.  
371	PA166104851	ticagrelor	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA165374673		Ticagrelor is a platelet inhibitor used to reduce the risk of thrombotic cardiovascular events for patients with acute coronary syndrome.  It is metabolized by CYP3A4/5; the label advises against using the drug in conjunction with CYP3A inhibitors and inducers.  
372	PA166122826	voriconazole	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA10233	"VCZ,""voriconazole"""	"The EMA European Public Assessment Report (EPAR) for voriconazole (VFEND) does not contain pharmacogenetic information. It contains warning information regarding the co-administration of drugs that are substrates, inhibitors or activators of CYP3A4, CYP2C9 or CYP2C19 due to drug-drug interactions.

"
373	PA166104818	voriconazole	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA10233	"VCZ,""voriconazole"""	"Voriconazole is an antifungal used to treat serious infections of Aspergillus fumigatu, Candida, Scedosporium, Fusarium and other species. Voriconazole is metabolized in the liver by CYP2C19, CYP2C9 and CYP3A4. It also influences expression of metabolizing enzymes and interacts with several other drugs.

"
374	PA166127730	voriconazole	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA10233	"VCZ,""voriconazole"""	The product monograph for voriconazole notes that CYP2C19 poor metabolizers have, on average, 4-fold higher exposure to the drug as compared to extensive metabolizers. However, the product monograph does not make any statements regarding genetic testing of CYP2C19 prior to treatment.
375	PA166122826	voriconazole	CYP2C9	PA126	cytochrome P450, family 2, subfamily C, polypeptide 9	NCBI Gene:1559	PA10233	"VCZ,""voriconazole"""	"The EMA European Public Assessment Report (EPAR) for voriconazole (VFEND) does not contain pharmacogenetic information. It contains warning information regarding the co-administration of drugs that are substrates, inhibitors or activators of CYP3A4, CYP2C9 or CYP2C19 due to drug-drug interactions.

"
376	PA166122826	voriconazole	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA10233	"VCZ,""voriconazole"""	"The EMA European Public Assessment Report (EPAR) for voriconazole (VFEND) does not contain pharmacogenetic information. It contains warning information regarding the co-administration of drugs that are substrates, inhibitors or activators of CYP3A4, CYP2C9 or CYP2C19 due to drug-drug interactions.

"
377	PA166153492	brivaracetam	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA166153491		The FDA-approved drug label for brivaracetam (BRIVIACT) states that CYP2C19 intermediate or poor metabolizers may have increased levels of brivaracetam, and that poor metabolizers may require a dose reduction.
378	PA166160289	brivaracetam	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA166153491		The Health Canada drug label for brivaracetam (BRIVIACT) states that individuals with one or two copies of CYP2C19 decreased activity alleles may have increased levels of brivaracetam.
379	PA166104832	carisoprodol	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA448809	"Carisoprodate,""Carisoprodatum"",""Isomeprobamate"",""Isoprotane"",""Isoprothane"""	Carisoprodol (SOMA) should be used with caution in patients with reduced CYP2C19 activity. Published studies indicate that patients who are poor CYP2C19 metabolizers have a 4-fold increase in exposure to carisoprodol and a 50% decreased exposure to meprobamate (a metabolite of carisoprodol) compared to normal CYP2C19 metabolizers.
380	PA166104884	clobazam	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA10888	clobazam	In patients known to be CYP2C19 poor metabolizers, the drug label states that the initial dose of clobazam (ONFI) should be 5 mg/day. Patients can be titrated initially to 10 - 20 mg/day, and then titrated further to a maximum daily dose of 40 mg, if tolerated. This is due to an increase in levels of N-desmethylclobazam, the active metabolite of clobazam.
381	PA166104863	dexlansoprazole	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA166110257		The FDA-approved drug label for dexlansoprazole (DEXILANT) notes that systemic exposure of the drug is generally higher in CYP2C19 intermediate and poor metabolizers, as compared to extensive metabolizers. 
382	PA166127661	dexlansoprazole	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA166110257		The product monograph for dexlansoprazole (DEXILANT) notes that CYP2C19 intermediate and poor metabolizers generally have higher exposure to the drug as compared to extensive metabolizers.
383	PA166104784	diazepam	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA449283	"DAP,""Methyldiazepinone"""	The FDA-approved drug label for diazepam (Diastat) notes that the drug is metabolized by CYP2C19 and CYP3A4, and that inter-individual variation in clearance of the drug is likely attributable to CYP2C19 or CYP3A4 genetic variability. 
384	PA166104814	drospirenone	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA164749409	"6beta,7beta,15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17 carbolactone,""DRSP"",""Drospirenona [inn-spanish]"",""Drospirenonum [inn-latin]"""	The FDA-approved drug label for drospirenone and ethinyl estradiol (Yaz) notes that _in vitro_ studies showed an inhibitory effect of drospirenone on the turnover of model substrates of CYP1A1, CYP2C9, CYP2C19 and CYP3A4. However, _in vivo_ studies using omeprazole as a marker substrate showed that drospirenone has little propensity to interact to a significant extent with cytochrome P450 enzymes at a clinical dose level. 
385	PA166127666	drospirenone	PROC	PA33799	protein C (inactivator of coagulation factors Va and VIIIa)	NCBI Gene:5624	PA164749409	"6beta,7beta,15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17 carbolactone,""DRSP"",""Drospirenona [inn-spanish]"",""Drospirenonum [inn-latin]"""	The product monograph for drospirenone and ethinyl estradiol (YAZ) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency and protein S deficiency (among other contraindications), due to the risk for arterial or venous thrombosis.
386	PA166127666	drospirenone	PROS1	PA33809	protein S (alpha)	NCBI Gene:5627	PA164749409	"6beta,7beta,15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17 carbolactone,""DRSP"",""Drospirenona [inn-spanish]"",""Drospirenonum [inn-latin]"""	The product monograph for drospirenone and ethinyl estradiol (YAZ) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency and protein S deficiency (among other contraindications), due to the risk for arterial or venous thrombosis.
387	PA166127666	drospirenone	F5	PA159	coagulation factor V (proaccelerin, labile factor)	NCBI Gene:2153	PA164749409	"6beta,7beta,15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17 carbolactone,""DRSP"",""Drospirenona [inn-spanish]"",""Drospirenonum [inn-latin]"""	The product monograph for drospirenone and ethinyl estradiol (YAZ) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency and protein S deficiency (among other contraindications), due to the risk for arterial or venous thrombosis.
388	PA166127666	drospirenone	SERPINC1	PA35026	serpin peptidase inhibitor, clade C (antithrombin), member 1	NCBI Gene:462	PA164749409	"6beta,7beta,15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17 carbolactone,""DRSP"",""Drospirenona [inn-spanish]"",""Drospirenonum [inn-latin]"""	The product monograph for drospirenone and ethinyl estradiol (YAZ) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency and protein S deficiency (among other contraindications), due to the risk for arterial or venous thrombosis.
389	PA166104814	ethinyl estradiol	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA449527	"17 alpha-Ethinylestradiol,""17 alpha-Ethynylestradiol"",""17 alpha-Ethynyloestradiol"",""Aethinyloestradiolum"",""Aethinyoestradiol [German]"",""EE"",""EO"",""Ethinyl-Oestranol"",""Ethinylestradiolum [INN-Latin]"",""Ethinylestriol"",""Ethinyloestradiol"",""Ethynylestradiol"",""Ethynyloestradiol"",""Etinilestradiol [INN-Spanish]"",""ethynyl estradiol"""	The FDA-approved drug label for drospirenone and ethinyl estradiol (Yaz) notes that _in vitro_ studies showed an inhibitory effect of drospirenone on the turnover of model substrates of CYP1A1, CYP2C9, CYP2C19 and CYP3A4. However, _in vivo_ studies using omeprazole as a marker substrate showed that drospirenone has little propensity to interact to a significant extent with cytochrome P450 enzymes at a clinical dose level. 
390	PA166127695	ethinyl estradiol	PROC	PA33799	protein C (inactivator of coagulation factors Va and VIIIa)	NCBI Gene:5624	PA449527	"17 alpha-Ethinylestradiol,""17 alpha-Ethynylestradiol"",""17 alpha-Ethynyloestradiol"",""Aethinyloestradiolum"",""Aethinyoestradiol [German]"",""EE"",""EO"",""Ethinyl-Oestranol"",""Ethinylestradiolum [INN-Latin]"",""Ethinylestriol"",""Ethinyloestradiol"",""Ethynylestradiol"",""Ethynyloestradiol"",""Etinilestradiol [INN-Spanish]"",""ethynyl estradiol"""	The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the _MTHFR_ gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.
391	PA166127666	ethinyl estradiol	PROC	PA33799	protein C (inactivator of coagulation factors Va and VIIIa)	NCBI Gene:5624	PA449527	"17 alpha-Ethinylestradiol,""17 alpha-Ethynylestradiol"",""17 alpha-Ethynyloestradiol"",""Aethinyloestradiolum"",""Aethinyoestradiol [German]"",""EE"",""EO"",""Ethinyl-Oestranol"",""Ethinylestradiolum [INN-Latin]"",""Ethinylestriol"",""Ethinyloestradiol"",""Ethynylestradiol"",""Ethynyloestradiol"",""Etinilestradiol [INN-Spanish]"",""ethynyl estradiol"""	The product monograph for drospirenone and ethinyl estradiol (YAZ) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency and protein S deficiency (among other contraindications), due to the risk for arterial or venous thrombosis.
392	PA166127695	ethinyl estradiol	PROS1	PA33809	protein S (alpha)	NCBI Gene:5627	PA449527	"17 alpha-Ethinylestradiol,""17 alpha-Ethynylestradiol"",""17 alpha-Ethynyloestradiol"",""Aethinyloestradiolum"",""Aethinyoestradiol [German]"",""EE"",""EO"",""Ethinyl-Oestranol"",""Ethinylestradiolum [INN-Latin]"",""Ethinylestriol"",""Ethinyloestradiol"",""Ethynylestradiol"",""Ethynyloestradiol"",""Etinilestradiol [INN-Spanish]"",""ethynyl estradiol"""	The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the _MTHFR_ gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.
393	PA166127666	ethinyl estradiol	PROS1	PA33809	protein S (alpha)	NCBI Gene:5627	PA449527	"17 alpha-Ethinylestradiol,""17 alpha-Ethynylestradiol"",""17 alpha-Ethynyloestradiol"",""Aethinyloestradiolum"",""Aethinyoestradiol [German]"",""EE"",""EO"",""Ethinyl-Oestranol"",""Ethinylestradiolum [INN-Latin]"",""Ethinylestriol"",""Ethinyloestradiol"",""Ethynylestradiol"",""Ethynyloestradiol"",""Etinilestradiol [INN-Spanish]"",""ethynyl estradiol"""	The product monograph for drospirenone and ethinyl estradiol (YAZ) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency and protein S deficiency (among other contraindications), due to the risk for arterial or venous thrombosis.
394	PA166127695	ethinyl estradiol	F2	PA157	coagulation factor II (thrombin)	NCBI Gene:2147	PA449527	"17 alpha-Ethinylestradiol,""17 alpha-Ethynylestradiol"",""17 alpha-Ethynyloestradiol"",""Aethinyloestradiolum"",""Aethinyoestradiol [German]"",""EE"",""EO"",""Ethinyl-Oestranol"",""Ethinylestradiolum [INN-Latin]"",""Ethinylestriol"",""Ethinyloestradiol"",""Ethynylestradiol"",""Ethynyloestradiol"",""Etinilestradiol [INN-Spanish]"",""ethynyl estradiol"""	The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the _MTHFR_ gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.
395	PA166127695	ethinyl estradiol	F5	PA159	coagulation factor V (proaccelerin, labile factor)	NCBI Gene:2153	PA449527	"17 alpha-Ethinylestradiol,""17 alpha-Ethynylestradiol"",""17 alpha-Ethynyloestradiol"",""Aethinyloestradiolum"",""Aethinyoestradiol [German]"",""EE"",""EO"",""Ethinyl-Oestranol"",""Ethinylestradiolum [INN-Latin]"",""Ethinylestriol"",""Ethinyloestradiol"",""Ethynylestradiol"",""Ethynyloestradiol"",""Etinilestradiol [INN-Spanish]"",""ethynyl estradiol"""	The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the _MTHFR_ gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.
396	PA166120287	ethinyl estradiol	F5	PA159	coagulation factor V (proaccelerin, labile factor)	NCBI Gene:2153	PA449527	"17 alpha-Ethinylestradiol,""17 alpha-Ethynylestradiol"",""17 alpha-Ethynyloestradiol"",""Aethinyloestradiolum"",""Aethinyoestradiol [German]"",""EE"",""EO"",""Ethinyl-Oestranol"",""Ethinylestradiolum [INN-Latin]"",""Ethinylestriol"",""Ethinyloestradiol"",""Ethynylestradiol"",""Ethynyloestradiol"",""Etinilestradiol [INN-Spanish]"",""ethynyl estradiol"""	The EMA European Public Assessment Report (EPAR) for norelgestromin and ethinyl estradiol (Evra) contains information regarding its contraindication in women with known predisposition to venous thromboembolism (including Factor V Leiden, [variant:rs6025]).
397	PA166127666	ethinyl estradiol	F5	PA159	coagulation factor V (proaccelerin, labile factor)	NCBI Gene:2153	PA449527	"17 alpha-Ethinylestradiol,""17 alpha-Ethynylestradiol"",""17 alpha-Ethynyloestradiol"",""Aethinyloestradiolum"",""Aethinyoestradiol [German]"",""EE"",""EO"",""Ethinyl-Oestranol"",""Ethinylestradiolum [INN-Latin]"",""Ethinylestriol"",""Ethinyloestradiol"",""Ethynylestradiol"",""Ethynyloestradiol"",""Etinilestradiol [INN-Spanish]"",""ethynyl estradiol"""	The product monograph for drospirenone and ethinyl estradiol (YAZ) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency and protein S deficiency (among other contraindications), due to the risk for arterial or venous thrombosis.
398	PA166127695	ethinyl estradiol	MTHFR	PA245	methylenetetrahydrofolate reductase (NAD(P)H)	NCBI Gene:4524	PA449527	"17 alpha-Ethinylestradiol,""17 alpha-Ethynylestradiol"",""17 alpha-Ethynyloestradiol"",""Aethinyloestradiolum"",""Aethinyoestradiol [German]"",""EE"",""EO"",""Ethinyl-Oestranol"",""Ethinylestradiolum [INN-Latin]"",""Ethinylestriol"",""Ethinyloestradiol"",""Ethynylestradiol"",""Ethynyloestradiol"",""Etinilestradiol [INN-Spanish]"",""ethynyl estradiol"""	The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the _MTHFR_ gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.
399	PA166127695	ethinyl estradiol	SERPINC1	PA35026	serpin peptidase inhibitor, clade C (antithrombin), member 1	NCBI Gene:462	PA449527	"17 alpha-Ethinylestradiol,""17 alpha-Ethynylestradiol"",""17 alpha-Ethynyloestradiol"",""Aethinyloestradiolum"",""Aethinyoestradiol [German]"",""EE"",""EO"",""Ethinyl-Oestranol"",""Ethinylestradiolum [INN-Latin]"",""Ethinylestriol"",""Ethinyloestradiol"",""Ethynylestradiol"",""Ethynyloestradiol"",""Etinilestradiol [INN-Spanish]"",""ethynyl estradiol"""	The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the _MTHFR_ gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.
400	PA166127666	ethinyl estradiol	SERPINC1	PA35026	serpin peptidase inhibitor, clade C (antithrombin), member 1	NCBI Gene:462	PA449527	"17 alpha-Ethinylestradiol,""17 alpha-Ethynylestradiol"",""17 alpha-Ethynyloestradiol"",""Aethinyloestradiolum"",""Aethinyoestradiol [German]"",""EE"",""EO"",""Ethinyl-Oestranol"",""Ethinylestradiolum [INN-Latin]"",""Ethinylestriol"",""Ethinyloestradiol"",""Ethynylestradiol"",""Ethynyloestradiol"",""Etinilestradiol [INN-Spanish]"",""ethynyl estradiol"""	The product monograph for drospirenone and ethinyl estradiol (YAZ) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency and protein S deficiency (among other contraindications), due to the risk for arterial or venous thrombosis.
401	PA166160049	lacosamide	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA166160048		The FDA-approved drug label for lacosamide states that plasma concentrations of the lacosamide O-desmethyl metabolite were reduced by approximately 70% in CYP2C19 poor metabolizers (PMs) as compared to extensive metabolizers (EMs). However, it also states that there are no clinically relevant differences in lacosamide pharmacokinetics between PMs and EMs.
402	PA166104898	lansoprazole	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA450180	"AG 1749,""lansoprazole"""	Lansoprazole delayed-release capsules are metabolized mainly by CYP3A and CYP2C19 isozymes. Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19
403	PA166104808	nelfinavir	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA450606	"1UN,""NFV"",""NLF"",""Nelfinavir mesylate"",""ag1343"""	Coadministration of VIRACEPT with drugs primarily metabolized by CYP3A may result in increased plasma concentrations of the other drug that could prolong its therapeutic and adverse effects. Coadministration of VIRACEPT and drugs that induce CYP3A or CYP2C19 may decrease nelfinavir plasma concentrations and reduce its therapeutic effect. Coadministration of VIRACEPT and drugs that inhibit CYP3A or CYP2C19 may increase nelfinavir plasma concentrations.
404	PA166105315	nelfinavir	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA450606	"1UN,""NFV"",""NLF"",""Nelfinavir mesylate"",""ag1343"""	The EMA European Public Assessment Report (EPAR) for nelfinavir (Viracept) contains information regarding the metabolism of the drug by CYP3A4, CYP2C19 and CYP2D6, and that concomitant use of CYP3A4 substrates or inducers is contraindicated. No genetic information is included. 
405	PA166104808	nelfinavir	CYP3A	PA27114	cytochrome P450, family 3, subfamily A	NCBI Gene:1574	PA450606	"1UN,""NFV"",""NLF"",""Nelfinavir mesylate"",""ag1343"""	Coadministration of VIRACEPT with drugs primarily metabolized by CYP3A may result in increased plasma concentrations of the other drug that could prolong its therapeutic and adverse effects. Coadministration of VIRACEPT and drugs that induce CYP3A or CYP2C19 may decrease nelfinavir plasma concentrations and reduce its therapeutic effect. Coadministration of VIRACEPT and drugs that inhibit CYP3A or CYP2C19 may increase nelfinavir plasma concentrations.
406	PA166104921	omeprazole	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA450704	"OMEP,""OMP"",""OMZ"",""Omeprazol [INN-Spanish]"",""Omeprazole magnesium"",""Omeprazolum [INN-Latin]"",""omeprazole"""	Omeprazole is an inhibitor of CYP2C19 enzyme. Avoid concomitant use of clopidogrel and omeprazole. 
407	PA166127698	omeprazole	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA450704	"OMEP,""OMP"",""OMZ"",""Omeprazol [INN-Spanish]"",""Omeprazole magnesium"",""Omeprazolum [INN-Latin]"",""omeprazole"""	The product monograph for omeprazole (LOSEC) states that CYP2C19 poor metabolizers have higher plasma concentrations of the drug as compared to extensive metabolizers. However, the monograph also notes that this has no implication on dosing of omeprazole.
408	PA166104901	pantoprazole	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA450774	"Pantoprazol [INN-Spanish],""Pantoprazole Na"",""Pantoprazole Sodium"",""Pantoprazolum [INN-Latin]"",""Pantoprozole"""	Pantoprazole is metabolized mainly by CYP2C19 and to minor extents by CYPs 3A4, 2D6, and 2C9. The FDA-approved drug label for pantoprazole (PROTONIX) states that pediatric patients who are CYP2C19 poor metabolizers have greater than a 6-fold increase in AUC and 10-fold lower clearance as compared to extensive metabolizers.
409	PA166104860	phenytoin	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA450947	"5,5-Dwufenylohydantoina,""5,5-diphenylhydantoin"",""DPH"",""Difenilhidantoina [Spanish]"",""Dihydantoin"",""Diphenylan Sodium"",""Diphenylhydantoin"",""Diphenylhydantoine [French]"",""Diphenylhydatanoin"",""Fenitoina [INN-Spanish]"",""Phenytoin Sodium"",""Phenytoine"",""Phenytoine [INN-French]"",""Phenytoinum [INN-Latin]"""	A strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA B gene, in patients using carbamazepine. Limited evidence suggests that HLAB*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. Consideration should be given to avoiding phenytoin as an alternative for carbamazepine in patients positive for HLA-B*1502.
410	PA166104860	phenytoin	CYP2C9	PA126	cytochrome P450, family 2, subfamily C, polypeptide 9	NCBI Gene:1559	PA450947	"5,5-Dwufenylohydantoina,""5,5-diphenylhydantoin"",""DPH"",""Difenilhidantoina [Spanish]"",""Dihydantoin"",""Diphenylan Sodium"",""Diphenylhydantoin"",""Diphenylhydantoine [French]"",""Diphenylhydatanoin"",""Fenitoina [INN-Spanish]"",""Phenytoin Sodium"",""Phenytoine"",""Phenytoine [INN-French]"",""Phenytoinum [INN-Latin]"""	A strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA B gene, in patients using carbamazepine. Limited evidence suggests that HLAB*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. Consideration should be given to avoiding phenytoin as an alternative for carbamazepine in patients positive for HLA-B*1502.
411	PA166104860	phenytoin	HLA-B	PA35056	major histocompatibility complex, class I, B	NCBI Gene:3106	PA450947	"5,5-Dwufenylohydantoina,""5,5-diphenylhydantoin"",""DPH"",""Difenilhidantoina [Spanish]"",""Dihydantoin"",""Diphenylan Sodium"",""Diphenylhydantoin"",""Diphenylhydantoine [French]"",""Diphenylhydatanoin"",""Fenitoina [INN-Spanish]"",""Phenytoin Sodium"",""Phenytoine"",""Phenytoine [INN-French]"",""Phenytoinum [INN-Latin]"""	A strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA B gene, in patients using carbamazepine. Limited evidence suggests that HLAB*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. Consideration should be given to avoiding phenytoin as an alternative for carbamazepine in patients positive for HLA-B*1502.
412	PA166127701	phenytoin	HLA-B	PA35056	major histocompatibility complex, class I, B	NCBI Gene:3106	PA450947	"5,5-Dwufenylohydantoina,""5,5-diphenylhydantoin"",""DPH"",""Difenilhidantoina [Spanish]"",""Dihydantoin"",""Diphenylan Sodium"",""Diphenylhydantoin"",""Diphenylhydantoine [French]"",""Diphenylhydatanoin"",""Fenitoina [INN-Spanish]"",""Phenytoin Sodium"",""Phenytoine"",""Phenytoine [INN-French]"",""Phenytoinum [INN-Latin]"""	The product monograph for phenytoin (DILANTIN) notes that individuals with the HLA-B*1502 allele have an increased risk of developing Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) when receiving the drug. It further notes that this allele is common in individuals of Asian ancestry, and HLA-B genotyping should be considered as a screening tool in these patients.
413	PA166104848	rabeprazole	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA451216	"Irsogladine Maleate,""Rebeprazole sodium"",""rabeprazole sodium"""	Rabeprazole is metabolized in the liver primarily by cytochromes P450 3A (CYP3A) and cytochrome P450 2C19 (CYP2C19). Patients with the CYP2C19 poor metabolizer genotypes may have slower rabeprazole metabolism and increased suppression of gastric acid as compared to more extensive metabolizers.
414	PA166127706	rabeprazole	CYP2C19	PA124	cytochrome P450, family 2, subfamily C, polypeptide 19	NCBI Gene:1557	PA451216	"Irsogladine Maleate,""Rebeprazole sodium"",""rabeprazole sodium"""	The product monograph for rabeprazole states that individuals with CYP2C19 deficiency have reduced metabolism of rabeprazole.
415	PA166104843	celecoxib	CYP2C9	PA126	cytochrome P450, family 2, subfamily C, polypeptide 9	NCBI Gene:1559	PA448871	"Celocoxib,""celecoxib"""	Celecoxib is metabolized primarily by CYP2C9. Patients who are known or suspected to be poor CYP2C9 metabolizers should be administered celecoxib with caution. Consider a dose reduction by 50% (or alternative management for juvenile rheumatoid arthritis (JRA)) in patients who are known or suspected to be CYP2C9 poor metabolizers.
416	PA166127647	celecoxib	CYP2C9	PA126	cytochrome P450, family 2, subfamily C, polypeptide 9	NCBI Gene:1559	PA448871	"Celocoxib,""celecoxib"""	The product monograph for celecoxib (CELEBREX) notes that patients who are CYP2C9 poor metabolizers should be administered celecoxib with caution. It further states that the drug should be introduced at half the lowest recommended dose in these individuals, with a maximum recommended dose of 100 mg/day. However, the product monograph does not discuss CYP2C9 genotyping prior to treatment.
417	PA166104922	flurbiprofen	CYP2C9	PA126	cytochrome P450, family 2, subfamily C, polypeptide 9	NCBI Gene:1559	PA449683	"FLP,""Flurbiprofen Sodium"",""Flurbiprofene [INN-French]"",""Flurbiprofeno [INN-Spanish]"",""Flurbiprofenum [INN-Latin]"""	In vitro studies have demonstrated that cytochrome P450 2C9 plays an important role in the metabolism of flurbiprofen. CYP2C9 poor metabolizers should be administered flurbiprofen with caution due to the possibility of high plasma levels resulting from decreased clearance.
418	PA166160007	lesinurad	CYP2C9	PA126	cytochrome P450, family 2, subfamily C, polypeptide 9	NCBI Gene:1559	PA166160006		The FDA-approved drug label for ZURAMPIC (lesinurad) states that exposure to the drug is increased in CYP2C9 poor metabolizers, and that caution should be used in these patients.
419	PA166104776	warfarin	CYP2C9	PA126	cytochrome P450, family 2, subfamily C, polypeptide 9	NCBI Gene:1559	PA451906	Warfarin sodium	Warfarin _(Coumadin)_ is an anticoagulant used as a prophylaxis and to treat venous thrombosis, pulmonary embolism, thromboembolic complications from atrial fibrillationa and cardiac valve replacement, and to reduce the recurrence of myocardial infarction. Pharmacogenomics-related dosing information for CYP2C9 and VKORC1 variants is provided within the label. The drug label notes that deficiency in protein C (_PROC_) or protein S (_PROS1_) have been associated with tissue necrosis following warfarin administration.
420	PA166127732	warfarin	CYP2C9	PA126	cytochrome P450, family 2, subfamily C, polypeptide 9	NCBI Gene:1559	PA451906	Warfarin sodium	The product monograph for warfarin (COUMADIN) notes that patients carrying one or two copies of the CYP2C9*2 or *3 alleles may require a decreased mean daily warfarin dose, and have an increased bleeding risk, as compared to those homozygous for the CYP2C9*1 allele. Additionally, variations in the _VKORC1_ gene, such as -1639G>A, are also associated with changes in the dose requirement of warfarin. 
421	PA166104776	warfarin	PROC	PA33799	protein C (inactivator of coagulation factors Va and VIIIa)	NCBI Gene:5624	PA451906	Warfarin sodium	Warfarin _(Coumadin)_ is an anticoagulant used as a prophylaxis and to treat venous thrombosis, pulmonary embolism, thromboembolic complications from atrial fibrillationa and cardiac valve replacement, and to reduce the recurrence of myocardial infarction. Pharmacogenomics-related dosing information for CYP2C9 and VKORC1 variants is provided within the label. The drug label notes that deficiency in protein C (_PROC_) or protein S (_PROS1_) have been associated with tissue necrosis following warfarin administration.
422	PA166104776	warfarin	PROS1	PA33809	protein S (alpha)	NCBI Gene:5627	PA451906	Warfarin sodium	Warfarin _(Coumadin)_ is an anticoagulant used as a prophylaxis and to treat venous thrombosis, pulmonary embolism, thromboembolic complications from atrial fibrillationa and cardiac valve replacement, and to reduce the recurrence of myocardial infarction. Pharmacogenomics-related dosing information for CYP2C9 and VKORC1 variants is provided within the label. The drug label notes that deficiency in protein C (_PROC_) or protein S (_PROS1_) have been associated with tissue necrosis following warfarin administration.
423	PA166104776	warfarin	VKORC1	PA133787052	vitamin K epoxide reductase complex, subunit 1	NCBI Gene:79001	PA451906	Warfarin sodium	Warfarin _(Coumadin)_ is an anticoagulant used as a prophylaxis and to treat venous thrombosis, pulmonary embolism, thromboembolic complications from atrial fibrillationa and cardiac valve replacement, and to reduce the recurrence of myocardial infarction. Pharmacogenomics-related dosing information for CYP2C9 and VKORC1 variants is provided within the label. The drug label notes that deficiency in protein C (_PROC_) or protein S (_PROS1_) have been associated with tissue necrosis following warfarin administration.
424	PA166127732	warfarin	VKORC1	PA133787052	vitamin K epoxide reductase complex, subunit 1	NCBI Gene:79001	PA451906	Warfarin sodium	The product monograph for warfarin (COUMADIN) notes that patients carrying one or two copies of the CYP2C9*2 or *3 alleles may require a decreased mean daily warfarin dose, and have an increased bleeding risk, as compared to those homozygous for the CYP2C9*1 allele. Additionally, variations in the _VKORC1_ gene, such as -1639G>A, are also associated with changes in the dose requirement of warfarin. 
425	PA166104844	erlotinib	UGT1A1	PA420	UDP glucuronosyltransferase 1 family, polypeptide A1	NCBI Gene:54658	PA134687924	OSI-774	The EMA European Public Assessment Report (EPAR) requires testing tumours for EGFR mutations in patients with non-small cell lung cancer prior to treatment with erlotinib and recommends using a well-validated method of testing. The drug should be used with caution in patients with low expression of UGT1A1 or Gilbert's disease (caused by genetic variants in UGT1A1 gene), due to the inhibitory effects of erlotinib on glucuronidation by UGT1A1 (UGT1A1 genetic testing is not required).
426	PA166104844	erlotinib	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA134687924	OSI-774	The EMA European Public Assessment Report (EPAR) requires testing tumours for EGFR mutations in patients with non-small cell lung cancer prior to treatment with erlotinib and recommends using a well-validated method of testing. The drug should be used with caution in patients with low expression of UGT1A1 or Gilbert's disease (caused by genetic variants in UGT1A1 gene), due to the inhibitory effects of erlotinib on glucuronidation by UGT1A1 (UGT1A1 genetic testing is not required).
427	PA166104785	erlotinib	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA134687924	OSI-774	TARCEVA (erlotinib) is a kinase inhibitor indicated for First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.  Information on FDA-approved tests for the detection of EGFR mutations in NSCLC is available at: http://www.fda.gov/CompanionDiagnostics.
428	PA166127669	erlotinib	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA134687924	OSI-774	The product monograph for erlotinib (TARCEVA) states that it is indicated for patients with non-small cell lung cancer (NSCLC) who have a confirmed activating EGFR mutation. 
429	PA166122488	regorafenib	UGT1A1	PA420	UDP glucuronosyltransferase 1 family, polypeptide A1	NCBI Gene:54658	PA166114943		The EMA European Public Assessment Report (EPAR) for regorafenib (Stivarga) is indicated in adult patients with metastatic colorectal cancer who have been previously treated with or are not considered candidates for other available therapies, including patients with KRAS mutant tumors, though physicians are recommended to carefully evaluate benefits and risks when prescribing regorafenib in patients with KRAS mutant tumours. It potentially blocks targets multiple protein kinases. It is also an inhibitor of UGT1A1 and therefore hyperbilirubinemia may occur in patients with Gilbert's syndrome (can be caused by genetic variants in the _UGT1A1_ gene).
430	PA166114944	regorafenib	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA166114943		"The FDA-approved drug label for regorafenib (Stivarga) states that it is intended for patients with metastatic colorectal cancer who were previously given fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if they were KRAS wild type, an anti-EGFR therapy. The label does not specifically mention any form of genetic testing. __This drug-biomarker pair was previously in the FDA's ""Table of Pharmacogenomic Biomarkers in Drug Labels"" but has subsequently been removed.__"
431	PA166114944	regorafenib	KRAS	PA30196	Kirsten rat sarcoma viral oncogene homolog	NCBI Gene:3845	PA166114943		"The FDA-approved drug label for regorafenib (Stivarga) states that it is intended for patients with metastatic colorectal cancer who were previously given fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if they were KRAS wild type, an anti-EGFR therapy. The label does not specifically mention any form of genetic testing. __This drug-biomarker pair was previously in the FDA's ""Table of Pharmacogenomic Biomarkers in Drug Labels"" but has subsequently been removed.__"
432	PA166122488	regorafenib	KRAS	PA30196	Kirsten rat sarcoma viral oncogene homolog	NCBI Gene:3845	PA166114943		The EMA European Public Assessment Report (EPAR) for regorafenib (Stivarga) is indicated in adult patients with metastatic colorectal cancer who have been previously treated with or are not considered candidates for other available therapies, including patients with KRAS mutant tumors, though physicians are recommended to carefully evaluate benefits and risks when prescribing regorafenib in patients with KRAS mutant tumours. It potentially blocks targets multiple protein kinases. It is also an inhibitor of UGT1A1 and therefore hyperbilirubinemia may occur in patients with Gilbert's syndrome (can be caused by genetic variants in the _UGT1A1_ gene).
433	PA166114944	regorafenib	VEGFA	PA37302	vascular endothelial growth factor A	NCBI Gene:7422	PA166114943		"The FDA-approved drug label for regorafenib (Stivarga) states that it is intended for patients with metastatic colorectal cancer who were previously given fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if they were KRAS wild type, an anti-EGFR therapy. The label does not specifically mention any form of genetic testing. __This drug-biomarker pair was previously in the FDA's ""Table of Pharmacogenomic Biomarkers in Drug Labels"" but has subsequently been removed.__"
434	PA166121326	pazopanib	UGT1A1	PA420	UDP glucuronosyltransferase 1 family, polypeptide A1	NCBI Gene:54658	PA165291492		The EMA European Public Assessment Report (EPAR) for pazopanib (Votrient) states that the drug may cause mild hyperbilirubinemia in patients with Gilbert's syndrome (associated with reduced UGT1A1 activity and in some cases is caused by an underlying _UGT1A1*28_ variant) because it is an inhibitor of UGT1A1. It also states that pazopanib may have a greater effect on irinotecan active metabolite exposure in patients with the _UGT1A1*28_ variant.
435	PA166105058	pazopanib	UGT1A1	PA420	UDP glucuronosyltransferase 1 family, polypeptide A1	NCBI Gene:54658	PA165291492		The drug label for pazopanib (VOTRIENT) states that patients with the _UGT1A1_ (TA)7/(TA)7 genotype (_UGT1A1_*28/*28) have an increased incidence of hyperbilirubinemia when taking pazopanib, as compared to those with the (TA)6/(TA)7 or (TA)6/(TA)6 genotype.
436	PA166129553	belinostat	UGT1A1	PA420	UDP glucuronosyltransferase 1 family, polypeptide A1	NCBI Gene:54658	PA165971474		The FDA-approved drug label for belinostat (Beleodaq) states that the starting dose should be reduced to 750 mg/m2 in patients known to be homozygous for the UGT1A1*28 allele to minimize dose limiting toxicities. However, testing or screening for the *28 allele is not mentioned.
437	PA166160010	dolutegravir	UGT1A1	PA420	UDP glucuronosyltransferase 1 family, polypeptide A1	NCBI Gene:54658	PA166114961		The FDA-approved drug label for TIVICAY (dolutegravir) states that subjects with _UGT1A1_ genotypes that result in poor metabolism of the drug have decreased clearance and increased AUC as compared to those who have _UGT1A1_ genotypes that result in normal dolutegravir metabolism. The label does not mention specific _UGT1A1_ variants or genetic testing.
438	PA166104831	irinotecan	UGT1A1	PA420	UDP glucuronosyltransferase 1 family, polypeptide A1	NCBI Gene:54658	PA450085	"Irinotecan Hcl,""Irinotecan Hydrochloride"",""Irinotecan Hydrochloride Trihydrate"",""Irinotecanum [INN-Latin]"",""irinotecan"""	Individuals who are homozygous for the UGT1A1*28 allele (UGT1A1 7/7 genotype) are at increased risk for neutropenia following initiation of CAMPTOSAR treatment. A reduction in the starting dose by at least one level of CAMPTOSAR should be considered for patients known to be homozygous for the UGT1A1*28 allele.
439	PA166127683	irinotecan	UGT1A1	PA420	UDP glucuronosyltransferase 1 family, polypeptide A1	NCBI Gene:54658	PA450085	"Irinotecan Hcl,""Irinotecan Hydrochloride"",""Irinotecan Hydrochloride Trihydrate"",""Irinotecanum [INN-Latin]"",""irinotecan"""	The product monograph for irinotecan (CAMPTOSAR) notes that a reduced irinotecan starting dose should be considered in individuals homozygous for the UGT1A1*28 ([variant:rs8175347]) allele, due to the risk for hematologic toxicity. 
440	PA166123526	irinotecan	UGT1A1	PA420	UDP glucuronosyltransferase 1 family, polypeptide A1	NCBI Gene:54658	PA450085	"Irinotecan Hcl,""Irinotecan Hydrochloride"",""Irinotecan Hydrochloride Trihydrate"",""Irinotecanum [INN-Latin]"",""irinotecan"""	The PMDA package insert for irinotecan states that it is for the treatment of refractory, inoperable pancreatic cancer and that patients should be selected for treatment based on their stage, general condition and UGT1A1 polymorphism.
441	PA166123048	cabazitaxel	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA165958401	taxoid xrp6258	The EMA European Public Assessment Report (EPAR) for cabazitaxel (Jevtana) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A, and coadministration of strong CYP3A inhibitors or inducers should be avoided.
442	PA166123424	darunavir	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA163522472	"AIDS073035,""Darunavirum [INN-latin]"",""TMC-114"",""TMC114"",""UIC-94017"""	The EMA European Public Assessment Report (EPAR) for darunavir (PREZISTA) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. It contains information regarding metabolism of darunavir by CYP3A and gives information regarding the coadministration of drugs that are CYP3A substrates, inhibitors or inducers. 
443	PA166123420	fosamprenavir	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA10084		The EMA European Public Assessment Report (EPAR) for fosamprenavir (Telzir) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. Concomitant use of drugs with a narrow therapeutic window that are substrates of CYP3A4 or CYP2D6 is contraindicated.
444	PA166123419	indinavir	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA449977	"Compound J,""Indinavir sulfate"""	The EMA European Public Assessment Report (EPAR) for indinavir (Crixivan) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and contraindicates concomitant use of drugs that are CYP3A4 substrates.
445	PA166123416	ivabradine	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA166123415		The EMA European Public Assessment Report (EPAR) for ivabradine (Corlentor) does not contain pharmacogenetic information. It contains information regarding metabolism of ivabradine by CYP3A4, and that concomitant use of potent CYP3A4 inhibitors is contraindicated.
446	PA166123418	posaconazole	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA151958574	posaconazole	The EMA European Public Assessment Report (EPAR) for posaconazole (Noxafil) does not contain pharmacogenetic information. It contains information regarding metabolism drug-drug interactions with CYP3A4 substrates.
447	PA166123388	ruxolitinib	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA166123386	INCB-018424	"The EMA European Public Assessment Report (EPAR) for ruxolitinib (Jakavi) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and CYP2C9, and suggests dosing adjustments and more frequent monitoring of hematology parameters if co-administered with strong CYP3A4 inhibitors or inducers, or dual inhibitors of CYP3A4 and CYP2C9.

"
448	PA166123411	sirolimus	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA451365	"(-)-rapamycin,""Antibiotic AY 22989"",""rapamycin"",""sirolimus"""	The EMA European Public Assessment Report (EPAR) for sirolimus (Rapamune) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and recommends therapeutic monitoring and dose adjustments when coadministrated with strong CYP3A inhibitors or inducers.
449	PA166123412	sunitinib	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA162372840	"SU11248,""Sunitinib malate"",""Sutent"""	The EMA European Public Assessment Report (EPAR) for sunitinib (SUTENT) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and that potent CYP3A4 inhibitors or inducers should be avoided as they may affect sunitinib plasma levels.
450	PA166123417	telithromycin	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA10202	telithromycin	The EMA European Public Assessment Report (EPAR) for telithromycin (Ketek) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4 and contains information regarding use of concomitant drugs that are CYP3A4 substrates, inhibitors or inducers.
451	PA166123423	tipranavir	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA163522473	"TPV,""tipranavir"""	The EMA European Public Assessment Report (EPAR) for tipranavir (Aptivus) does not contain human pharmacogenetic information, but does contain pharmacogenetic information related to the genotype of the HIV virus. It contains information regarding metabolism of tipranavir by CYP3A4, and gives information regarding the coadministration of drugs that are CYP3A substrates, inhibitors or inducers.
452	PA166123413	zonisamide	CYP3A4	PA130	cytochrome P450, family 3, subfamily A, polypeptide 4	NCBI Gene:1576	PA451978	"Zonisamida [Spanish],""Zonisamidum [Latin]"",""zonisamide"""	The EMA European Public Assessment Report (EPAR) for zonisamide (Zonegran) does not contain pharmacogenetic information. It contains information regarding metabolism by CYP3A4, and recommends dose adjustments if CYP3A4 inducers are taken concomitantly.
453	PA166127645	carbamazepine	HLA-B	PA35056	major histocompatibility complex, class I, B	NCBI Gene:3106	PA448785	"CBZ,""Carbamezepine"",""carbamazepine"""	The product monograph for carbamazepine states that the individuals with the _HLA-A*31:01_ and _HLA-B*15:02_ alleles are at risk of developing serious cutaneous adverse drug reactions when receiving the drug, and it is recommended that physicians consider _HLA-A*31:01_ and _HLA-B*15:02_ genotyping as a screening tool in genetically at-risk populations.
454	PA166104780	carbamazepine	HLA-B	PA35056	major histocompatibility complex, class I, B	NCBI Gene:3106	PA448785	"CBZ,""Carbamezepine"",""carbamazepine"""	The FDA-approved label for carbamazepine (Tegretol) states screening of patients with ancestry in genetically at-risk populations (patients of Asian descent) for the presence of the HLA-B*1502 allele should be carried out prior to treatment due to a high risk of serious and something fatal dermatologic reactions. It also notes that a moderate association has been found between HLA-A*3101 and the risk of developing hypersensitivity reactions to carbamazepine, though it does not mention testing for this allele. 
455	PA166123532	carbamazepine	HLA-B	PA35056	major histocompatibility complex, class I, B	NCBI Gene:3106	PA448785	"CBZ,""Carbamezepine"",""carbamazepine"""	The PMDA package insert for carbamazepine notes that the _HLA-A*3101_ allele appeared at a high frequency in Japanese patients who developed a serious drug rash when taking carbamazepine. The insert also notes that the _HLA-B*1502_ allele appeared in nearly all of a group of Han Chinese patients who developed Stevens-Johnson syndrome or toxic epidermal necrolysis when taking carbamazepine.
456	PA166151882	carbamazepine	HLA-A	PA35055	major histocompatibility complex, class I, A	NCBI Gene:3105	PA448785	"CBZ,""Carbamezepine"",""carbamazepine"""	"The FDA-approved label for carbamazepine (Tegretol) states that a moderate association has been found between HLA-A*3101 and the risk of developing hypersensitivity reactions to carbamazepine, though it does not mention testing for this allele. However, the label does state that screening of patients with ancestry in genetically at-risk populations (patients of Asian descent) for the presence of the HLA-B*1502 allele should be carried out prior to treatment due to a high risk of serious and something fatal dermatologic reactions. 

"
457	PA166127645	carbamazepine	HLA-A	PA35055	major histocompatibility complex, class I, A	NCBI Gene:3105	PA448785	"CBZ,""Carbamezepine"",""carbamazepine"""	The product monograph for carbamazepine states that the individuals with the _HLA-A*31:01_ and _HLA-B*15:02_ alleles are at risk of developing serious cutaneous adverse drug reactions when receiving the drug, and it is recommended that physicians consider _HLA-A*31:01_ and _HLA-B*15:02_ genotyping as a screening tool in genetically at-risk populations.
458	PA166104896	abacavir	HLA-B	PA35056	major histocompatibility complex, class I, B	NCBI Gene:3106	PA448004	"ABC,""abacavir"""	The EMA European Public Assessment Report (EPAR) states screening for the HLA-B*5701 allele should be carried out prior to initiating abacavir treatment and recommends screening in patients of unknown HLA-B*5701 allele status who are reinitiating treatment with abacavir. Due to a high risk of hypersensitivity reaction abacavir is not recommended in individuals carrying this allele.
459	PA166104833	abacavir	HLA-B	PA35056	major histocompatibility complex, class I, B	NCBI Gene:3106	PA448004	"ABC,""abacavir"""	The FDA-approved label for abacavir states that genetic testing for the HLA-B*5701 allele is required prior to initiating or reinitiating treatment with abacavir in patients of unknown HLA-B*5701 status. Abacavir is contraindicated in patients with the HLA-B*5701 allele due to risk for abacavir hypersensitivity reactions. 
460	PA166127627	abacavir	HLA-B	PA35056	major histocompatibility complex, class I, B	NCBI Gene:3106	PA448004	"ABC,""abacavir"""	The product monograph for abacavir (ZIAGEN) states that all patients should be screened for the HLA-B*5701 allele prior to initiating or re-initiating treatment with abacavir, due to the high risk of experiencing a hypersensitivity reaction (HSR) for patients carrying this allele.
461	PA166123553	abacavir	HLA-B	PA35056	major histocompatibility complex, class I, B	NCBI Gene:3106	PA448004	"ABC,""abacavir"""	The _HLA-B*57:01_ allele is associated with a high risk of experiencing a hypersensitivity reaction to abacavir in multiple populations, including Caucasians and African-Americans. However, the PMDA package insert for abacavir notes that the association between _HLA-B*57:01_ and risk of an abacavir hypersensitivity reaction is unknown in Japanese patients, and that the _*57:01_ allele has a reported prevalence of only 0.1% in the Japanese population.
462	PA166105213	oxcarbazepine	HLA-B	PA35056	major histocompatibility complex, class I, B	NCBI Gene:3106	PA450732	oxcarbazepine	The FDA-approved drug label for oxcarbazepine states that testing for the presence of the HLA-B*1502 allele should be considered in patients with ancestry in genetically at-risk populations prior to initiating treatment with the drug, due to the risk for Stevens-Johnson syndrome or toxic epidermal necrolysis. 
463	PA166127695	norelgestromin	PROC	PA33799	protein C (inactivator of coagulation factors Va and VIIIa)	NCBI Gene:5624	PA164953212		The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the _MTHFR_ gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.
464	PA166127695	norelgestromin	PROS1	PA33809	protein S (alpha)	NCBI Gene:5627	PA164953212		The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the _MTHFR_ gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.
465	PA166127695	norelgestromin	F2	PA157	coagulation factor II (thrombin)	NCBI Gene:2147	PA164953212		The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the _MTHFR_ gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.
466	PA166127695	norelgestromin	F5	PA159	coagulation factor V (proaccelerin, labile factor)	NCBI Gene:2153	PA164953212		The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the _MTHFR_ gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.
467	PA166120287	norelgestromin	F5	PA159	coagulation factor V (proaccelerin, labile factor)	NCBI Gene:2153	PA164953212		The EMA European Public Assessment Report (EPAR) for norelgestromin and ethinyl estradiol (Evra) contains information regarding its contraindication in women with known predisposition to venous thromboembolism (including Factor V Leiden, [variant:rs6025]).
468	PA166127695	norelgestromin	MTHFR	PA245	methylenetetrahydrofolate reductase (NAD(P)H)	NCBI Gene:4524	PA164953212		The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the _MTHFR_ gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.
469	PA166127695	norelgestromin	SERPINC1	PA35026	serpin peptidase inhibitor, clade C (antithrombin), member 1	NCBI Gene:462	PA164953212		The product monograph for norelgestromin and ethinyl estradiol (EVRA) states that the drug is contraindicated in women with Factor V Leiden mutation, antithrombin-III-deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia due to mutations in the _MTHFR_ gene and prothrombin mutation G20210A (among other contraindications), due to the risk for arterial or venous thrombosis.
470	PA166119823	afatinib	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA165981154	BIBW 2992	Afatinib (GIOTRIF) is indicated in adult patients with non-small cell lung cancer with activating EGFR mutations. The EMA European Public Assessment Report (EPAR) for afatinib (GIOTRIF) states that EGFR mutation status should be established before initiation of afatinib therapy using a well-validated and robust methodology.
471	PA166114903	afatinib	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA165981154	BIBW 2992	Afatinib (GILOTRIF) is indicated for patients with metastatic non-small cell lung cancer (NSCLC) who have tumors with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test. 
472	PA166127629	afatinib	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA165981154	BIBW 2992	The product monograph for afatinib (GIOTRIF) states that it is indicated for the treatment of patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s), including exon 19 deletions and the exon 21 L858R point mutation. A validated test is required to identify EGFR mutation status.
473	PA166104908	cetuximab	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA10040	"Anti EGFR,""IMC-C225"",""cetuximab"""	The EMA European Public Assessment Report (EPAR) highlights information regarding the contraindication of Cetuximab (Erbitux) in colorectal cancer patients with tumors with KRAS mutations or if tumor status is not known.
474	PA166104826	cetuximab	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA10040	"Anti EGFR,""IMC-C225"",""cetuximab"""	"Cetuximab is used in alone or in combination therapy to treat advanced squamous cell carcinoma of the head and neck and to treat _K-Ras_ mutation-negative, EGFR expressing metastatic colorectal cancer.  In cases of colorectal cancer, the label states ""Determine K-Ras mutation and EGFR-expression status using FDA-approved tests prior to initiating treatment."""
475	PA166127648	cetuximab	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA10040	"Anti EGFR,""IMC-C225"",""cetuximab"""	The product monograph for cetuximab (ERBITUX) states that it is indicated for treatment of EGFR-expressing K-ras wild-type metastatic colorectal carcinoma.
476	PA166104908	cetuximab	KRAS	PA30196	Kirsten rat sarcoma viral oncogene homolog	NCBI Gene:3845	PA10040	"Anti EGFR,""IMC-C225"",""cetuximab"""	The EMA European Public Assessment Report (EPAR) highlights information regarding the contraindication of Cetuximab (Erbitux) in colorectal cancer patients with tumors with KRAS mutations or if tumor status is not known.
477	PA166104826	cetuximab	KRAS	PA30196	Kirsten rat sarcoma viral oncogene homolog	NCBI Gene:3845	PA10040	"Anti EGFR,""IMC-C225"",""cetuximab"""	"Cetuximab is used in alone or in combination therapy to treat advanced squamous cell carcinoma of the head and neck and to treat _K-Ras_ mutation-negative, EGFR expressing metastatic colorectal cancer.  In cases of colorectal cancer, the label states ""Determine K-Ras mutation and EGFR-expression status using FDA-approved tests prior to initiating treatment."""
478	PA166127648	cetuximab	KRAS	PA30196	Kirsten rat sarcoma viral oncogene homolog	NCBI Gene:3845	PA10040	"Anti EGFR,""IMC-C225"",""cetuximab"""	The product monograph for cetuximab (ERBITUX) states that it is indicated for treatment of EGFR-expressing K-ras wild-type metastatic colorectal carcinoma.
479	PA166131627	osimertinib	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA166131626	mereletinib	The FDA-approved drug label for osimertinib states that it is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy.
480	PA166104809	panitumumab	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA162373091	"ABX-EGF,""panitumumab"""	The panitumumab drug label contains information about EGFR-expressing metastatic colorectal carcinoma with disease progression on or following certain chemotherapy regimens. Detection of EGFR protein expression is necessary for selection of patients appropriate for Vectibix therapy. The label was updated to include information about treatment of patients with KRAS mutations. Retrospective subset analyses of metastatic colorectal cancer trials have not shown a treatment benefit for Vectibix in patients whose tumors had KRAS mutations in codon 12 or 13. Use of Vectibix is not recommended for the treatment of colorectal cancer with these mutations.
481	PA166127699	panitumumab	EGFR	PA7360	epidermal growth factor receptor	NCBI Gene:1956	PA162373091	"ABX-EGF,""panitumumab"""	The product monograph for panitumumab (VECTIBIX) states that it is indicated for patients with EGFR-expressing metastatic colorectal carcinoma (mCRC) with wild-type _KRAS_, and should not be used in patients with _KRAS_-mutant mCRC or for whom _KRAS_ mutation status is unknown.
482	PA166104809	panitumumab	KRAS	PA30196	Kirsten rat sarcoma viral oncogene homolog	NCBI Gene:3845	PA162373091	"ABX-EGF,""panitumumab"""	The panitumumab drug label contains information about EGFR-expressing metastatic colorectal carcinoma with disease progression on or following certain chemotherapy regimens. Detection of EGFR protein expression is necessary for selection of patients appropriate for Vectibix therapy. The label was updated to include information about treatment of patients with KRAS mutations. Retrospective subset analyses of metastatic colorectal cancer trials have not shown a treatment benefit for Vectibix in patients whose tumors had KRAS mutations in codon 12 or 13. Use of Vectibix is not recommended for the treatment of colorectal cancer with these mutations.
483	PA166127699	panitumumab	KRAS	PA30196	Kirsten rat sarcoma viral oncogene homolog	NCBI Gene:3845	PA162373091	"ABX-EGF,""panitumumab"""	The product monograph for panitumumab (VECTIBIX) states that it is indicated for patients with EGFR-expressing metastatic colorectal carcinoma (mCRC) with wild-type _KRAS_, and should not be used in patients with _KRAS_-mutant mCRC or for whom _KRAS_ mutation status is unknown.
484	PA166105319	panitumumab	KRAS	PA30196	Kirsten rat sarcoma viral oncogene homolog	NCBI Gene:3845	PA162373091	"ABX-EGF,""panitumumab"""	The EMA European Public Assessment Report (EPAR) for panitumumab (Vectibix) contains information regarding the requirement for testing of KRAS mutations before initiating treatment, as the drug is indicated for patients with wildtype KRAS.   
485	PA166123547	panitumumab	KRAS	PA30196	Kirsten rat sarcoma viral oncogene homolog	NCBI Gene:3845	PA162373091	"ABX-EGF,""panitumumab"""	The PMDA package insert for panitumumab (Vectibix) states that it is indicated for patients with wild-type _KRAS_ colorectal cancer, and that patients should be selected based on _RAS_ (_KRAS_ and _NRAS_) mutation status.
486	PA166104911	everolimus	ESR1	PA156	estrogen receptor 1	NCBI Gene:2099	PA164746311	everolimus	The EMA European Public Assessment Report (EPAR) for everolimus (Afinitor) contains biomarker information regarding the indication in postmenopausal women with oestrogen receptor-positive, HER2/neu negative advanced breast cancer. It is also indicated in patients with Neuroendocrine tumors of pancreatic origin or advanced renal cell carcinoma.
487	PA166104913	everolimus	ESR1	PA156	estrogen receptor 1	NCBI Gene:2099	PA164746311	everolimus	Everolimus (AFINITOR) is indicated for treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. It is also indicated for adults with neuroendocrine tumors of pancreatic origin or advanced renal cell carcinoma.
488	PA166127671	everolimus	ESR1	PA156	estrogen receptor 1	NCBI Gene:2099	PA164746311	everolimus	The product monograph for everolimus (AFINITOR) states that it is indicated for treatment of hormone receptor-positive, HER2-negative breast cancer.
489	PA166104911	everolimus	ESR2	PA27886	estrogen receptor 2 (ER beta)	NCBI Gene:2100	PA164746311	everolimus	The EMA European Public Assessment Report (EPAR) for everolimus (Afinitor) contains biomarker information regarding the indication in postmenopausal women with oestrogen receptor-positive, HER2/neu negative advanced breast cancer. It is also indicated in patients with Neuroendocrine tumors of pancreatic origin or advanced renal cell carcinoma.
490	PA166104913	everolimus	ESR2	PA27886	estrogen receptor 2 (ER beta)	NCBI Gene:2100	PA164746311	everolimus	Everolimus (AFINITOR) is indicated for treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. It is also indicated for adults with neuroendocrine tumors of pancreatic origin or advanced renal cell carcinoma.
491	PA166127671	everolimus	ESR2	PA27886	estrogen receptor 2 (ER beta)	NCBI Gene:2100	PA164746311	everolimus	The product monograph for everolimus (AFINITOR) states that it is indicated for treatment of hormone receptor-positive, HER2-negative breast cancer.
492	PA166104911	everolimus	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA164746311	everolimus	The EMA European Public Assessment Report (EPAR) for everolimus (Afinitor) contains biomarker information regarding the indication in postmenopausal women with oestrogen receptor-positive, HER2/neu negative advanced breast cancer. It is also indicated in patients with Neuroendocrine tumors of pancreatic origin or advanced renal cell carcinoma.
493	PA166104913	everolimus	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA164746311	everolimus	Everolimus (AFINITOR) is indicated for treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. It is also indicated for adults with neuroendocrine tumors of pancreatic origin or advanced renal cell carcinoma.
494	PA166127671	everolimus	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA164746311	everolimus	The product monograph for everolimus (AFINITOR) states that it is indicated for treatment of hormone receptor-positive, HER2-negative breast cancer.
495	PA166160133	palbociclib	ESR1	PA156	estrogen receptor 1	NCBI Gene:2099	PA166153469		The FDA-approved drug label for palbociclib (IBRANCE) states that it is indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with either letrozole or fulvestrant.
496	PA166160133	palbociclib	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA166153469		The FDA-approved drug label for palbociclib (IBRANCE) states that it is indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with either letrozole or fulvestrant.
497	PA166104919	fulvestrant	ESR1	PA156	estrogen receptor 1	NCBI Gene:2099	PA164747170	"ICI 182,780,""fulvestrant"""	The EMA European Public Assessment Report (EPAR) contains biomarker information regarding the indication of Fulvestrant (Faslodex) in postmenopausal women with estrogen receptor positive breast cancer due to its mechanism of action.
498	PA166104792	fulvestrant	ESR1	PA156	estrogen receptor 1	NCBI Gene:2099	PA164747170	"ICI 182,780,""fulvestrant"""	Fulvestrant is used to treat hormone-receptor positive breast cancer in postmenopausal women whose disease has spread after treatment with an antiestrogen medicine.
499	PA166123540	fulvestrant	ESR1	PA156	estrogen receptor 1	NCBI Gene:2099	PA164747170	"ICI 182,780,""fulvestrant"""	The PMDA package insert for fulvestrant states that it is indicated for postmenopausal women with hormone-receptor positive breast cancer, and that fulvestrant should not be used in women negative for hormone receptor. 
500	PA166104919	fulvestrant	ESR2	PA27886	estrogen receptor 2 (ER beta)	NCBI Gene:2100	PA164747170	"ICI 182,780,""fulvestrant"""	The EMA European Public Assessment Report (EPAR) contains biomarker information regarding the indication of Fulvestrant (Faslodex) in postmenopausal women with estrogen receptor positive breast cancer due to its mechanism of action.
501	PA166123540	fulvestrant	ESR2	PA27886	estrogen receptor 2 (ER beta)	NCBI Gene:2100	PA164747170	"ICI 182,780,""fulvestrant"""	The PMDA package insert for fulvestrant states that it is indicated for postmenopausal women with hormone-receptor positive breast cancer, and that fulvestrant should not be used in women negative for hormone receptor. 
502	PA166104919	fulvestrant	MKI67	PA30825	marker of proliferation Ki-67	NCBI Gene:4288	PA164747170	"ICI 182,780,""fulvestrant"""	The EMA European Public Assessment Report (EPAR) contains biomarker information regarding the indication of Fulvestrant (Faslodex) in postmenopausal women with estrogen receptor positive breast cancer due to its mechanism of action.
503	PA166104792	fulvestrant	PGR	PA266	progesterone receptor	NCBI Gene:5241	PA164747170	"ICI 182,780,""fulvestrant"""	Fulvestrant is used to treat hormone-receptor positive breast cancer in postmenopausal women whose disease has spread after treatment with an antiestrogen medicine.
504	PA166105070	anastrozole	ESR1	PA156	estrogen receptor 1	NCBI Gene:2099	PA448432	"Anastrozol,""anastrozole"""	Anastrozole (ARIMIDEX) is an aromatase inhibitor indicated for use in postmenopausal women as an adjuvant treatment for hormone receptor-positive early breast cancer, as a first-line treatment for hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer, or to treat advanced breast cancer with disease progression following tamoxifen therapy. 
505	PA166127630	anastrozole	ESR1	PA156	estrogen receptor 1	NCBI Gene:2099	PA448432	"Anastrozol,""anastrozole"""	The product monograph for anastrozole states that it is indicated for treatment of postmenopausal women with hormone receptor positive advanced breast cancer. 
506	PA166105070	anastrozole	ESR2	PA27886	estrogen receptor 2 (ER beta)	NCBI Gene:2100	PA448432	"Anastrozol,""anastrozole"""	Anastrozole (ARIMIDEX) is an aromatase inhibitor indicated for use in postmenopausal women as an adjuvant treatment for hormone receptor-positive early breast cancer, as a first-line treatment for hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer, or to treat advanced breast cancer with disease progression following tamoxifen therapy. 
507	PA166127630	anastrozole	ESR2	PA27886	estrogen receptor 2 (ER beta)	NCBI Gene:2100	PA448432	"Anastrozol,""anastrozole"""	The product monograph for anastrozole states that it is indicated for treatment of postmenopausal women with hormone receptor positive advanced breast cancer. 
508	PA166105070	anastrozole	PGR	PA266	progesterone receptor	NCBI Gene:5241	PA448432	"Anastrozol,""anastrozole"""	Anastrozole (ARIMIDEX) is an aromatase inhibitor indicated for use in postmenopausal women as an adjuvant treatment for hormone receptor-positive early breast cancer, as a first-line treatment for hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer, or to treat advanced breast cancer with disease progression following tamoxifen therapy. 
509	PA166127630	anastrozole	PGR	PA266	progesterone receptor	NCBI Gene:5241	PA448432	"Anastrozol,""anastrozole"""	The product monograph for anastrozole states that it is indicated for treatment of postmenopausal women with hormone receptor positive advanced breast cancer. 
510	PA166104923	exemestane	ESR1	PA156	estrogen receptor 1	NCBI Gene:2099	PA449563	"Exemestano [INN-Spanish],""Exemestanum [INN-Latin]"",""exemestane"""	Aromasin is an aromatase inhibitor indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen.
511	PA166127672	exemestane	ESR1	PA156	estrogen receptor 1	NCBI Gene:2099	PA449563	"Exemestano [INN-Spanish],""Exemestanum [INN-Latin]"",""exemestane"""	The product monograph for exemestane states that it is indicated for the treatment of estrogen receptor-positive early breast cancer.
512	PA166127672	exemestane	ESR2	PA27886	estrogen receptor 2 (ER beta)	NCBI Gene:2100	PA449563	"Exemestano [INN-Spanish],""Exemestanum [INN-Latin]"",""exemestane"""	The product monograph for exemestane states that it is indicated for the treatment of estrogen receptor-positive early breast cancer.
513	PA166104923	exemestane	PGR	PA266	progesterone receptor	NCBI Gene:5241	PA449563	"Exemestano [INN-Spanish],""Exemestanum [INN-Latin]"",""exemestane"""	Aromasin is an aromatase inhibitor indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen.
514	PA166104797	letrozole	ESR1	PA156	estrogen receptor 1	NCBI Gene:2099	PA450196	"Letrozol,""letrozole"""	Letrozole (Femara) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. It is also indicated as a first-line treatment for advanced breast cancer in postmenopausal women with hormone receptor positive or unknown tumors, or for extended adjuvant treatment of post-menopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy.
515	PA166127687	letrozole	ESR1	PA156	estrogen receptor 1	NCBI Gene:2099	PA450196	"Letrozol,""letrozole"""	The product monograph for letrozole (FEMARA) states that it is indicated for the treatment of hormone-receptor positive early breast cancer.
516	PA166127687	letrozole	ESR2	PA27886	estrogen receptor 2 (ER beta)	NCBI Gene:2100	PA450196	"Letrozol,""letrozole"""	The product monograph for letrozole (FEMARA) states that it is indicated for the treatment of hormone-receptor positive early breast cancer.
517	PA166104797	letrozole	PGR	PA266	progesterone receptor	NCBI Gene:5241	PA450196	"Letrozol,""letrozole"""	Letrozole (Femara) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. It is also indicated as a first-line treatment for advanced breast cancer in postmenopausal women with hormone receptor positive or unknown tumors, or for extended adjuvant treatment of post-menopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy.
518	PA166127687	letrozole	PGR	PA266	progesterone receptor	NCBI Gene:5241	PA450196	"Letrozol,""letrozole"""	The product monograph for letrozole (FEMARA) states that it is indicated for the treatment of hormone-receptor positive early breast cancer.
519	PA166104905	capecitabine	DPYD	PA145	dihydropyrimidine dehydrogenase	NCBI Gene:1806	PA448771	"R340,""capecitabine"""	The EMA European Public Assessment Report (EPAR) highlights information regarding the contraindication of capecitabine in patients with known DPD (_DPYD_) deficiency due to an increased likelihood of severe, life-threatening or fatal toxicity. However, the label does not provide information regarding testing for DPD deficiency. 
520	PA166104802	capecitabine	DPYD	PA145	dihydropyrimidine dehydrogenase	NCBI Gene:1806	PA448771	"R340,""capecitabine"""	"The FDA-approved label for capecitabine (Xeloda) notes that patients who have low or absent dihydropyrimidine dehydrogenase (DPD) activity are at increased risk for severe or fatal adverse reactions. However, the label does not mention genetic testing or screening for DPD activity. 

"
521	PA166127644	capecitabine	DPYD	PA145	dihydropyrimidine dehydrogenase	NCBI Gene:1806	PA448771	"R340,""capecitabine"""	The product monograph for capecitabine states that it is contraindicated in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. However, genetic testing or screening for DPD deficiency is not mentioned.
522	PA166123531	capecitabine	DPYD	PA145	dihydropyrimidine dehydrogenase	NCBI Gene:1806	PA448771	"R340,""capecitabine"""	The PMDA package insert for capecitabine states that severe adverse events have occurred in patients receiving the drug who are dihydropyrimidine dehydrogenase (DPD)-deficient. DPD is the enzyme responsible for the degradation of capecitabine and other fluoropyrimidines. 
523	PA166104807	fluorouracil	DPYD	PA145	dihydropyrimidine dehydrogenase	NCBI Gene:1806	PA128406956		Fluorouracil is available in both a topical cream and as an injection. These two formulations have different indications. Both FDA-approved labels contain information about the potential for severe toxicity in patients with dipyrimidine dehydrogenase (DPD) deficiency. However, neither label mentions testing for genetic variants or activity of DPD. 
524	PA166127674	fluorouracil	DPYD	PA145	dihydropyrimidine dehydrogenase	NCBI Gene:1806	PA128406956		The product monograph for fluorouracil states that it should be used with care in patients who have a dihydropyrimidine dehydrogenase (_DYPD_) deficiency, due to the risk for experiencing toxicity.
525	PA166123539	fluorouracil	DPYD	PA145	dihydropyrimidine dehydrogenase	NCBI Gene:1806	PA128406956		The PMDA package insert for fluorouracil states that severe adverse events have occurred in patients receiving the drug who are dihydropyrimidine dehydrogenase (DPD)-deficient. DPD is the enzyme responsible for the degradation of fluorouracil and other fluoropyrimidines.
526	PA166104840	lapatinib	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA152241907	"FMM,""GW 572016"",""GW572016"",""Lapatinib ditosylate"",""Lapatinib tosilate hydrate"",""lapatinib"""	The EMA European Public Assessment Report (EPAR) for lapatinib (Tyverb)  contains pharmacogenetic information regarding the indication of the drug in HER2+ (ERBB2) breast cancer, and that HER2 status should be determined using an accurate technique. It also contains pharmacogenetic information regarding an increased risk of drug-induced hepatotoxicity in patients carrying the DQA1*02:01 or DRB1*07:01 HLA alleles.
527	PA166104791	lapatinib	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA152241907	"FMM,""GW 572016"",""GW572016"",""Lapatinib ditosylate"",""Lapatinib tosilate hydrate"",""lapatinib"""	Lapatinib (TYKERB) is indicated for patients with breast cancer whose tumors overexpress HER2 (_ERBB2_). The FDA-approved drug label for lapatinib notes that the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have been associated with hepatotoxicity in individuals received the drug, but does not discuss genetic testing for these alleles. 
528	PA166127685	lapatinib	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA152241907	"FMM,""GW 572016"",""GW572016"",""Lapatinib ditosylate"",""Lapatinib tosilate hydrate"",""lapatinib"""	The product monograph for lapatinib (TYKERB) states that it is indicated for patients with metastatic breast cancer whose tumours overexpress HER2. It also notes that those with the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have an increased risk of lapatinib-associated hepatotoxicity. The product monograph does not comment on genotyping for the HLA alleles.
529	PA166123544	lapatinib	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA152241907	"FMM,""GW 572016"",""GW572016"",""Lapatinib ditosylate"",""Lapatinib tosilate hydrate"",""lapatinib"""	The PMDA package insert for lapatinib states that it is indicated for individuals with breast cancer whose tumors overexpress HER2. It also contains information about the risk of severe liver injury in patients with the HLA-DQA1*02:01 or HLA-DRB1*07:01 variants.
530	PA166104840	lapatinib	HLA-DQA1	PA35066	major histocompatibility complex, class II, DQ alpha 1	NCBI Gene:3117	PA152241907	"FMM,""GW 572016"",""GW572016"",""Lapatinib ditosylate"",""Lapatinib tosilate hydrate"",""lapatinib"""	The EMA European Public Assessment Report (EPAR) for lapatinib (Tyverb)  contains pharmacogenetic information regarding the indication of the drug in HER2+ (ERBB2) breast cancer, and that HER2 status should be determined using an accurate technique. It also contains pharmacogenetic information regarding an increased risk of drug-induced hepatotoxicity in patients carrying the DQA1*02:01 or DRB1*07:01 HLA alleles.
531	PA166127685	lapatinib	HLA-DQA1	PA35066	major histocompatibility complex, class II, DQ alpha 1	NCBI Gene:3117	PA152241907	"FMM,""GW 572016"",""GW572016"",""Lapatinib ditosylate"",""Lapatinib tosilate hydrate"",""lapatinib"""	The product monograph for lapatinib (TYKERB) states that it is indicated for patients with metastatic breast cancer whose tumours overexpress HER2. It also notes that those with the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have an increased risk of lapatinib-associated hepatotoxicity. The product monograph does not comment on genotyping for the HLA alleles.
532	PA166151878	lapatinib	HLA-DQA1	PA35066	major histocompatibility complex, class II, DQ alpha 1	NCBI Gene:3117	PA152241907	"FMM,""GW 572016"",""GW572016"",""Lapatinib ditosylate"",""Lapatinib tosilate hydrate"",""lapatinib"""	Lapatinib (TYKERB) is indicated for patients with breast cancer whose tumors overexpress HER2 (_ERBB2_). The FDA-approved drug label for lapatinib notes that the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have been associated with hepatotoxicity in individuals received the drug, but does not discuss genetic testing for these alleles. 
533	PA166104840	lapatinib	HLA-DRB1	PA35072	major histocompatibility complex, class II, DR beta 1	NCBI Gene:3123	PA152241907	"FMM,""GW 572016"",""GW572016"",""Lapatinib ditosylate"",""Lapatinib tosilate hydrate"",""lapatinib"""	The EMA European Public Assessment Report (EPAR) for lapatinib (Tyverb)  contains pharmacogenetic information regarding the indication of the drug in HER2+ (ERBB2) breast cancer, and that HER2 status should be determined using an accurate technique. It also contains pharmacogenetic information regarding an increased risk of drug-induced hepatotoxicity in patients carrying the DQA1*02:01 or DRB1*07:01 HLA alleles.
534	PA166127685	lapatinib	HLA-DRB1	PA35072	major histocompatibility complex, class II, DR beta 1	NCBI Gene:3123	PA152241907	"FMM,""GW 572016"",""GW572016"",""Lapatinib ditosylate"",""Lapatinib tosilate hydrate"",""lapatinib"""	The product monograph for lapatinib (TYKERB) states that it is indicated for patients with metastatic breast cancer whose tumours overexpress HER2. It also notes that those with the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have an increased risk of lapatinib-associated hepatotoxicity. The product monograph does not comment on genotyping for the HLA alleles.
535	PA166151878	lapatinib	HLA-DRB1	PA35072	major histocompatibility complex, class II, DR beta 1	NCBI Gene:3123	PA152241907	"FMM,""GW 572016"",""GW572016"",""Lapatinib ditosylate"",""Lapatinib tosilate hydrate"",""lapatinib"""	Lapatinib (TYKERB) is indicated for patients with breast cancer whose tumors overexpress HER2 (_ERBB2_). The FDA-approved drug label for lapatinib notes that the HLA-DQA1*02:01 and HLA-DRB1*07:01 alleles have been associated with hepatotoxicity in individuals received the drug, but does not discuss genetic testing for these alleles. 
536	PA166122066	pertuzumab	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA165290933	"Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer,""LS-185920"",""Omnitarg"""	The EMA European Public Assessment Report (EPAR) for pertuzumab (Perjeta) states that testing by a specialized laboratory must be performed to establish HER2 (_ERBB2_)-positive tumor status due to the action of the drug.
537	PA166104889	pertuzumab	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA165290933	"Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer,""LS-185920"",""Omnitarg"""	Pertuzumab is a targeted antibody drug designed to bind to ERBB2. Detection of HER2 protein overexpression is necessary for selection of patients appropriate for PERJETA therapy because these are the only patients studied and for whom benefit has been shown.
538	PA166127700	pertuzumab	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA165290933	"Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer,""LS-185920"",""Omnitarg"""	The product monograph for pertuzumab (PERJETA) states that it is indicated in combination with trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer. 
539	PA166114481	trastuzumab	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA451743	"Anti HER2,""Ig gamma-1 chain C region"""	The EMA European Public Assessment Report (EPAR) for trastuzumab (Herceptin) requires testing of tumours for HER2 overexpression or gene amplification prior to initiating therapy. Trastuzumab (Herceptin) targets human epidermal growth factor receptor 2 (HER2) to inhibit growth of HER2 overexpressing cancer cells.
540	PA166104920	trastuzumab	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA451743	"Anti HER2,""Ig gamma-1 chain C region"""	Trastuzumab _(Herceptin)_ is used for the treatment of HER2 overexpressing node positive or node negative breast cancer, metastatic breast cancer and metastatic gastric cancer.  The FDA requires test results demonstrating HER2 protein overexpression prior to initiating therapy.
541	PA166127724	trastuzumab	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA451743	"Anti HER2,""Ig gamma-1 chain C region"""	The product monograph for trastuzumab (HERCEPTIN) states that it is indicated for patients with early or metastatic breast cancer, or metastatic adenocarcinoma of the stomach or gastroesophageal junction, whose tumors are HER2 positive. 
542	PA166123550	trastuzumab	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA451743	"Anti HER2,""Ig gamma-1 chain C region"""	The PMDA package insert for trastuzumab states that it is indicated for patients with HER2-overexpressing breast or gastric cancers.
543	PA166122547	trastuzumab emtansine	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA165958441	"T-DM1,""Trastuzumab-DM1"",""Trastuzumab-MCC-DM1"",""Trastuzumab-MCC-DM1 antibody-drug conjugate"""	The EMA European Public Assessment Report (EPAR) for trastuzumab emtansine (Kadcyla) contains information regarding indication of the drug in patients with HER2-positive (encoded by the _ERBB2_ gene) breast cancer due to its mechanism of action, and HER2 positive status should be tested for by a validated method.
544	PA166104796	trastuzumab emtansine	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA165958441	"T-DM1,""Trastuzumab-DM1"",""Trastuzumab-MCC-DM1"",""Trastuzumab-MCC-DM1 antibody-drug conjugate"""	The FDA-approved label requires test results demonstrating HER2 protein overexpression prior to initiating therapy with trastuzumab emtansine using FDA-approved tests by laboratories with demonstrated proficiency.
545	PA166127723	trastuzumab emtansine	ERBB2	PA27844	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2	NCBI Gene:2064	PA165958441	"T-DM1,""Trastuzumab-DM1"",""Trastuzumab-MCC-DM1"",""Trastuzumab-MCC-DM1 antibody-drug conjugate"""	The product monograph for trastuzumab emtansine (KADCYLA) states that it is indicated for patients with HER2-positive, metastatic breast cancer who received prior treatment with trastuzumab and a taxane, separately or in combination.
546	PA166104907	eltrombopag	F5	PA159	coagulation factor V (proaccelerin, labile factor)	NCBI Gene:2153	PA165981594	Eltrombopag olamine	The EMA European Public Assessment Report (EPAR) highlights that caution should be taken when administering eltrombopag in patients with known risk factors for thromboembolism, including Factor V Leiden (F5 gene) and ATIII deficiency (SERPINC1 gene).
547	PA166104912	eltrombopag	F5	PA159	coagulation factor V (proaccelerin, labile factor)	NCBI Gene:2153	PA165981594	Eltrombopag olamine	The FDA-approved drug label for eltrombopag (PROMACTA) notes that patients taking the drug have an increased risk of thromboembolism if they have antithrombin III deficiency (SERPINC1) or Factor V Leiden (F5). 
548	PA166127668	eltrombopag	F5	PA159	coagulation factor V (proaccelerin, labile factor)	NCBI Gene:2153	PA165981594	Eltrombopag olamine	The product monograph for eltrombopag (REVOLADE) states that caution should be used when administering the drug to patients with risk factors for thromboembolism, such as Factor V Leiden mutation ([variant:rs6025] in _F5_) and antithrombin III deficiency (_SERPINC1_). 
549	PA166104907	eltrombopag	SERPINC1	PA35026	serpin peptidase inhibitor, clade C (antithrombin), member 1	NCBI Gene:462	PA165981594	Eltrombopag olamine	The EMA European Public Assessment Report (EPAR) highlights that caution should be taken when administering eltrombopag in patients with known risk factors for thromboembolism, including Factor V Leiden (F5 gene) and ATIII deficiency (SERPINC1 gene).
550	PA166104912	eltrombopag	SERPINC1	PA35026	serpin peptidase inhibitor, clade C (antithrombin), member 1	NCBI Gene:462	PA165981594	Eltrombopag olamine	The FDA-approved drug label for eltrombopag (PROMACTA) notes that patients taking the drug have an increased risk of thromboembolism if they have antithrombin III deficiency (SERPINC1) or Factor V Leiden (F5). 
551	PA166127668	eltrombopag	SERPINC1	PA35026	serpin peptidase inhibitor, clade C (antithrombin), member 1	NCBI Gene:462	PA165981594	Eltrombopag olamine	The product monograph for eltrombopag (REVOLADE) states that caution should be used when administering the drug to patients with risk factors for thromboembolism, such as Factor V Leiden mutation ([variant:rs6025] in _F5_) and antithrombin III deficiency (_SERPINC1_). 
552	PA166123538	eltrombopag	SERPINC1	PA35026	serpin peptidase inhibitor, clade C (antithrombin), member 1	NCBI Gene:462	PA165981594	Eltrombopag olamine	The PMDA package insert for eltrombopag notes that caution should be taken when administering the drug to patients with antithrombin III (AT III; _SERPINC1_ gene) deficiency.
553	PA166159064	elosulfase alfa	GALNS	PA28535	galactosamine (N-acetyl)-6-sulfatase	NCBI Gene:2588	PA166159062		Elosulfase alfa (VIMIZIM) is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with mucopolysaccharidosis type IVA, also known as Morquio A syndrome. This disease results from deficiency or marked reduction of the galactosamine (N-acetyl)-6-sulfatase (GALNS) enzyme.
554	PA166122548	velaglucerase alfa	GBA	PA28591	glucosidase, beta, acid	NCBI Gene:2629	PA166115366		The EMA European Public Assessment Report (EPAR) for velaglucerase alfa (VPRIV) states that the drug is indicated as a long-term enzyme replacement therapy for patients with type 1 Gaucher disease. Gaucher disease is caused by mutations in the _GBA_ gene, resulting in a deficiency of the lysosomal enzyme beta-glucocerebrosidase.
555	PA166115367	velaglucerase alfa	GBA	PA28591	glucosidase, beta, acid	NCBI Gene:2629	PA166115366		Velaglucerase alfa (VPRIV) is indicated as a long-term enzyme replacement therapy for patients with type 1 Gaucher disease. Gaucher disease is caused by mutations in the _GBA_ gene, resulting in a deficiency of the enzyme beta-glucocerebrosidase. Velaglucerase alfa has the same amino acid sequence as naturally occurring glucocerebrosidase.
556	PA166127727	velaglucerase alfa	GBA	PA28591	glucosidase, beta, acid	NCBI Gene:2629	PA166115366		The product monograph for velaglucerase alfa (VPRIV) states that it is indicated for the treatment of type 1 Gaucher disease. Gaucher disease is caused by mutations in the _GBA_ gene, resulting in a deficiency of the enzyme beta-glucocerebrosidase. Velaglucerase alfa is an enzyme replacement therapy.
557	PA166104877	mycophenolic acid	HPRT1	PA29427	hypoxanthine phosphoribosyltransferase 1	NCBI Gene:3251	PA164748728	Mycophenoic acid	Myfortic is an IMPDH Inhibitor that should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
558	PA166127692	mycophenolic acid	HPRT1	PA29427	hypoxanthine phosphoribosyltransferase 1	NCBI Gene:3251	PA164748728	Mycophenoic acid	The product monograph for mycophenolic acid (MYFORTIC) states that it should be avoid in patients with hereditary deficiencies of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT, encoded by _HPRT1_), such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
559	PA166123546	mycophenolic acid	HPRT1	PA29427	hypoxanthine phosphoribosyltransferase 1	NCBI Gene:3251	PA164748728	Mycophenoic acid	The PMDA package insert for mycophenolic acid notes that caution should be used in patients with deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndromes, due to the risk for exacerbation of hyperuricemia.
560	PA166104872	boceprevir	IFNL3	PA134952671	interferon, lambda 3	NCBI Gene:282617	PA165948902	n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	The EMA European Public Assessment Report (EPAR) contains pharmacogenetic information regarding a genetic variant within the _IL28B_ gene that is associated with response to treatment with peginterferon alfa-2b/ribavirin (drugs taken concomitantly with boceprevir), but highlight caveats in studies carried out so far and that the association with boceprevir is currently being investigated further.  
561	PA166104855	boceprevir	IFNL3	PA134952671	interferon, lambda 3	NCBI Gene:282617	PA165948902	n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	The FDA-approved drug label for boceprevir (Victrelis) contains information regarding a genetic variant near the IFNL3 gene (IL28B, [variant:rs12979860], a C to T change) which is a strong predictor of response to peginterferon alfa-2b (PegIntron) / ribavirin (Rebetol) treatment. Boceprevir must not be used as a monotherapy and should only be used in combination with these drugs for the treatment of chronic hepatitis C genotype 1. 
562	PA166127640	boceprevir	IFNL3	PA134952671	interferon, lambda 3	NCBI Gene:282617	PA165948902	n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	The product monograph for boceprevir (VICTRELIS) contains information regarding a genetic variant near the IFNL3 gene (_IL28B_, [variant:rs12979860], a C to T change) which is a strong predictor of response to peginterferon alfa-2b/ribavirin treatment. 
563	PA166114378	telaprevir	IFNL3	PA134952671	interferon, lambda 3	NCBI Gene:282617	PA165958354	"aids-213006,""aids213006"",""ly-570310"",""mp-424"",""vx-950"""	The EMA European Public Assessment Report (EPAR) for telaprevir (Incivo) contains a table showing higher SVR rates for patients with the IL28B (IFNL3) CC genotype compared to those with CT or TT when treated with the telaprevir, peginterferon alfa-2a and ribavirin drug combination, though this is not discussed further in the main text.
564	PA166104867	telaprevir	IFNL3	PA134952671	interferon, lambda 3	NCBI Gene:282617	PA165958354	"aids-213006,""aids213006"",""ly-570310"",""mp-424"",""vx-950"""	Among both treatment-naïve and previous treatment failures patients with HCV genotype 1 infections, subjects of all IL28B genotypes appeared to have higher SVR rates with INCIVEK(telaprevir)-containing regimens compared to PEG-IFN alpha and RBV only. Patients with the favorable IFNL3 genotype ([variant:rs12979860] CC) tend to have higher response rates (SVR) as compared to patients with the CT or TT genotype with the protease inhibitor combination in treatment naïve patients.
565	PA166104801	peginterferon alfa-2b	IFNL3	PA134952671	interferon, lambda 3	NCBI Gene:282617	PA164784024		Pegylated recombinant human interferon alfa-2b is an inducer of the innate antiviral immune response. A single nucleotide polymorphism near the gene encoding interferon-lambda-3 (IL28B [variant:rs12979860]) was associated with variable sustained viral response (SVR) rates. SVR rates by [variant:rs12979860] genotype were as follows: CC 66% vs. CT 30% vs. TT 22%. 
566	PA166122592	simeprevir	IFNL3	PA134952671	interferon, lambda 3	NCBI Gene:282617	PA166122590		The FDA-approved drug label for simeprevir (OLYSIO) contains information regarding a genetic variant near the _IFNL3_ gene (_IL28B_, [variant:rs12979860], a C to T change) which is a strong predictor of response to peginterferon alfa and ribavirin treatment. Simeprevir must not be used as a monotherapy, and should be administered in combination with both peginterferon alfa and ribavirin for treatment of chronic hepatitis C genotype 1.
567	PA166127710	simeprevir	IFNL3	PA134952671	interferon, lambda 3	NCBI Gene:282617	PA166122590		The product monograph for simeprevir (GALEXOS) contains information regarding a genetic variant near the IFNL3 gene (_IL28B_, [variant:rs12979860]) which is a strong predictor of response to peginterferon alfa (PegIFN-alfa) and ribavirin (RBV) treatment. Simeprevir is only indicated in combination with PegIFN-alfa and RBV, it is not indicated as a monotherapy.
568	PA166122594	sofosbuvir	IFNL3	PA134952671	interferon, lambda 3	NCBI Gene:282617	PA166122593		Sofosbuvir (SOVALDI) is indicated for the treatment of chronic hepatitis C in combination with ribavirin and/or peg-interferon alfa. The FDA-approved drug label for sofosbuvir contains information regarding a genetic variant near the IFNL3 gene (IL28B, [variant:rs12979860], a C to T change). Though the sofosbuvir label itself does not discuss why this variant is relevant, literature evidence has shown that this variant is a strong predictor of response to peginterferon alfa and ribavirin treatment.
569	PA166160005	viekira pak	IFNL3	PA134952671	interferon, lambda 3	NCBI Gene:282617	PA166160002		The FDA-approved drug label for VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir, and dasabuvir) notes the percentage of subjects in clinical studies that carried the IL28B rs12979860 non-CC genotype. However, the label does not discuss the effect of this variant or genetic testing.
570	PA166104883	denileukin diftitox	IL2RA	PA29828	interleukin 2 receptor, alpha	NCBI Gene:3559	PA164750594	"DT,""Diphtheria toxin precursor"",""NAD(+--diphthamide ADP- ribosyltransferase)"",""denileukin diftitox"""	The FDA-approved drug label for denileukin diftitox (Ontak) notes that it is indicated for patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor. Confirmation of malignant cells expressing CD25 is necessary prior to administration of the drug. 
571	PA166121246	ibritumomab	MS4A1	PA31111	membrane-spanning 4-domains, subfamily A, member 1	NCBI Gene:931	PA164781375	"Ig gamma-2A chain C region, membrane-bound form,""radiolabeled murine anti-CD20"""	The EMA European Public Assessment Report (EPAR) for ibritumomab (Zevalin) contains information regarding the indication of the drug for the treatment of  CD20+ (_MS4A1_) follicular B-cell non-Hodgkin's lymphoma due to its mechanism of action.
572	PA166114921	ibritumomab	MS4A1	PA31111	membrane-spanning 4-domains, subfamily A, member 1	NCBI Gene:931	PA164781375	"Ig gamma-2A chain C region, membrane-bound form,""radiolabeled murine anti-CD20"""	Ibritumomab tiuxetan (Zevalin) is used to treat patients with B-cell non-Hodgkin's lymphoma. The drug is a CD20-directed radiotherapeutic antibody, but there is no association with genetic variation within the coding gene, _MS4A1_, and therefore no mention of genetic testing in the drug label.   
573	PA166121252	ofatumumab	MS4A1	PA31111	membrane-spanning 4-domains, subfamily A, member 1	NCBI Gene:931	PA165291493		The EMA European Public Assessment Report (EPAR) for ofatumumab (Arzerra) contains information regarding its mechanism of action by targeting CD20 (expressed by the _MS4A1_ gene).
574	PA166105059	ofatumumab	MS4A1	PA31111	membrane-spanning 4-domains, subfamily A, member 1	NCBI Gene:931	PA165291493		Ofatumumab (ARZERRA) is used to treat patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, _MS4A1_, and therefore no mention of genetic testing in the drug label.
575	PA166122546	rituximab	MS4A1	PA31111	membrane-spanning 4-domains, subfamily A, member 1	NCBI Gene:931	PA451261	"AntiCD20,""Ig gamma-1 chain C region"""	The EMA European Public Assessment Report (EPAR) for rituximab (MabThera) contains information regarding one of the indications of the drug in patients with CD20-positive diffuse large V cell non-Hodgkin's lymphoma in combination with CHOP chemotherapy regimen. The drug targets CD20 (_MS4A1_) expressing B cells to induce cell lysis.
576	PA166105240	rituximab	MS4A1	PA31111	membrane-spanning 4-domains, subfamily A, member 1	NCBI Gene:931	PA451261	"AntiCD20,""Ig gamma-1 chain C region"""	"Rituximab (Rituxan) is used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis or granulomatosis polyangiitis and microscopic polyangiitis. The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, _MS4A1_, and therefore no mention of genetic testing in the drug label.

"
577	PA166122589	afutuzumab	MS4A1	PA31111	membrane-spanning 4-domains, subfamily A, member 1	NCBI Gene:931	PA166122586	"GA101,""obinutuzumab"""	Afutuzumab (GAZYVA; obinutuzumab) is used in combination with chlorambucil in patients with chronic lymphocytic leukemia who are previously untreated. The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, _MS4A1_, and therefore no mention of genetic testing in the drug label.
578	PA166159584	afutuzumab	MS4A1	PA31111	membrane-spanning 4-domains, subfamily A, member 1	NCBI Gene:931	PA166122586	"GA101,""obinutuzumab"""	Afutuzumab (GAZYVA; obinutuzumab) is used in combination with chlorambucil in patients with chronic lymphocytic leukemia who are previously untreated. The drug is a CD20-directed cytolytic monoclonal antibody, but there is no association with genetic variation within the coding gene, _MS4A1_, and therefore no mention of genetic testing in the drug label.
579	PA166104804	tositumomab	MS4A1	PA31111	membrane-spanning 4-domains, subfamily A, member 1	NCBI Gene:931	PA164748364	Ig gamma-1 chain C region	Tositumomab is used to treat patients with CD20-positive non-Hodgkin's lymphoma.   The drug is a monoclonal antibody that targets the CD20 antigen, but there is no association with genetic variation within the coding gene, MS4A1, and therefore no mention of genetic testing in the drug label.   
580	PA166160061	dinutuximab	MYCN	PA31359	v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog	NCBI Gene:4613	PA166160060		The FDA-approved drug label for dinutuximab (UNITUXIN) provides information on the MYCN status of patients in a clinical study of the drug.
581	PA166104828	hydralazine	NAT2	PA18	N-acetyltransferase 2 (arylamine N-acetyltransferase)	NCBI Gene:10	PA449894	Hydralazine hydrochloride	Isosorbide dinitrate and hydralazine hydrochloride (Bidil) is metabolized by acetylation, and individuals who are 'fast acetylators' may have increased exposure to the drug, whereas individuals who are 'slow acetylators' may have increased drug bioavailability. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene.
582	PA166104828	isosorbide dinitrate	NAT2	PA18	N-acetyltransferase 2 (arylamine N-acetyltransferase)	NCBI Gene:10	PA450125	"Dianhydrosorbitol 2,5-dinitrate,""Sorbide nitrate"",""Sorbide, dinitrate"",""Sorbidnitrate"""	Isosorbide dinitrate and hydralazine hydrochloride (Bidil) is metabolized by acetylation, and individuals who are 'fast acetylators' may have increased exposure to the drug, whereas individuals who are 'slow acetylators' may have increased drug bioavailability. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene.
583	PA166104850	isoniazid	NAT2	PA18	N-acetyltransferase 2 (arylamine N-acetyltransferase)	NCBI Gene:10	PA450112	"HIA,""Hydrazid"",""Hydrazide"",""INH"",""Isohydrazide"",""Isonicotinhydrazid"",""Isonicotinic acid hydrazide"",""Isonicotinic hydrazide"",""Isonicotinohydrazide"",""Isonicotinoyl hydrazide"",""Isonicotinyl hydrazide"",""Isonicotinyl hydrazine"",""Isonicotinylhydrazine"""	"'Slow inactivators' of isoniazid may be more susceptible to drug toxicity when taking Rifator due to higher blood concentrations of the drug in these individuals. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. 

 "
584	PA166104850	pyrazinamide	NAT2	PA18	N-acetyltransferase 2 (arylamine N-acetyltransferase)	NCBI Gene:10	PA451182	"PZA,""Pirazimida"",""Pirazinamid"",""Pyrazinamdie"",""Pyrazine carboxylamide"",""Pyrazineamide"",""Pyrazinecarboxamide"",""Pyrazinecarboxylic acid amide"",""Pyrazinoic acid amide"""	"'Slow inactivators' of isoniazid may be more susceptible to drug toxicity when taking Rifator due to higher blood concentrations of the drug in these individuals. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. 

 "
585	PA166104850	rifampin	NAT2	PA18	N-acetyltransferase 2 (arylamine N-acetyltransferase)	NCBI Gene:10	PA451250	"RFP,""rifampin"""	"'Slow inactivators' of isoniazid may be more susceptible to drug toxicity when taking Rifator due to higher blood concentrations of the drug in these individuals. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene. 

 "
586	PA166104821	arsenic trioxide	PML	PA33439	promyelocytic leukemia	NCBI Gene:5371	PA448486	"Acide Arsenieux [French],""Anhydride Arsenieux [French]"",""Arseni Trioxydum"",""Arsenic Blanc [French]"",""Arsenic Oxide"",""Arsenic Oxidearsenous Trioxide"",""Arsenic Sesquioxide"",""Arsenic Trioxide [UN1561] [Poison]"",""Arsenic, White"",""Arsenicum Album"",""Arsenigen Saure [German]"",""Arsenious Acid"",""Arsenious Acid Anhydride"",""Arsenious Oxide"",""Arsenious Trioxide"",""Arsenous Acid"",""Arsenous Acid Anhydride"",""Arsenous Anhydride"",""Arsenous Oxide"",""Arsenous Oxide Anhydride"",""Arsentrioxide"",""Crude Arsenic"",""Di-Arsenic Trioxide"",""Diarsenic Trioxide"",""Diarsonic Trioxide"",""HSDB 419"",""Oxyde Arsenieux [ISO-French]"",""Poison Flour"",""White Arsenic"",""arsenic trioxide"""	"The EMA European Public Assessment Report (EPAR) contains pharmacogenetic information regarding the indication of arsenic trioxide in patients with APL characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RAR-alpha gene.  

"
587	PA166104846	arsenic trioxide	PML	PA33439	promyelocytic leukemia	NCBI Gene:5371	PA448486	"Acide Arsenieux [French],""Anhydride Arsenieux [French]"",""Arseni Trioxydum"",""Arsenic Blanc [French]"",""Arsenic Oxide"",""Arsenic Oxidearsenous Trioxide"",""Arsenic Sesquioxide"",""Arsenic Trioxide [UN1561] [Poison]"",""Arsenic, White"",""Arsenicum Album"",""Arsenigen Saure [German]"",""Arsenious Acid"",""Arsenious Acid Anhydride"",""Arsenious Oxide"",""Arsenious Trioxide"",""Arsenous Acid"",""Arsenous Acid Anhydride"",""Arsenous Anhydride"",""Arsenous Oxide"",""Arsenous Oxide Anhydride"",""Arsentrioxide"",""Crude Arsenic"",""Di-Arsenic Trioxide"",""Diarsenic Trioxide"",""Diarsonic Trioxide"",""HSDB 419"",""Oxyde Arsenieux [ISO-French]"",""Poison Flour"",""White Arsenic"",""arsenic trioxide"""	The FDA-approved drug label for arsenic trioxide (Trisenox) contains information regarding indication of the drug in patients whose acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. The label also states that some patients treated with arsenic trioxide have experienced symptoms similar to a syndrome called the retinoic-acid-Acute Promyelocytic Leukemia (RA-APL) or APL differentiation syndrome, which can be fatal, and high-dose steroids (dexamethasone 10 mg intravenously BID) should be immediately initiated at the first signs.
588	PA166127632	arsenic trioxide	PML	PA33439	promyelocytic leukemia	NCBI Gene:5371	PA448486	"Acide Arsenieux [French],""Anhydride Arsenieux [French]"",""Arseni Trioxydum"",""Arsenic Blanc [French]"",""Arsenic Oxide"",""Arsenic Oxidearsenous Trioxide"",""Arsenic Sesquioxide"",""Arsenic Trioxide [UN1561] [Poison]"",""Arsenic, White"",""Arsenicum Album"",""Arsenigen Saure [German]"",""Arsenious Acid"",""Arsenious Acid Anhydride"",""Arsenious Oxide"",""Arsenious Trioxide"",""Arsenous Acid"",""Arsenous Acid Anhydride"",""Arsenous Anhydride"",""Arsenous Oxide"",""Arsenous Oxide Anhydride"",""Arsentrioxide"",""Crude Arsenic"",""Di-Arsenic Trioxide"",""Diarsenic Trioxide"",""Diarsonic Trioxide"",""HSDB 419"",""Oxyde Arsenieux [ISO-French]"",""Poison Flour"",""White Arsenic"",""arsenic trioxide"""	The product monograph for arsenic trioxide (TRISENOX) states that is indicated for patients with acute promyelotic leukemia (APL) characterized by the presence of the t(15;17) translocation or promyelocytic leukemia-retinoic-acid-receptor alpha (PML-RARa) gene expression. 
589	PA166123527	arsenic trioxide	PML	PA33439	promyelocytic leukemia	NCBI Gene:5371	PA448486	"Acide Arsenieux [French],""Anhydride Arsenieux [French]"",""Arseni Trioxydum"",""Arsenic Blanc [French]"",""Arsenic Oxide"",""Arsenic Oxidearsenous Trioxide"",""Arsenic Sesquioxide"",""Arsenic Trioxide [UN1561] [Poison]"",""Arsenic, White"",""Arsenicum Album"",""Arsenigen Saure [German]"",""Arsenious Acid"",""Arsenious Acid Anhydride"",""Arsenious Oxide"",""Arsenious Trioxide"",""Arsenous Acid"",""Arsenous Acid Anhydride"",""Arsenous Anhydride"",""Arsenous Oxide"",""Arsenous Oxide Anhydride"",""Arsentrioxide"",""Crude Arsenic"",""Di-Arsenic Trioxide"",""Diarsenic Trioxide"",""Diarsonic Trioxide"",""HSDB 419"",""Oxyde Arsenieux [ISO-French]"",""Poison Flour"",""White Arsenic"",""arsenic trioxide"""	Arsenic trioxide is indicated for treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL). The PMDA package insert for arsenic trioxide states that patients with APL should be characterized by presence of the t(15;17) translocation or PML/RAR-alpha gene expression. 
590	PA166104821	arsenic trioxide	RARA	PA34225	retinoic acid receptor, alpha	NCBI Gene:5914	PA448486	"Acide Arsenieux [French],""Anhydride Arsenieux [French]"",""Arseni Trioxydum"",""Arsenic Blanc [French]"",""Arsenic Oxide"",""Arsenic Oxidearsenous Trioxide"",""Arsenic Sesquioxide"",""Arsenic Trioxide [UN1561] [Poison]"",""Arsenic, White"",""Arsenicum Album"",""Arsenigen Saure [German]"",""Arsenious Acid"",""Arsenious Acid Anhydride"",""Arsenious Oxide"",""Arsenious Trioxide"",""Arsenous Acid"",""Arsenous Acid Anhydride"",""Arsenous Anhydride"",""Arsenous Oxide"",""Arsenous Oxide Anhydride"",""Arsentrioxide"",""Crude Arsenic"",""Di-Arsenic Trioxide"",""Diarsenic Trioxide"",""Diarsonic Trioxide"",""HSDB 419"",""Oxyde Arsenieux [ISO-French]"",""Poison Flour"",""White Arsenic"",""arsenic trioxide"""	"The EMA European Public Assessment Report (EPAR) contains pharmacogenetic information regarding the indication of arsenic trioxide in patients with APL characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RAR-alpha gene.  

"
591	PA166104846	arsenic trioxide	RARA	PA34225	retinoic acid receptor, alpha	NCBI Gene:5914	PA448486	"Acide Arsenieux [French],""Anhydride Arsenieux [French]"",""Arseni Trioxydum"",""Arsenic Blanc [French]"",""Arsenic Oxide"",""Arsenic Oxidearsenous Trioxide"",""Arsenic Sesquioxide"",""Arsenic Trioxide [UN1561] [Poison]"",""Arsenic, White"",""Arsenicum Album"",""Arsenigen Saure [German]"",""Arsenious Acid"",""Arsenious Acid Anhydride"",""Arsenious Oxide"",""Arsenious Trioxide"",""Arsenous Acid"",""Arsenous Acid Anhydride"",""Arsenous Anhydride"",""Arsenous Oxide"",""Arsenous Oxide Anhydride"",""Arsentrioxide"",""Crude Arsenic"",""Di-Arsenic Trioxide"",""Diarsenic Trioxide"",""Diarsonic Trioxide"",""HSDB 419"",""Oxyde Arsenieux [ISO-French]"",""Poison Flour"",""White Arsenic"",""arsenic trioxide"""	The FDA-approved drug label for arsenic trioxide (Trisenox) contains information regarding indication of the drug in patients whose acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. The label also states that some patients treated with arsenic trioxide have experienced symptoms similar to a syndrome called the retinoic-acid-Acute Promyelocytic Leukemia (RA-APL) or APL differentiation syndrome, which can be fatal, and high-dose steroids (dexamethasone 10 mg intravenously BID) should be immediately initiated at the first signs.
592	PA166127632	arsenic trioxide	RARA	PA34225	retinoic acid receptor, alpha	NCBI Gene:5914	PA448486	"Acide Arsenieux [French],""Anhydride Arsenieux [French]"",""Arseni Trioxydum"",""Arsenic Blanc [French]"",""Arsenic Oxide"",""Arsenic Oxidearsenous Trioxide"",""Arsenic Sesquioxide"",""Arsenic Trioxide [UN1561] [Poison]"",""Arsenic, White"",""Arsenicum Album"",""Arsenigen Saure [German]"",""Arsenious Acid"",""Arsenious Acid Anhydride"",""Arsenious Oxide"",""Arsenious Trioxide"",""Arsenous Acid"",""Arsenous Acid Anhydride"",""Arsenous Anhydride"",""Arsenous Oxide"",""Arsenous Oxide Anhydride"",""Arsentrioxide"",""Crude Arsenic"",""Di-Arsenic Trioxide"",""Diarsenic Trioxide"",""Diarsonic Trioxide"",""HSDB 419"",""Oxyde Arsenieux [ISO-French]"",""Poison Flour"",""White Arsenic"",""arsenic trioxide"""	The product monograph for arsenic trioxide (TRISENOX) states that is indicated for patients with acute promyelotic leukemia (APL) characterized by the presence of the t(15;17) translocation or promyelocytic leukemia-retinoic-acid-receptor alpha (PML-RARa) gene expression. 
593	PA166123527	arsenic trioxide	RARA	PA34225	retinoic acid receptor, alpha	NCBI Gene:5914	PA448486	"Acide Arsenieux [French],""Anhydride Arsenieux [French]"",""Arseni Trioxydum"",""Arsenic Blanc [French]"",""Arsenic Oxide"",""Arsenic Oxidearsenous Trioxide"",""Arsenic Sesquioxide"",""Arsenic Trioxide [UN1561] [Poison]"",""Arsenic, White"",""Arsenicum Album"",""Arsenigen Saure [German]"",""Arsenious Acid"",""Arsenious Acid Anhydride"",""Arsenious Oxide"",""Arsenious Trioxide"",""Arsenous Acid"",""Arsenous Acid Anhydride"",""Arsenous Anhydride"",""Arsenous Oxide"",""Arsenous Oxide Anhydride"",""Arsentrioxide"",""Crude Arsenic"",""Di-Arsenic Trioxide"",""Diarsenic Trioxide"",""Diarsonic Trioxide"",""HSDB 419"",""Oxyde Arsenieux [ISO-French]"",""Poison Flour"",""White Arsenic"",""arsenic trioxide"""	Arsenic trioxide is indicated for treatment of patients with relapsed or refractory acute promyelocytic leukemia (APL). The PMDA package insert for arsenic trioxide states that patients with APL should be characterized by presence of the t(15;17) translocation or PML/RAR-alpha gene expression. 
594	PA166104817	tretinoin	PML	PA33439	promyelocytic leukemia	NCBI Gene:5371	PA451746	"ATRA,""All Trans Retinoic Acid"",""All Trans-Retinoic Acid"",""Retionic Acid"",""beta-Retinoic Acid"",""tretinoin"""	Tretinoin is a derivative of vitamin A (retinol) used for the treatment of skin conditions and acute promyelocytic leukemia (APL). APL is characterized by the translocation t(15;17) and PML/RAR alpha (RARA) fusion protein. 
595	PA166127725	tretinoin	PML	PA33439	promyelocytic leukemia	NCBI Gene:5371	PA451746	"ATRA,""All Trans Retinoic Acid"",""All Trans-Retinoic Acid"",""Retionic Acid"",""beta-Retinoic Acid"",""tretinoin"""	Tretinoin (VESANOID) is a derivative of vitamin A (retinol) used for the treatment of skin conditions and acute promyelocytic leukemia (APL). APL is characterized by the translocation t(15;17) and PML/RAR alpha (RARA) fusion protein.
596	PA166123551	tretinoin	PML	PA33439	promyelocytic leukemia	NCBI Gene:5371	PA451746	"ATRA,""All Trans Retinoic Acid"",""All Trans-Retinoic Acid"",""Retionic Acid"",""beta-Retinoic Acid"",""tretinoin"""	Tretinoin is indicated for the treatment of acute promyelocytic leukemia (APL). The PMDA package insert for tretinoin (VESANOID) notes that it acts on the PML-RAR-&alpha; fusion gene, allowing immature promyelocytes to differentiate into normal mature blood cells.
597	PA166104817	tretinoin	RARA	PA34225	retinoic acid receptor, alpha	NCBI Gene:5914	PA451746	"ATRA,""All Trans Retinoic Acid"",""All Trans-Retinoic Acid"",""Retionic Acid"",""beta-Retinoic Acid"",""tretinoin"""	Tretinoin is a derivative of vitamin A (retinol) used for the treatment of skin conditions and acute promyelocytic leukemia (APL). APL is characterized by the translocation t(15;17) and PML/RAR alpha (RARA) fusion protein. 
598	PA166127725	tretinoin	RARA	PA34225	retinoic acid receptor, alpha	NCBI Gene:5914	PA451746	"ATRA,""All Trans Retinoic Acid"",""All Trans-Retinoic Acid"",""Retionic Acid"",""beta-Retinoic Acid"",""tretinoin"""	Tretinoin (VESANOID) is a derivative of vitamin A (retinol) used for the treatment of skin conditions and acute promyelocytic leukemia (APL). APL is characterized by the translocation t(15;17) and PML/RAR alpha (RARA) fusion protein.
599	PA166123551	tretinoin	RARA	PA34225	retinoic acid receptor, alpha	NCBI Gene:5914	PA451746	"ATRA,""All Trans Retinoic Acid"",""All Trans-Retinoic Acid"",""Retionic Acid"",""beta-Retinoic Acid"",""tretinoin"""	Tretinoin is indicated for the treatment of acute promyelocytic leukemia (APL). The PMDA package insert for tretinoin (VESANOID) notes that it acts on the PML-RAR-&alpha; fusion gene, allowing immature promyelocytes to differentiate into normal mature blood cells.
600	PA166122907	vandetanib	RET	PA34335	ret proto-oncogene	NCBI Gene:5979	PA166118341		The EMA European Public Assessment Report (EPAR) for vandetanib (Caprelsa) recommends testing for _RET_ mutation status, as patients without _RET_  mutations may have decreased benefit from vandetanib treatment.
601	PA166160021	cabozantinib	RET	PA34335	ret proto-oncogene	NCBI Gene:5979	PA165906891	XL-184	The FDA-approved drug label for COMETRIQ (cabozantinib) states that _RET_ mutation status was determined in clinical studies of the drug, and that the drug inhibits the activity of the RET protein.
602	PA166104929	clomifene	RHD	PA34387	Rh blood group, D antigen	NCBI Gene:6007	PA449046	"Chlomaphene,""Chloramifene"",""Chloramiphene"",""Cisclomiphene"",""Clomifene citrate"",""Clomifeno"",""Clomiphene Citrate"",""Clomiphene citrate"",""Clomiphene dihydrogen citrate"",""Racemic clomiphene citrate"",""Zuclomiphene citrate"",""clomiphene"""	"Clomiphene citrate is used to treat ovulatory dysfunction in women trying to become pregnant.  __This drug-biomarker pair was previously in the FDA's ""Table of Pharmacogenomic Biomarkers in Drug Labels"" but has subsequently been removed.__"
603	PA166123390	fampridine	SLC22A2	PA331	solute carrier family 22 (organic cation transporter), member 2	NCBI Gene:6582	PA166123389	4-Aminopyridine	The EMA European Public Assessment Report (EPAR) for fampridine (Fampyra) does not contain pharmacogenetic information. It contains information regarding the role of OCT2 (SLC22A2) in the secretion of fampridine, and states that concomitant use of drugs that are onohibitors of OCT2 are contraindicated, and cautions the use of concomitant drugs that are substrates of OCT2.
604	PA166104904	brentuximab vedotin	TNFRSF8	PA36616	tumor necrosis factor receptor superfamily, member 8	NCBI Gene:943	PA165948903	"124490327,""SGN-35"",""brentuximab vedotin"""	The EMA European Public Assessment Report (EPAR) contains information regarding the indication of brentuximab vedotin in patients with CD30-expressing tumour cells due to the drug's mechanism of action.
605	PA166104778	brentuximab vedotin	TNFRSF8	PA36616	tumor necrosis factor receptor superfamily, member 8	NCBI Gene:943	PA165948903	"124490327,""SGN-35"",""brentuximab vedotin"""	Brentuximab vedotin (Adcetris) is an antibody-drug conjugate (ADC) directed at TNFRSF8 (CD30), and nonclinical data suggests its anti-cancer mechanism of action is by binding to CD30-expressing cells and then releasing a small molecule that disrupts microtubules. 
606	PA166160288	brentuximab vedotin	TNFRSF8	PA36616	tumor necrosis factor receptor superfamily, member 8	NCBI Gene:943	PA165948903	"124490327,""SGN-35"",""brentuximab vedotin"""	Brentuximab vedotin (Adcetris) is an antibody-drug conjugate (ADC) directed at TNFRSF8 (CD30), and nonclinical data suggests its anti-cancer mechanism of action is by binding to CD30-expressing cells and then releasing a small molecule that disrupts microtubules.
607	PA166119824	belimumab	TNFSF13B	PA434	tumor necrosis factor (ligand) superfamily, member 13b	NCBI Gene:10673	PA166114904		The EMA European Public Assessment Report (EPAR) for belimumab (Benlysta) contains information regarding its mechanism of action for use in the treatment of systemuc lupus erythematosus (SLE). It is a human IgG1lambda that blocks binding of TNFSF13B to its receptor to inhibit B cell survival and reduce differentiation. 
608	PA166114905	belimumab	TNFSF13B	PA434	tumor necrosis factor (ligand) superfamily, member 13b	NCBI Gene:10673	PA166114904		"Belimumab (BENLYSTA) is a human IgG1lambda monoclonal antibody, indicated for use in adults with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. It acts by blocking binding of soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B-cell survival factor, to its receptors on B cells. __This drug-biomarker pair was previously in the FDA's ""Table of Pharmacogenomic Biomarkers in Drug Labels"" but has subsequently been removed.__"
609	PA166159938	belimumab	TNFSF13B	PA434	tumor necrosis factor (ligand) superfamily, member 13b	NCBI Gene:10673	PA166114904		Belimumab (BENLYSTA) is a human IgG1&lambda; monoclonal antibody, indicated for use in adults with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. It acts by blocking binding of soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B-cell survival factor, to its receptors on B cells.
610	PA166121251	mercaptopurine	TPMT	PA356	thiopurine S-methyltransferase	NCBI Gene:7172	PA450379	"6 MP,""6-Mercaptopurine"",""MP"",""Mercaptopurine Monohydrate"",""Mercapurin"""	The EMA European Public Assessment Report (EPAR) for mercaptopurine (Xaluprine) contains information regarding its metabolism by TPMT, and that patients with reduced activity are at increased risk of severe toxicity and likely require a reduced dose. TPMT genotyping or phenotyping can be used to identify these patients, although this should not replace close monitoring of blood counts.
611	PA166104810	mercaptopurine	TPMT	PA356	thiopurine S-methyltransferase	NCBI Gene:7172	PA450379	"6 MP,""6-Mercaptopurine"",""MP"",""Mercaptopurine Monohydrate"",""Mercapurin"""	TPMT genotyping or phenotyping can identify patients who are homozygous deficient, which predisposes them to mercaptopurine toxicity, and generally require substantial dose reduction. It also can identify those who have low/intermediate TPMT activity, which makes them more likely to experience mercaptopurine toxicity than people with normal TPMT activity, and may require a dose reduction.
612	PA166127690	mercaptopurine	TPMT	PA356	thiopurine S-methyltransferase	NCBI Gene:7172	PA450379	"6 MP,""6-Mercaptopurine"",""MP"",""Mercaptopurine Monohydrate"",""Mercapurin"""	The product monograph for mercaptopurine (PURINETHOL) states that individuals who are TPMT deficient are at risk of developing life-threatening bone marrow suppression when receiving the drug, and that substantial dose reductions are usually required for these individuals.
613	PA166104782	azathioprine	TPMT	PA356	thiopurine S-methyltransferase	NCBI Gene:7172	PA448515	"Azathioprin,""Azathioprine Sodium"",""Azatioprin"",""Azothioprine"""	The azathioprine (Imuran) FDA-approved drug label recommends testing for TPMT genotype or phenotype to identify patients who are at increased risk of myelotoxicity: those with low or absent TPMT activity. Dosage reduction is recommended in those with reduced activity. The label also recommends a further reduced dosage or alternative therapies in patients with low or absent TPMT activity treated with azathioprine and allopurinol concomitantly.
614	PA166127635	azathioprine	TPMT	PA356	thiopurine S-methyltransferase	NCBI Gene:7172	PA448515	"Azathioprin,""Azathioprine Sodium"",""Azatioprin"",""Azothioprine"""	The product monograph for azathioprine notes that individuals with an inherited deficiency of the thiopurine methyltransferase (TPMT) enzyme may be at risk for developing myelosuppression when treated with the drug. 
615	PA166123530	azathioprine	TPMT	PA356	thiopurine S-methyltransferase	NCBI Gene:7172	PA448515	"Azathioprin,""Azathioprine Sodium"",""Azatioprin"",""Azothioprine"""	The PMDA package insert for azathioprine notes that individuals with certain TPMT genetic variations may be at increased risk of developing myelotoxicity. The insert also notes that this myelotoxicity could be exacerbated by co-administration of drugs that inhibit TPMT, such as aminosalicylic acid derivatives.
616	PA166104853	cisplatin	TPMT	PA356	thiopurine S-methyltransferase	NCBI Gene:7172	PA449014	"CACP,""CPDC"",""CPDD"",""Cis-DDP"",""Cis-Diaminedichloroplatinum"",""Cis-Diamminedichloroplatinum"",""DDP"",""DDPT"",""Diamminedichloroplatinum"",""Platinum Ammine Chloride"",""Platinum Ammonium Chloride"",""Platinum Diamine Dichloride"",""Trans-DDP"",""Trans-Diaminedichloroplatinum"",""Trans-Diamminedichloroplatinum"",""Trans-Dichlorodiammine Platinum"",""Trans-Platinumdiammine Dichloride"""	The FDA-approved drug label for cisplatin was changed (in 2015) to reflect the level of uncertainty about the relationship between TPMT and cisplatin-induced ototoxicity. The Pharmacogenomics section was removed, and text was modified in the Warnings, Precautions and Adverse Reactions sections.
617	PA166104838	thioguanine	TPMT	PA356	thiopurine S-methyltransferase	NCBI Gene:7172	PA451663	"2-Amino 6MP,""2-Amino-6-mercaptopurine"",""2-Amino-6-merkaptopurin"",""2-Amino-6-purinethiol"",""2-Aminopurin-6-thiol"",""2-Aminopurine-6(1H)-thione"",""2-Aminopurine-6-thiol"",""6-Mercapto-2-aminopurine"",""6-Mercaptoguanine"",""6-Thioguanine"",""TG"",""ThG"",""Tioguanin"",""Tioguanine"""	The drug label states that substantial dosage reductions may be required in individuals with an inherited deficiency of the enzyme thiopurine methyltransferase (TPMT) to avoid the development of life-threatening bone marrow suppression. Prescribers should be aware that some laboratories offer testing for TPMT deficiency.
618	PA166127720	thioguanine	TPMT	PA356	thiopurine S-methyltransferase	NCBI Gene:7172	PA451663	"2-Amino 6MP,""2-Amino-6-mercaptopurine"",""2-Amino-6-merkaptopurin"",""2-Amino-6-purinethiol"",""2-Aminopurin-6-thiol"",""2-Aminopurine-6(1H)-thione"",""2-Aminopurine-6-thiol"",""6-Mercapto-2-aminopurine"",""6-Mercaptoguanine"",""6-Thioguanine"",""TG"",""ThG"",""Tioguanin"",""Tioguanine"""	The product monograph for thioguanine (LANVIS) notes that individuals with deficiency of the thiopurine methyltransferase (TPMT) enzyme may be at increased risk of developing myelosuppression when receiving the drug, and that testing for TPMT deficiency is available. 
